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Synopsis.
B-cell chronic lymphocytic leukaemia (B-CLL) is an acquired neoplastic disease 
characterised by a clonal accumulation of long-lived, functionally immature and CDS'*' 
B-lymphocytes, which particularly accumulate in the lymphatic system, peripheral blood, 
bone marrow, spleen and liver. Symptoms include lymphocytosis, immune system 
dysfunction and autoimmune disease, but transformation to more aggressive forms of 
neoplastic disease occur and development of a second malignancy is not uncommon.
The disease is one of later years being unusual before 50 years of age, the rates of 
incidence vary on a racial basis, and it has a highly variable prognosis. Some patients die 
within months of diagnosis despite intensive treatment, whilst others survive for 30-plus 
years without any form of medical intervention and die of unrelated causes. The principal 
causes of death in patients whose deaths are directly related to the disease are 
opportunistic infection due to the impairment of immune system function and bleeding 
disorders. No treatment has been shown to cure the disease or consistently extend life 
expectancy.
It has been recognised for more than 30 years that the accumulation of malignant cells in 
B-CLL is at least as important in the pathogenesis of the disease as their neoplastic 
proliferation. With the discoveries that Bcl-2 extended the life of follicular lymphoma cells 
by conferring resistance to apoptosis and was commonly expressed in B-CLL cells, it was 
extrapolated that Bcl-2 might play a similar role in the development of the disease by 
extending the life span of B-CLL cells. Bcl-2 has frequently been shown to be over 
expressed in B-CLL cells and genetic translocations and/or malfunction of Bcl-2 family 
regulating molecular entities may play a part in this. However, since its discovery, Bcl-2 
has been shown to be part of a large family of genes which is highly and evolutionarily 
conserved. Members of the bcl-2 family are defined by sequence homology in four Bcl-2 
homology (BH) regions and a hydrophobic membrane-spanning domain, with the 
possession of specific BH domains determining whether individual proteins have pro- or 
anti-apoptotic activity. Family members such as Bcl-2 and BcI-Xl extend the life span of 
cells, whilst others such as Bax and Bak shorten it.
Oltvai, Milliman and Korsmeyer have proposed a general model of apoptosis, in which the 
cell's apoptotic fate is determined by the cellular balance between pro- and anti-apoptotic 
bcl-2 family members.
The effect of unregulated expression of Bcl-2 family members in B-CLL cells conforms to 
this paradigm and resistance to apoptosis appears to be conferred through a cellular 
imbalance of power between pro- and anti-apoptotic bcl-2 family members, particularly 
Bcl-2 and Bax, which is tilted in favour of cell survival. However, the apoptotic fate of 
B-CLL cells, and hence the neoplasm, may be influenced by other family members, with 
Mcl-1, Bcl-Xj_, Bak, with the non-family but Bcl-2-associated protein, Bag-1, also found 
expressed in B-CLL cells.
Similarities between the structure of the more conserved family members and other 
pore-forming proteins, along with the ability of Bcl-2, Bcl-x^, and Bax to form pores in 
synthetic membranes, suggest that they may exert their influence through pore-forming 
activities in intracellular membranes, particularly mitochondrial membranes. Bcl-2 family 
members may regulate apoptosis by changing the permeability of membranes to ions and 
apoptosis-inducing molecules, and physical interactions between Bcl-2 family proteins 
mediated by the BH domains may be important in both pore-forming and pore-inhibiting 
activities.
Research findings suggest that the levels of Bcl-2 family members in B-CLL cells may be 
modulated by a wide range of largely extracellular influences, including the cytokines 
interleukin-4 (IL-4), IL-8, IL-10, interferon-a (IFN-a), IFN-y, and basic fibroblast growth 
factor (bFGF). Levels of Bcl-2 family members may also be modulated by contact 
between B-CLL cells and bone marrow (BM) stromal cells, activation of IgM, CD95, CD40 
or CD6, the p53 gene product, and co-cultivation with CDw32-transfected murine 
fibroblasts. Such modulation may offer some insight into the pathogenesis of the disease, 
an explanation for the higher level expression of Bcl-2 family members in B-CLL, and an 
explanation for the highly variable prognosis. Additionally, if Bcl-2 family members can be 
shown unequivocally to be controlled by any of these molecular entities, the existence of 
these influences may offer the opportunity to reduce the neoplastic cells' apoptotic 
threshold by manipulating the relative levels of pro- and anti-apoptotic Bcl-2 family 
members as a treatment regime, or prior to more conventional treatment regimes.
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1 Introduction (the disease).
B-cell chronic lymphocytic leukaemia is an acquired neoplastic disease characterised by a 
clonal accumulation of long-lived, functionally immature lymphocytes which proliferate in 
the lymphatic system. Neoplastic B-cells accumulate particularly in the peripheral blood, 
bone marrow, lymph nodes, spleen and liver, but in later stage disease may infiltrate the 
skin, tonsils, lung, pleura, gastrointestinal tract, prostrate and central nervous system. 
B-CLL commonly presents with cells of a marginally mature morphology and 
immunophenotype typical of early virgin B-lymphocytes, but prolymphocytes and 
lymphocytes of a more variable morphology may be present. The majority of peripheral 
blood cells are small, apparently homogeneous cells, with a rounded shape and a 
diameter larger than an erythrocyte. Cytoplasm is scanty, usually visible around half the 
circumference of the cell, with a centrally placed nucleus containing heavily condensed 
chromatin clumped in blocks and surrounded by paler areas. Typically there is little 
organelle development, particularly of the endoplasmic reticulum and golgi apparatus. 
Intracytoplasmic inclusions, globular and K-chain associated, or crystalline and \-chain 
associated, are visible in 5-10% of cases. Examples of a B-PLL cell and a B-CLL cell 
showing an intracytoplasmic inclusion, follow in Figure 1.
%
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(a) (b)
Figure 1. Examples of B-CLL (a) and B-PLL (b) cells in blood films. Reprinted, by permission, 
from Ghulam J Mufti et. al.. An atlas of malignant haematology. Figures 4 1 & 4.2. ©  Martin Dunitz Limited 
1996.
A persistent clonal lymphocytosis of > 5 x 10^ | i  of peripheral blood (normal value 1.5 
3.5 X 10^ I'"’ ), with bone marrow infiltration representing at least 25% of the nucleated 
cells, is a fundamental requirement of diagnosis.
However, more typically lymphocytosis ranges from 20-250 x 10® 1"^  and may be as high 
as 1000 X 10® I'T The accumulation of B-CLL cells is commonly described as relentless, 
but the rate of accumulation varies enormously and in some patients it may be very slow 
or arrested. The neoplastic B-cells in the peripheral blood are generally regarded as 
being frozen at Gq/G-i of the cell cycle and are thought to be non- or very slowly-dividing. 
The relative contributions made to the clonal accumulation by the propagation of the 
neoplasm in the secondary lymphoid organs, and/or by the longevity of the cells, remains 
unclear.
Immune system dysfunction is caused by the progressive infiltration of the BM by 
neoplastic lymphocytes leading to the displacement of normal bone marrow elements. 
The four stages of infiltration, in order of progression and illustrated in Figure 2, are 
described as nodular, interstitial, mixed (nodular and interstitial) and diffuse.
(a) (b)
(c) (d)
Figure 2. Examples of bone marrow biopsies (a) nodular, (b) interstitial, (c) mixed, and 
(d) diffuse. Reprinted, by permission, from Ghulam  J. Mufti et. al., An atlas of malignant haematology, 
Figures 4.12, 4.13, 4.15, & 4.16. ©  Martin Dunitz Limited 1996.
Resulting bone marrow failure may produce non-haemolytic anaemia, neutropenia, 
hypergammaglobuiinaemia (typically IgM and IgG, but occasionally including IgA), 
hypogammaglobuiinaemia, and a more generalised dysfunction of the immune system. 
Serum Igs typically show a progressive fall with advancing disease, with IgA generally 
reduced more than IgG or IgM, but with a fall in serum IgG usually providing the first sign 
of a failing immune system. T-cell function and cellular immunity are relatively normal in 
early stage disease, but BM failure leads to the loss of cellular immunity, as measured 
with recall antigens, in progressive disease. An increase in absolute numbers of CD4'^' 
and GD8'^ T-cells, but with a relative reduction in CD4’^  and a relative increase in CD8'*' 
cells to the point where the normal CD4'‘‘ :CD8‘^  ratio is inverted, is common. It is not 
clear to what degree the impairment of the immune function is due to the change in the 
balance between CD4"^ and CD8'*' T-cells, the effective dilution of T-cells as the ratio of 
T:B cells in peripheral blood changes from the normal 3 to 1 to between 1 to 20-50 with 
increasing lymphocytosis, or the absence of normally functioning B lymphocytes, but the 
resulting failure provides an opening for opportunistic infections.
Autoimmune events are common in B-CLL, but generally restricted to haemato-poiesis 
and reported, depending on the nature of the event, in between 2-36% of cases. 
Coombs-positive autoimmune haemolytic anaemia (AIHA) is most common, with immune 
thrombocytopenia and pure red blood cell aplasia running, respectively, a poor second 
and third. B-CLL patients do not appear to have a higher rate of incidence of other 
autoimmune phenomena such as systemic lupus erythematosus, polyarteritis nodosa, 
pernicious anaemia and autoimmune thyroiditis, although occasional non-haematological 
autoimmune disease is reported (Diele, 1998; Efremov, 1996; Hamblin, 1986; Jonsson, 
1996; Keating, 1996; Pritsch, 1998). The source and the mechanics of induction of 
haematopoietic autoantibodies in B-CLL remains unclear. B-CLL clones, which are 
overwhelmingly positive for the CDS antigen normally found on a CDS"^ B-1 subset of 
B-cells associated with autoantibody production, are the natural suspect. However, 
support for the non-leukaemic source of autoantibodies comes from a study showing the 
autoantibodies to be polyclonal IgG displaying activity against monomorphic elements of 
the rhesus system and not the product of a neoplastic clone (Dighiero, 1988). In contrast, 
a more recent investigation of the neoplastic cells of patients with B-CLL-associated AIHA 
found the preferential expression of two heavy chain variable region (VH) gene segments 
and the complementary determinant region 3 (CDR3). Expression of such a limited VH 
region repertoire would suggest that the teukaemic cells are also directly involved in the 
pathogenesis of the AIHA (Efremov, 1996).
A third, and not necessarily mutually incompatible possibility, is that the emergence of 
autoimmune events in B-CLL are linked to the initiation of radiation or chemical therapy 
between which a close temporal relationship is often observed (Keating, 1996). This view 
is supported by two studies suggesting that the onset of autoimmune phenomena is 
triggered by treatment with fludarabine (Bastion, 1992; Di Raimondo, 1993).
Transformation of B-CLL to more aggressive forms of B-lineage neoplastic disease 
occurs in -5-10% of cases. In the prolymphocytoid transformation, characterised by a 
significant increase in the cells with a prolymphocytic appearance from the 2-5% of 
neoplastic cells typical of earlier stage disease, B-CLL is transformed into 
B-prolymphocytic leukaemia (B-PLL) or B-CLL/PLL. Little is known about the mechanics 
of the transformation, but cells from the same clone as B-CLL exhibit a relatively 
immature morphology juxtaposed with an immunophenotype more indicative of a later 
stage of development by virtue of profusely expressed Ig. The disease is more refractory 
to treatment than B-CLL. with a median survival of 2-3 years from diagnosis. 
Transformation to Richter's syndrome, a diffuse large cell lymphoma (DLL) with 
pleomorphic and giant multinucleate cells, occurs in at least 3% of B-CLL cases, but the 
actual rate may be higher as occult transformations may go undetected by autopsy. 30- 
50% of the transformations have received no previous treatment and in some cases cells 
stem from the same clone (as defined by rearrangement of the Ig-heavy chain (H) gene 
and particularly the CDR3 region of the IgH gene), suggesting that Richter's syndrome is a 
natural progression in B-CLL. However, some studies have shown that Richter's 
Syndrome is not a clonal extension of B-CLL using the CDR3 and Ig V|_|DJ^ (variable 
heavy, diversity and joining heavy) sequences as markers of clonality. The transformation 
to Richter's Syndrome has also been linked, sometimes very tenuously, to Epstein-Barr 
virus (EBV), trisomy 12, trisomy 7, an exon 7 missense point mutation of the p53 gene, as 
well as, paradoxically, arising de novo. No satisfactory treatment is currently available 
and most B-CLL patients die within six months of the diagnosis of Richter's syndrome 
(Ansell, 1999; Byrnes, 1995; Cuneo, 1996; Giles, 1998; Matolcsy, 1994, 1995(1 & 2); 
Ohno, 1998; Petrella, 1997). Blast cell transformation in the terminal phase of B-CLL is 
rare and in approximately half of these the blast cells are myeloid in origin, most 
frequently myeloblastic, myelomonobiastic or acute erythroleukaemic. It is unclear 
whether the transformation to blast cells, myeloid or otherwise, is a natural progression of 
the disease or an artefact of treatment, e.g., with alkylating agents such as chlorambucil 
(Keating, 1996).
Spontaneous regression is relatively rare In B-CLL \with studies suggesting that the rate is 
between 1.8-3%, but interestingly the evidence suggests that in some cases the remission 
coincided with the onset of viral infections {varicella-zoster and bilateral orchitis), small 
pox vaccinations, and with the development of a second malignancy (Han, 1987; Ribera, 
1987).
B-CLL is a disease of later years. Its occurrence is rare under the age of 30, unusual 
under the age of 50, and rates grow exponentially with age until the 6th. decade. It is 
commoner in men than in women with the male;female ratio reported as being between 
1.5- 2.0. In the USA the disease is common in those of European and African ancestry, 
but uncommon in Asians, American Indians, those of Filipino origin and Los Angeles' 
Hispanics. In Israel the disease is very common amongst Ashkenazi Jews compared to 
non-Ashkenazi Jews, with a ratio of 4:1. B-CLL represents ?w30% of all leukaemia 
diagnosed in the Western World, but 38% in Denmark and only 2.5-5.0% in the Orient 
and Philippines. However, the lower rates of incidence in some Asian countries may be a 
reflection of shorter life-expectancy or a lower frequency of routine blood tests producing a 
lower rate of diagnosis. Demographic differences in the incidence of B-CLL are unlikely to 
be explained by environmental factors, as Japanese and Filipino Americans retain a rate 
of incidence of B-CLL comparable to the incidence of B-CLL in their countries of origin, 
suggesting that the differential incidence is due to genetic factors. B-CLL has a familial 
incidence with rates of disease being demonstrably higher in first degree relatives. 
Although environmental causes also cannot be absolutely excluded as the cause of this, 
the absence of any convincing indication of external cause, along with the different 
incidence of disease in ethnic groups regardless of where they are living, would suggest 
the most likely underlying cause is a genetic predisposition to develop the disease (Bartal, 
1978; Brincker, 1982; Cuttner, 1992; Keating, 1996; Linet, 1989).
No treatment regime has been shown to consistently produce long term complete 
remissions or survival benefit. There is a general consensus that patients in Binet A-B 
(Rai O-ll), which are illustrated in Table 1, should only be treated in the event of disease 
progression typically indicated by a consistent decrease in the peripheral blood 
lymphocyte doubling time, lymphocytosis at unacceptable levels (~ 150 x 10® l"'l), BM 
dysfunction, impairment of immune function, or by significant enlargement of organs. The 
cytotoxic drug of first resort is chlorambucil, which is sometimes used in combination with 
the corticosteroid prednisone, but more complex combination chemotherapy, including 
drugs such as vincristine sulphate, cyclophosphamide, doxorubicin, cytosine arabinoside, 
and etoposide, is commonly used in later stage or refractory disease.
Rai Binet
stage Stage
0
1
Absolute lymphocytosis > 15 x 
lO^r'"
As stage 0 + enlarged lymph 
nodes (adenopathy)
A 0 - 2  areas of organ enlargementf
II
III
As stage 0 + enlarged liver 
and/or spleen ± adenopathy
As stage 0 + anaemia (Mb < 
10.0 g df^)* ±  adenopathy + 
organomegaly
B 3 - 5  areas of organ enlargement 
Hb > 10 g dr and platelets > 100 x 
10®!'"'
IV As stage 0 + thrombocytopenia 
(platelets < 100 x 10® 1" )* + 
adenopathy ± organomegaly
C Organ enlargement not 
considered Hb < 10 gdl" and/or 
platelets < 100 x 10®1'^
Table 1. Comparison of Rai and Binet stages of B-CLL.
* Secondary causes of anaem ia (e.g. iron deficiency) or autoimmune haemolytic anaem ia or 
thrombocytopenia must be treated before staging.
t  Organ enlargement comprises enlarged spleen or liver, and lymph nodes > 1 cm in neck, 
axillae or groin each represent one area of enlargement.
Newer drugs include the purine analogues fludarabine monophosphate, 2-chlorodeoxy- 
adenosine, and deoxycoformycin, which appear to have significant cytotoxic activity in 
B-CLL. Fludarabine has been shown to be superior to the cyclophosphamide, doxorubicin 
& prednisone regime in a multicentre randomised trial of previously treated and untreated 
patients and has been shown to produce partial and complete remissions in refractory 
B-CLL. However, time is needed to determine if using fludarabine monophosphate 
translates into better survival (Brittinger, 1997; Dighiero, 1996; Johnson, 1996; Montserrat, 
1996, 1997; Sorensen, 1997). Other options seen as holding out the hope of a cure for 
B-CLL include treatment with monoclonal antibodies and/or stem cell rescue. The 
anti-CD52 antibody (Campath-IH) has been used to purge residual disease in patients 
where drugs have failed to displace persistent leukaemic infiltration of blood and BM, 
before successful autologous stem cell transplantation. Allogeneic and autologous stem 
cell transplants probably offer the best opportunity of curing B-CLL. A retrospective study 
spanning 1984-1992 involving patients with an age range of 21-58 in all stages of disease, 
showed mixed results. More recent studies have concentrated on patients with late 
stage/refractory disease. Three of these have shown more encouraging results with 89%, 
59% and 87% of the patients reported as displaying complete remission.
These results are particularly hopeful as these patients had largely exhausted 
conventional treatment regimes and. interestingly, one of the studies showed little 
difference in the complete remission success rate between patients given allogeneic 
(6/11) and those given autologous or syngeneic BM transplants (7/11). However, stem cell 
rescue is still in the experimental stage and it remains to be seen to what extent this 
treatment translates into improved survival and/or a cure (Dyer, 1997; Khouri, 1994, 1997; 
Michallet, 1996; Rabinowe, 1993).
The principal cause of death in patients whose deaths are directly related to the disease is 
opportunistic infection due to impairment of immune function. However, death as a result 
of bleeding disorders, other malignancies and transformation to more aggressive 
neoplasias, is also common. Survival time varies enormously, as indicated in Figs 3 and 
4, with some patients surviving untreated for 30+ years, whilst others die within months of 
diagnosis. B-CLL is normally categorised by Rai or Binet stage, which are compared 
above, and Figures 3 and 4 show that prognosis appears to be directly related to both the 
Binet stage and age at diagnosis (a similar picture emerges when survival is analysed by 
Rai stage). It is not immediately clear if these phenomena are due simply to "lesser 
disease" and disease occurrence at an age when general health and resilience may be 
expected to be better, or whether the different survival curves hint that there may be 
subtypes of B-CLL with different underlying biologies and prognoses. Factors that have 
been linked to a poor prognosis or progressive disease include trisomy 12, aberrant 
overexpression of the mutant form of p53 recognised by the monoclonal antibody (MoAb) 
PAb240, a higher Bcl-2/Bax^ ratio, and a higher expression of Bcl-2 alone. In contrast
some research has failed to link p53 mutants to the stage of disease and deletions of 13q 
have been linked to good prognosis . Unfortunately no clear explanation has emerged 
that might explain such distinct survival curves (Aguilar-Santelises, 1994, 1996; Gaidano, 
1994; Juliusson, 1993; Robertson, 1996).
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Figure 3. Survival of untreated B-CLL patients by Binet stage. Reprinted, by permission, from 
Keating, M. J., Chronic Lymphocytic Leukemia, Figure 3. ©  Marcel Dekker Inc 1993,
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Figure 4. Survival of untreated B-CLL patients by age at diagnosis. Reprinted, by permission, 
from Keating, M. J., Chronic Lymphocytic Leukemia, Figure 4. ©  Marcel Dekker Inc 1993.
2 B-cell lymphopoiesis.
2.1 Preamble.
Most adult human B-cells originate from a small population of self-renewing pluripotent 
stem cells (PSC) in the BM by what is essentially a two phase process. During the 
primary antigen-independent phase of differentiation and proliferation in the BM 
microenvironment, PSCs differentiate through a lymphoid stem cell (LSC) stage, 
pre-B-cell stages defined by the absence of membrane Ig. to become immature IgM"^ IgD" 
virgin B-cells. The post-LSC, pre-B-cell stages are generally referred to as pro- and 
pre-B-cell stages or as the pre-B-l and pre-B-ll cell stages, with an equivalence between 
pro-B-cell and pre-B-l stages, and between pre-B-cell and pre-B-ll cell stages. In the 
second, generally antigen-dependent phase, virgin B-cells which have migrated via the 
BM sinuses and peripheral blood to the secondary lymphoid tissues, are activated by a 
cognate encounter with antigen. Once activated and with appropriate T-cell support, 
these develop through centroblast and centrocyte stages to become Ig-secreting plasma 
or long-lived memory cells. The development process is summarised In Figures 5 & 6.
Differentiation and proliferation is orchestrated by unique endogenous patterns of gene 
expression, by cell-cell, cell-BM matrix and cytokine cues. The process is characterised 
to some extent by changes in morphology, but is particularly characterised by the 
expression of molecules of the immunoglobulin rearrangement machinery, the 
rearrangement states of the Ig heavy (H)- and Ig light chain genes, the state of the pre- 
and B-cell-receptor complexes, and the expression of membrane-associated antigens.
2.2 Antigen-Independent development.
In the primary antigen-independent phase illustrated in Figure 5, the earliest marker of 
B-lineage commitment was traditionally regarded as being CD19, the principal phenotypic 
marker of human B-lineage, but earlier stages exist. A CD10'*', CD19" common lymphoid 
progenitor of T-, B-, natural killer, and dendritic cells has been identified in humans (Galy,
1995). More recently murine G D I9" cells purified into three separate fractions by 
multiparameter flow cytometry appeared to show a linear development to B-committed 
cells, but with the earliest fraction not expressing genes associated with B-lineage 
commitment. Fraction Ag (004'°^^, AA4.1"*" (stem cell antigen), B220") expressed low or 
undetectable levels of germline IgHp, recombination-activating gene {rag-1), rag-2, Iga, or 
Igj3 gene transcripts.
Fraction (CD4'°^ AA4.1'^, B220''') expressed germline IgHp, along with low levels of 
rag-1, rag-2, Iga, and Igfi, Fraction A 2  (CD4". AA4.1*^, B220'*') expressed germline IgHp, 
rag-1, rag-2, Iga, lg/5, and 15 (Li, Y.S., 1996). Given the similarities between 
B-lymphopoiesis in mouse and man, this Ag fraction may be the equivalent of the CDIO"^, 
CD19" common lymphoid progenitor in man and offer insights into the earliest stages of 
B-cell differentiation in humans.
The earliest indication of B-lineage commitment is found in a small compartment of BM 
cells which are reported to be CD34“‘" CD10" G D I9", although the fact that both LSGs and 
all of the early stages of B-lymphopoiesis are GDIO"^ inevitably brings into question the 
GDI 0-negativity of these early B-cells. However, some of these also express the 
a-chain of the interleukin-7 receptor (IL-7Ra) and have been reported as expressing 
vpreB, a gene encoding one of the two components of surrogate light chains (SLG), 
germline IgHp and DnQ52 transcripts, terminal deoxynucleotidyl transferase (TdT), the Ig 
p signalling molecule, Rag-1 and Pax-5 (a B-cell specific transcription factor critical to 
B-cell development) mRNA, as well as DJ rearrangements in both adult and foetal cells. 
G D I9 is expressed in all but the very earliest stages of B-lymphopoiesis, as is GD10 
which is expressed from a very early stage up to the IgM"*" immature B-cell stage 
(Bertrand, 1997; Billips, 1995; Davi, 1997; Loken, 1987; Ryan, 1997). In the 
circumstances GDI 9 appears more of a manifestation of B-lineage commitment and not 
the potential effector of B-cell lineage as it has traditionally been seen. Human G D I9'"', 
GD10'*', GD34'*' pre-B-l cells also express TdT and Rag-1 in their nucleus from a very 
early stage. At this point the majority of pre-B-l cells are DJ|_| rearranged with Ig light 
chain genes in germline configuration (Ghia, 1996, 1998). Additional early 
B-lymphopoietIc antigens include GD45 (B220), IL-7R, and GD43, the latter of which 
subsequently shows a marked decrease in the pre-B-ll cell stage (Gandeias, 1997; Hardy, 
1991; Karasuyama, 1994; Li, Y.S. 1996; Melchers, 1995).
The pre-B-l cell stage is also marked by expression of SLC (a dimer consisting of VpreB 
and 15) in the absence of membrane IgHp, but apparently in association with several 
other molecules of varying molecular weight including the possibility of a molecular 
structure described as a surrogate heavy chain (SHG) (Ghia, 1996; Grawunder, 1995; 
Karasuyama, 1993; Meffre, 1996; Sanz, 1996). Also expressed In the pre-B-l cell stage 
are Iga and Igp. Together these form a signalling dimer and are an integral part of both 
the B-cell receptor complex (BCR), which consists of IgHp, rearranged light chain, and Iga 
/Igp, and the pre-BGR, in which SLC takes the place of rearranged light chain (Rajewsky,
1996).
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The pre-B-l! cell stage is marked by the expression of high levels of cytoplasmic IgHp, the 
expression of which requires a functional V^DJ^ rearrangement, but the absence of TdT 
expression and CD34, with a recent study suggesting that cytoplasmic IgHp is responsible 
for the downregulation of TdT (Ghia, 1998; Wasserman, 1997). The expression of a 
functionally rearranged IgHp,allows it to associate with SLC and Iga/lgp on the 
membrane, forming the pre-BCR which appears to be a sine qua non for progression to 
subsequent stages of differentiation (Grawunder, 1995). For example, in both mouse and 
man expression of the 15 gene appears not to be essential for successful progression to 
the pre-B-l cell stage, up to the emergence of a rearranged IgHp chain. However, 15 
defective mice produced by a targeted mutation, do not form a pre-BCR despite 
production of an IgHp chain and are significantly B-cell deficient, suggesting that 
expression of 15 and the pre-BCR are essential for a progression to the large proliferative 
pre-B-ll cell stage and beyond (Ehlich, 1993; Karasuyama, 1994; Kitamura, 1992; 
Minegishi, 1998; Roiink, 1993). Similarly mice harbouring mutations of the IgHp or tgp 
genes exhibit severe disruption of B-cell development (Gong, 1996; Kitamura, 1991; 
Torres, 1996). A similar picture emerges from studies of 15 expression in common 
variable immune deficiency (CVID) in humans. Differentiation to the pre-B-l cell stage is 
unaffected by the condition, but there is a significant reduction in the pre-B-ll cell 
population in patients with CVID and peripheral cells are IgM^-^ and CD3 8 ^o (Minegishi, 
1998),
Expression of rearranged IgHp and the pre-BCR coincides with the downregulation of 
Rag-1 and Rag-2 at both the protein and mRNA level (Grawunder, 1995) and this may be 
part of the mechanism by which allelic exclusion prevents productive V^ to DJ^ 
rearrangements of the second H-chain allele. Activation of the rearrangement machinery 
appears to be a bimodal event in both mice and humans, with the rag genes expressed as 
both mRNA and protein during the first wave of rearrangement of the H-chain locus at the 
CD34'*’ CDIO"^ pre-B-l cell stage. However, the rag genes are down regulated at the large 
cycling CD10"^ clgHf.C pre-B-ll cell stage, but are again detectable during the VpreB"*" 
CD10"*" clgHp"*" small pre-B-ll cell stage where, on the basis that V lJ l rearrangements are 
detectable, a second wave of rearrangement appears to occur, rag-1 & -2 genes continue 
to be expressed throughout the pre-B-ll cell and in the immature IgM"*" stages, suggesting 
that rearrangement of the L-chain loci continues throughout these development stages 
(Ghia. 1995, 1996, 1998; Grawunder, 1995; Li, Y.S. 1993; Li. Z. 1996; Lin, W.C. 1993;
Ma, 1992), Immature lgM"*"-expressing B-cells continue to express CD10"*", which is 
subsequently down regulated on mature B-cells, low levels of rag mRNA, and with Rag-2 
protein levels as high as those in small pre-B-ll cells.
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The continued expression of rag genes is in keeping with the recent findings that a 
proportion of B-cells undergo a secondary rearrangement of the L-chain, changing the 
specificity of the BCR and testing it on the membrane {Ghia, 1995; Harada, 1991; Prak, 
1995; Rolink, 1993).
This microenvironment in which the primary antigen-independent stage of 
B-lymphopoiesis occurs, consists of other [ymphohaematopoietic cells, a complex 
framework of non-lymphohaematopoietic stromal cells and the extracellular matrix. The 
stromal cells, including fat cells, endothelial cells, fibroblasts and macrophages, provide 
an haematopoiesis-inducing environment where membrane-bound antigens or diffusibie 
growth factors are crucial for the proliferation and differentiation of PSCs into LSCs and 
subsequently into lineage-committed progenitor lymphocytes and later stages of B-cell 
development (Pribyl, 1996; Rawlings, 1995). Cell membrane molecules such as the 
integrins, that mediate cell-cell and cell-substratum interactions with stromal cells, appear 
to play a critical role in regulating the growth and differentiation of B lymphocytes. For 
example, the very late antigen (VLA) integrin subfamily of surface antigens can bind to 
receptor molecules on other cells and to components of the extracellular matrix such as 
fibronectin, various collagens and laminin. B-cell precursors (BCP) express two members 
of the VLA family designated VLA-4 and VLA-5. The receptors for VLA-4 include the 
vascular cell adhesion molecule-1 (VCAM-1), a member of the immunoglobulin 
superfamily, and the CS-1 domain of fibronectin. The receptor for VLA-5 is the central 
cell-binding domain of fibronectin. Human bone marrow cells that support the growth and 
differentiation of BCPs constitutively express VCAM-1 in contrast to vascular endothelial 
cells where it appears to be cytokine-regulated. BCPs adhere to stromal cells via a 
VLA-4A/CAM-1 interaction and this, along with the VLA-5/fibronectin interaction, is thought 
to be of central importance in B-lymphopoiesis (LeBien, 1996; Oostendorp. 1997),
When infection is present the major source of the growth factors acting on the BM 
lymphohaematopoietic microenvironment are the haematopoietic cytokines produced by 
activated macrophages and helper T-cells, in comparison to the situation which prevaiis in 
the absence of infection, when the stromal cells are the major source of cytokines which 
induce homeostatic haematopoiesis. Proliferation and development of different lineages 
can be altered by either a change in the local concentrations of particular growth factors, 
or by altered expression of the membrane receptors/adhesion molecules. The stage of 
differentiation and the state of activation influence both the type and quantity of 
receptors/adhesion proteins expressed.
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These may be influenced by the presence and concentration of specific cytokines, so the 
regulatory system is a complex and dynamic one consisting of controls within controls 
which responds to the changing needs of the immune system. No definitive picture has 
emerged of the regulation of lymphohaematopoiesis by cytokines, but in vitro studies on 
human and murine cells have shown a number of growth factors to affect the proliferation 
and/or differentiation of lymphocyte progenitors. Multi lineage colony-stimulating factor 
(multl-CSF also known as (aka) IL-3), lL-1a, IL-ip, lL-2, IL-4, IL-5, IL-6, IL-10, îL-11, 
transforming growth factor-beta (TGF-p), IFN-y, tumour necrosis factor-alpha (TNF-a), 
IFN-a, macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating 
factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) have all 
been shown to influence some aspect of haematopoiesis in culture (Dorshkind, 1991; 
Hirayama, 1994; Kincade, 1989; LeBien, (1996); Lee, 1993; Maraskovsky, 1998; Nilsson, 
(1993); Witte, 1993; Yamada, 1996). IL-7 and IL-7R have both been implicated in murine 
B-iymphopoiesis. Mice deficient in IL-7 production or the IL-7Ra/y chains exhibit a severe 
disruption of B-cell development, but with deficiencies of the receptor causing more 
severe effects than deficiency of IL-7 (Stephan, 1997, 1998; von Freeden-Jeffry, 1995). 
One explanation put forward for this, proposes that the IL-7R has an as yet unidentified 
ligand other than IL-7 which is involved in B-lymphopoietic signalling during B-cell 
development. It remains to be seen if IL-7 plays a similar role in human B-lymphopoiesis, 
but one in vitro study found that addition of IL-7 or goat anti-IL-7 antibody to the culture 
conditions made no significant difference to the tempo and phenotype of B-cell 
development (Pribyl, 1996). The full range of influences of cytokines, either singly or in 
combination in vivo, and particularly at different stages of differentiation, remains to be 
elucidated.
During their development, immature B cells acquire the degree of flexibility that allows 
them to pass through the sinusoidal wall into the sinuses of the bone marrow, from where 
they enter the peripheral blood circulation and home to the secondary lymphoid tissues 
where the maturation process continues with the expression of IgD (Rajewsky, 1996) and 
the antigen-dependent phase of B-ceil development occurs. Homing by blood- borne 
lymphocytes to the secondary lymphoid tissues is mediated by multiple cell surface 
adhesion molecules including the (31 (VLA), (32, and particularly by the selectins. For 
example leukocyte selectin, CD62L, is expressed at relatively low levels during the early 
stages of B-cell ontogeny, but increases as B-cells mature in the bone marrow. Such 
differential expression of adhesion molecules is wholly consistent with a requirement for 
homing to secondary lymphoid tissues.
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In this context, selectin is thought to mediate adhesion to activated epithelium using 
GlyCAM-1 (a major L-selectin ligand), MAdCAM-1 (mucosal addressin cell adhesion 
molecule-1 ), and CD34 ligands (LeBien, 1996).
2.3 Secondary B-cell development.
Secondary B-cell development is largely antigen-dependent, but multimeric antigen can 
also stimulate B-cells, predominantly though not exclusively B-1 cells, to proliferate and 
differentiate into plasma cells (Forster, 1987; Mond, 1995; Rajewsky, 1996). Like the 
primary antigen-independent phase of B-cell development, the continued development of 
B-cells in lymphoid tissues is aiso characterised by changes of morphoiogy, by changed 
patterns of gene expression, by changes in immunophenotype, and is summarised in 
Figure 6,
In antigen-driven development and differentiation, naive B-cells in a primary follicle or in 
the circulation are activated by a cognate encounter between antigen and the BCR. 
Activation results in the formation of a germinai centre (GO), in which the activated cells 
undergo a complex development process including cytokine stimulation by IL-1 and IL-4. 
and dependent on association with T,^- and follicular dendritic cells (FDCs). This process 
begins with a rapid clonal expansion, during which rapidly proliferating B-cells have their 
apoptotic potential increased by the expression of c-myc mRNA and protein. The 
expanding clone is then subject to somatic hypermutation (SHM), during which the V 
regions of Ig genes are subject to a high rate of point mutation, before isotype switch 
recombination (ISR), and receptor editing of the Ig L-chain genes (Cutrona, 1997; Han, S. 
1995; Kuppers, 1993; Liu, Y. J. 1996(1-3)). Centroblasts, which are subject to several 
rounds of SHM, ISR, and selection whilst cycling between the dark and light zones of the 
GCs, migrate to the light zone where they are subject to positive selection for high-affinity 
antibody and negative selection for low-affinity or autoreactive antibody (Kelsoe, 1995, 
1996(1 & 2); MacLennan, 1994). After undergoing successful rounds of SHM, receptor 
editing, ISR and selection, B-cells, in the form of plasmablasts, begin to proliferate before 
leaving the GC and differentiating into either long-lived memory cells or plasma cells 
(Henderson, 1998).
The initial activating encounter with antigen results in the upregulation of cell membrane 
molecules involved In B-T-cell interactions and the expression of membrane antigens 
involved in the formation of GCs.
14
These include class II major histocompatibility (MHCI!) proteins, B7-1, B7-2, CD40, CD19, 
and the tumour necrosis factor receptor type I (TNFR-1) {Clark, 1989, 1991; Glimcher, 
1992; Han, S. 1995; Lenschow, 1996; Matsumoto, 1996; Rickert, 1995). Additionally, 
expression of NF-IL-6 (nuclear factor-1 L-6), Oct-2 (octamer binding site protein 2), ST ATI 
(signal transducer and activator of transcription 1) and Jaks (Janus kinases) are 
increased in activated B-celis. In keeping with the recombination that occurs in GC 
centroblasts for the purpose of generating high-affinity antibody, the rag-1 and rag-2 
genes are reexpressed at this stage. Bcl-6 is also increased but expression of IgM is 
reduced (Han, S. 1996; Henderson, 1998).
In the light zone B-cells interact with T-cells and FDCs via CD20, LFA-1 and VLA-4 
(Holder, 1995; Pound, 1997). in addition centrocytes continue to express CD40, B7-1, 
B7-2, CD23, but they also express IgM without IgD (Liu, Y. J. 1996c). Centrocytes also 
express genes concerned with apoptosis including fas (CD95), c-myc, bax, p53, but with 
only low levels of bcl-2 expression (Lagresle, 1995; Martlnez-Valdez, 1996; Smith, 1995). 
On exiting the GC, differentiating into piasma or memory cells coincides with the down- 
regulation of fas expression, but with an increase in the expression of Bcl-2, Bcl-Xi_, and 
the cyclin-dependent kinases 4 (Cdk4) and 6(Cdk6) and the IL-6 receptor (Choe, 1996; 
Ishida, 1995; Koopman, 1997). Additionally, expression of the transcription factors jun, 
NF-kB, and NF-AT is increased (Berberich, 1994; Choi, 1994; Li, Y. Y. 1996).
The mechanisms by which the fate of the B-cells exiting the GC is determined remains 
imperfectly understood, but human memory cells are CD38", CD20'*', CD39'*', and can be 
stimulated to proliferate in response to CD40L (Arpin, 1995). Outside the GC, 
piasmablasts become plasma cells which are stimulated by increased expression of IL-6 
to Induce Ig, and Oct-2 expression (Henderson, 1998; Natkunam, 1994). Plasma cells 
have superabundant levels of Ig and J chain mRNA and inducement of the transcription 
factor Blimp-1 coincides with differentiation into plasma cells (Turner, 1994).
Differentiation into plasma cells also results in the reduction of expression of many genes 
including those expressing CD19, CD23, CD22, class II MHO, c-Myc, BSAP, early B-cell 
factor (EBF), and CIITA (Hagman, 1993; Henderson, 1998; Lin, 1997; Rinkenberger,
1996; Ruzek, 1995; Scheuermann, 1995; Silacci, 1994; Tedder, 1997). Memory cells can 
be distinguished from GC B-cells and plasma cells on the basis of CD38 and CD20 
expression. GC B-cells are CD38'‘‘ CD20''', whereas plasma cells are CD38*^ CD20", and 
memory cells are CD38“ CD20'*'. Additionally memory cells are reported to be HSA*-^ and 
CD44'** (Arpin, 1995; Sprent, 1994).
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Although normal B-cells can also be involved in T-cell-independent activation, a particular 
exception to the normal two-phase process of lymphopoiesis described in the preceding 
paragraphs involves a subset of B-cells which have been mainly studied in mice but which 
are also present in humans. These cells are designated B-1 a if they are CD5(Ly-1)'^, and 
B-1 b if CD5(Ly-1 )" and in adults they are most commonly found in the pleural and 
peritoneal cavities where they participate in gut- and lung-associated immune responses. 
Studies in chickens, sheep and mice suggest that they are produced in the early stages of 
life and unlike normal B-cells, may subsequently have their origins founded in 
self-replication rather than in PSCs. Furthermore, multimeric antigens on cell surfaces 
can stimulate T-independent proliferation into plasma cells via efficient cross linking of 
BCR, resulting particularly in the production of IgM and !gG3 antibodies. B-1 cells may be 
either CDS"^ (expression of which is increased upon activation) or CD5", CD23“, 6220"*", 
IL-SR"*", CD72‘^ , are typically IgM^', express variable amounts of IgD, and are CDIIb '*' in 
the peritoneal cavity but CD11b" in the spleen (Henderson, 1998: Kantor, 1993; Rajewsky,
1996). Development and differentiation of B-1 cells is less well characterised than the 
lymphopoiesis of normal B-cells and is not illustrated in Figures 5 & 6.
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3 B-CLL Ontogeny.
The origins of the progenitors of the neopiastic clones found in B-CLL remains unclear. 
Proliferation is believed to occur in the lymphatic system, but the ambiguity posed by a 
relentless and often aggressive accumulation of apparently non- or slowly-dividing 
neoplastic cells in peripheral blood, bone marrow and lymphoid tissues, has yet to be 
resolved by the unequivocal identification of the neoplastic progenitor and the proliferative 
compartment
Speculation about the identity of the normal counterpart of the putative neoplastic parent 
is based to a very limited extent on the morphology of B-CLL cells, but mainly on a 
comparison of the immunophenotype of the typical neoplastic B-CLL cell with the various 
subsets/developmental stages of normal B-cells. A simplified version of the latter is 
illustrated in Figure 7, which includes, as well as the antigens and developmental stage 
molecular markers described in previous paragraphs, other membrane antigens that have 
been reported in studies of B-cells (Freedman, 1993; Keating, 1996; LeBien, 1996; 
Nilsson, 1993). Most B-CLL clones appear to have a morphology equivalent to those of 
small recirculating B lymphocytes resting at Gq of the cell cycle and the 
immunophenotype is strongly suggestive of B cells that are marginally immature, e.g. the 
limited surface expression of IgM along with high levels of cIgM. However, markers 
suggesting a relatively earlier stage of development may include CD9, CD10, mouse red 
blood cell receptors (MRBC-R) and the presence on cell membranes of fewer receptors 
for ABO blood group antigens, for "i" antigen and for sialic acid residues.
Figure 8 represents, as far as it is possible to do so in a condition which is notoriously 
heterogeneous, the immunophenotype found on B-CLL cells grouped by the 
developmental stage/lineage which they are normally thought to represent (Freedman, 
1993; Keating, 1996; Nilssson, 1993).
Of particular interest in typical B-CLL cells, when Figures 7 & 8 are compared, is the 
juxtaposition of antigens normally associated with normal resting Gq B-cells (clgM, sIgM, 
CD11a/CD18, CD44, L-Selectin, CD22, CD21 and CD35), antigens more typical of 
activated B-cells (B5, Blast-1, CD23 (low-affinity Fee receptor), CD25, BB-1/B7, B8.7, 
CD54, CD71, CD77, and 4F2), antigens normally regarded as being representative of 
myelomonocytic lineage, with CDS, a pan-T antigen expressed on both a subset of 
B-cells and on B-cells during activation.
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Setting aside the possibility that B-CLL may be as heterogeneous in its neoplastic origins, as 
it is in almost every other respect, the similarities between B-CLL lymphocytes and CDS'*" 
B-cells seem to raise three possibilities.
Pan-B
antigens
MHO II (la)
CD19
CD20
CD24
CD40
CD45R
Antigens common to B-CLL cells by lineage/stage
Pre-B Immature/ Activation Myelo/
monocytic
CD9(20%)
CD10
Mature B-cell Antigens
antigens
c/slgM/D B5
CD Ic Blast-1 (50%)
CD11a/18 CD23
CD21 CD25(50%)
CD22(25%)
CD35 BB-1/B7
0044(76%) CD54
L-Selectin CD71
CD77
88.7
4F2
CD11b/18
CD11C/18
CD14
CD15
Other
CD5
MRBC-R
DCA-1
CD38
Figure 8. Antigens typically found expressed in B-CLL with the fingerprint immunophenotype 
highlighted in bold, the less commonly expressed activation antigens highlighted with italics, 
and reported percentage occurrence in brackets.
First, the CDS’*" subset of B-lymphocytes, which are found in foetal lymph node and spleen, in 
adult peripheral blood, the periphery of adult lymph nodes, adult tonsils, after allogenic 
transplantation and in autoimmune disease such as rheumatoid arthritis or systemic lupus 
erythematosis (Freedman, 1993), is a genuine and distinct population of B-cells and that 
B-CLL is derived from it. This hypothesis is supported by similarities between B-CLL cells 
and those of the normal small subpopulation of CDS'*' B-lymphocytes which are quite striking. 
Within generally similar immunophenotypes, 95% of B-CLL cells and this putative 
subpopulation of B-cells are positive for the almost-pan-T CDS antigen, both weakly express 
slgM, both express MRBC-Rs and have a long survival in vitro (Kipps, 1989). In common 
with B-CLL cells, normal CDS"^ cells express myelomonocytic antigens as part of their normal 
repertoire, although it is uncertain if the expression of the myelomonocytic antigens 
CD11b/CD18, CD11C/CD18, CD14and C D ISon CD5+ B-CLL cells (Nilsson, 1993) 
represents a neoplasia-induced lineage infidelity, or if it offers further support to the theory 
that B-CLL is derived from the normal population of CDS"  ^cells. In addition they also share 
the frequent production of polyreactive autoreactive antibodies, the ability to cap sig and the 
expression of low levels of CD20 (Caligaris-Cappio, 1993).
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Furthermore, the fact that some of these B-1 cells are apparently CD5", offers a ready­
made explanation for the much rarer and less-studied CD5" B-CLL clones.
Secondly, the suggestion that B-CLL is derived from a subtype of normal activated B-cells 
and that expression of CDS is representative of a particular activation stage is supported 
by the fact that many clones are known to express antigens normally associated with the 
activated B-cell phenotype. B5, Blast-1, CD23 and CD25 are expressed with a variable 
frequency while BB-1/B7, CD54, CD71 and CD77 are less commonly expressed and/or 
weakly expressed. Although many of the stimuli that activate B-cells, e.g. anti-lg, EBV, 
the anti-CD20 monoclonal antibody 1F5, recombinant interleukin-1 (rlL-1), rlL-2, rlL-4, 
recombinant interferon-y (rIFN-y) and B-cell growth factor do not induce the expression of 
CDS, CDS expression has been induced by 12-0-tetradecanoylphorbol-13-acetate (TPA) 
which was found to induce the expression of CDS on splenic B-cells between 48 and 96 
hours after activation. In the case of TPA, the parallels between activated splenic B-cells 
and B-CLL were supported by the expression of BS, CD23 and CD2S on the splenic 
B-cells activated by this phorbol ester (Freedman, 1989).
Although the balance appears to be tilted in favour of B-CLL originating from a cell from 
the subpopulation of B-1 CDS"^ B-lymphocytes, the phenotypic heterogeneity of B-CLL 
clones, particularly the CDS" nature of some, the lack of knowledge of the extent, if any, to 
which expression of a B-CLL marker is caused by the malignancy, and the currently 
limited knowledge of the normal CDS"^ population of B-cells, prevents the putative 
precursor from being identified with any certainty. In such circumstances the third 
possibility remains that B-CLL is derived from an ordinary B-lymphocyte and that the 
juxtaposition of CDS, resting, myelomonocytic and activation antigens on the cell 
membrane is the genetic consequence of the neoplastic event(s).
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4 Apoptosis.
4.1 Preamble.
B-CLL is characterised by the enigmatic and often relentless clonal accumulation of 
functionally immature B-lymphocytes juxtaposed with a non-existent or low proliferation 
coefficient. There is a general consensus, traceable to Dameshek's comments in 1967, 
that chronic lymphocytic leukaemia was a lymphoaccumulative disease of 
immunologicalty immature lymphocytes, and those of Kerr, Wyllie and Currie in 1972, 
concerning the role that apoptosis might play in the spontaneous and therapeutically- 
induced regression of malignant neoplasms, that the apoptosis-resistant nature of the 
neoplastic B-cells is the source of the enigma and a major contributor to tumourigenesis 
in B-CLL.
Apoptotic cell death is a fundamental biological mechanism involved in, for example, 
embryogenesis, morphogenesis, tissue homeostasis and defence against pathogens. 
Disturbed apoptosis is a major contributor to autoimmune disease and malignancy, 
although the genes involved in tumourigenesis, e.g. the Myc proteins, in deregulating the 
cell cycle, appear to prime the cell for apoptosis at the same time. However, of some 
relevance to B-CLL is the critical role apoptosis plays in B-cell homeostasis and in the 
negative and positive selection of lymphoid cells (Adams, 1998; Evan, 1998; Osario,
1998).
A proportion of cells are thought to die apoptotically at the pre-B-cell stage of development 
as a result of their failure to rearrange their Ig genes and express functional receptors. 
Mice harbouring mutations of the IgHp or Igp genes exhibit severe disruption of B-cell 
development (Gong, 1996; Kitamura, 1991; Torres, 1996). Furthermore, B-cells devoid of 
surface Ig (sIg) are seldom observed in the peripheral immune system and Bcl-2 is 
downregulated in small pre-B and immature B-cells consistent with the belief that these 
cells are deleted apoptotically unless rescued by a BCR-mediated signal (Rajewsky,
1996). Similarly, virgin B-cells that fail to be activated by antigen are thought to meet a 
similar fate. In a recent review of B-cell life span in mice, it was suggested that 
approximately 15% of peripheral blood B-cells are short-lived immature cells (B220 
(CD45RA)^°) with a life-span of several days. These newly generated cells populate the 
B-cell follicles where they are lost apoptotically by natural attrition if they fail to be 
activated (Fulcher, 1997).
23
Apoptotic deletion of immature B-cells is believed to occur in the BM when B-cells 
expressing receptors for self-antigen are eliminated (Rajewsky, 1996). Studies in mice 
indicated that this occurred in two separate and sequential stages. The binding of self­
antigen appears to block the developmental acquisition of adhesion molecules and 
receptors which are important for migration and activation (i.e. increased expression of 
IgM and expression of CD45R and IgD), prior to the B-cell's apoptotic deletion within the 
bone marrow where their median life-span was 15 hr. Expression of transgenic Bcl-2 
extends the longevity of the cells resulting in the escape of large numbers of self-reactive 
B-cells from the BM, but fails to overcome the developmental arrest. This can be 
reversed by the removal of self-antigen, when development recommences and proceeds 
normally (Hartley, 1993).
Centrocytes which have undergone a process of hypermutation of the variable area of 
their Ig genes in GCs appear to be selected on the basis of their resulting changed affinity 
for antigen. In vitro tests on centrocytes isolated from human tonsillar tissue indicated 
that a minority of centrocytes could be rescued from apoptosis by either interaction with 
antigen-presenting FDCs via CD1 la  (LFA-1 a) and CD49d (VLA-4a) or by cross-linking 
the B-cell antigen receptors, while the other unsupported centrocytes died by apoptosis. 
Apoptotic death in these circumstances is apparently mediated by a pre-existing 
Zn2+-dependent 18 kDa murine NUC-18-like endonuclease and interestingly rescue from 
apoptosis correlates with increasing expression of Bcl-2 (Lindhout, 1993, 1995; Liu, 1989, 
1991). Similarly, GC B-cells can be rescued from CD95-induced apoptosis by ligation of 
CD40 or by attachment via LFA-1 and VLA-4 on B-cells to their counter receptors, ICAM-1 
and VCAM-1, on FDCs (Koopman, 1997).
The morphology of apoptosis is well characterised. Its morphological hallmark is the 
condensation of the nucleus whilst other organelles remain relatively normal, but other 
visible changes in the ultrastructure include compaction of the nuclear chromatin, 
condensation of the cytoplasm accompanied by an increase in density, and mild 
convolution of the nuclear envelope and cell membrane. The nuclear chromatin typically 
condenses into sharply delineated and uniformly dense masses that lie against the inside 
face of the nuclear envelope, the cytoplasm condenses without any obvious deterioration 
of organelles and both the cell membrane and the nuclear envelope adopt increasingly 
convoluted shapes. As apoptosis progresses compaction of organelles and dilation of the 
endoplasmic reticulum occurs, the nuclear envelope becomes convoluted to the point 
where it breaks up into discrete fragments which may contain pieces of compacted 
chromatin, and the cell membrane adopts a shape displaying many protruding lobes.
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In the final stage of ultrastructural decay the lobes break away forming membrane-bound 
apoptotic bodies which contain small amounts of cytoplasm and which may also contain 
discrete parts of the nucleus and/or organelles. Apoptotic bodies of lymphocytes are 
phagocytosed by macrophages and apoptotic bodies from other types of cell in solid 
tissues may be phagocytosed by surrounding cells, both without any indication of the 
inflammation which accompanies necrotic cell death (Cohen, 1993; Kerr, 1991; Kroemer,
1997). The ultrastructural deterioration may only take minutes to complete from the point 
where change first becomes apparent and is illustrated below in Figure 9.
Figure 9. Ultrastructural changes in apoptosis (right) compared to necrosis (left). 
Reprinted, by permission, from L. D. Tomei & F O. Cope (eds), Apoptosis: The molecular basis of cell death. 
Figure 1. ©  Cold Spring Harbor Laboratory Press 1991.
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Apoptosis is a phenomenon that is believed to occur in all metazoans, albeit with 
apparently much greater complexity in mammals, and the extent to which it is 
evolutionarily-conserved is, for example, obvious from the structural and functional 
similarities between mammalian genes/proteins and those of the nematode worm 
Caenorhabtidis elegans (C. elegans). The current three-phase model of apoptosis, 
although incompletely understood, is increasingly well characterised in terms of the 
functions of the molecules involved. The paradigm includes an induction phase in which 
heterogeneous signals including DNA damage from ionising radiation or 
chemotherapeutic agents, deprivation of growth factors or metabolites, and ligation of cell 
death signal-transmitting receptors such as CD95, initiate the apoptotic process by 
separate molecular pathways.
This initiation stage is followed by a regulation phase, in which apoptosis-inducing and 
apoptosis-inhibiting members of the Bcl-2 family of homologues compete to determine if 
the cell is deleted apoptotically or remains viable. If a point-of-no-return is passed, the 
execution phase of apoptosis is activated and a cascade of caspases complete the 
process by effectively dismantling the cell from within (Adams, 1998; Kroemer, 1997).
The apoptotic process Is illustrated in Figure 11.
4.2 Apoptosis initiation.
Apoptosis may be initiated by a wide range of events and agents, including oncogenic 
events, heat shock, hypoxia, IFN, TNF, protein synthesis inhibitors, cytokine deprivation, 
glucorcorticoids, staurosporine, y- and uv-irradiation, and cytotoxic drugs. However, as 
well as the different stimuli acting through different receptors/cellular entities, there are 
clearly at least two distinct paths that activate apoptosis. Bcl-2 and Bcl-w expression can 
protect cells from many of the diverse cellular insults listed, but apoptosis initiated by 
ligation of CD95 (APO-1/Fas) is apparently unaffected by these anti-apoptotic proteins 
(Adams, 1998; Ashkenazi, 1998; Evan, 1998; Gibson, 1996). Bcl-2's inability to inhibit 
apoptosis caused by activation of CD95 may be explained by the fact that, in lymphoid 
cells at least, GD95 triggers apoptosis through activation of procaspase-8 rather than the 
more common activation of procaspase-9 (Green, 1998; Thornberry, 1998). The extent of 
the differences between apoptosis induced by CD95 and by other means, is highlighted by 
the effect of caspase inhibitors. Caspase inhibitors such as benzyloxycarbonyl-valinyl- 
alaninyl-aspartyl-(0-methyl)-fluoromethyiketone (zVAD-fmk) and the caspase-inhibiting 
protein X-IAP have no effect on the release of cytochrome c (cyt c) from mitochondria or 
apoptosis induced by over expression of Bax.
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In contrast, the release of cyt c induced by CD95 ligation is affected by caspase inhibitors, 
which particularly appear to inhibit apoptosis initiated by caspase-8. However, where 
apoptosis is instigated by caspase-8, subsequent release of cyt c can contribute to the 
caspase cascade by amplifying the effect of caspases downstream of caspase-8, 
presumably through caspase-9 (Jurgensmeier, 1998; Vander Helden, 1997). The ability of 
caspase-inhibitors to influence the release of cyt c in CD95-induced apoptosis suggests 
that the difference between this route and the other route(s) is so great that the apparent 
chain of events may be reversed to some extent.
4.3 Apoptosis regulation.
The biochemical and molecular events that have been detected in the regulatory phase of 
apoptosis include the opening of the mitochondria permeability transition (PT) pore (aka 
megachannel), the collapse of the mitochondrial inner membrane potential 
(AT^), and the subsequent disruption of electron transport and energy metabolism. 
Additionally the holochrome c form of cyt c, apoptosis-inducing factor (AIF), reactive 
oxygen species (ROS), and pro-caspase-3 are released from mitochondria.
Opening of PT pores and loss of A Y ^ is detectable at an early stage of apoptosis before 
cells exhibit the classic gel electrophoretic DNA fragmentation patterns and 
phosphatidylserine residues are aberrantly expressed on the outer leaflet of the cell 
membrane. Opening of the PT pores allows molecules of < 1.5 kDa to pass into the 
mitochondrial matrix, e.g. protons, calcium, glutathione etc. The resulting hyper 
osmolality causes a volume disregulation which results in the rupture of the membrane 
and release of molecules including cyt c, AIF, procaspase-3, and Ca^L into the cytosol. 
Cells with a low A\|/^ rapidly proceed to DNA fragmentation even after the apoptosis- 
inducing stimulus is withdrawn, suggesting that loss of A^m is irreversible and constitutes 
a point of no return in the apoptotic process (Bernardi, 1996; Castedo, 1996; Green, 1998; 
Mancini, 1998; Zamzami, 1995(1 & 2); Zoratti, 1995).
Both procaspase-3 and the ~50 kDa protein AIF are mediators of apoptosis, the latter 
causing isolated nuclei to display characteristics of apoptosis such as chromatin 
condensation and DNA fragmentation in a cell free system. AIF appears to be stored in 
mitochondria and Bcl-2 inhibits its release in association with maintenance of Avy^, but is 
unable to offset its apoptotic effect once released from mitochondria. AIF and 
procaspase-3 appear to be associated, with the former causing the zVAD-fmk-inhibitable 
proteolytic activation of the latter, suggesting that AIF is, or acts through, a protease.
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Interestingly Bcl-2 does not inhibit apoptosis induced by interleukin converting enzyme 
(ICE), but in this case apoptosis is induced through the activation of caspase-3, rather 
than caspase-8 o r -9 (Susin, 1996, 1997).
Inhibitors of PT, including cyclosporins and bongkrekic acid, appear to block apoptosis in 
a number of experimental systems, providing support for the Idea that the permeability 
transition in mitochondria is pivotal to the apoptotic process. Bcl-2 can prevent the PT, 
whilst Bax and the adenine nucleotide transporter (a component of the PT pore) activator, 
atracytloside, induce both PT and apoptosis. Additionally, transfection-induced 
hyperexpression of Bcl-2 inhibits both the normal Av|/^ reduction and apoptosis caused 
by DNA damage, glucorcorticoids and ceramide (although not by anti-CD3-induced Ar|;^ 
and apoptosis). This would appear to support the view that PT is a sine qua non for 
apoptosis and that it is at this juncture in the apoptotic pathway that the Bcl-2 family of 
proteins exert their influence. However, the evidence is not entirely unanimous and one 
study which induced apoptosis in CEM and HeLa cells using uv irradiation and 
staurosporine, found that the reduction in Ay/^ occurred considerably later than cyt c 
release and caspase activation. Furthermore, a reduction in A i|;^ was not apparently 
necessary for DNA fragmentation (Bossy-Wetzel, 1998; Xiang, 1996; Zamzami, 1995(1 & 
2), 1996(1 &2)).
Other stimuli that act directly on the PT pore, such as oxidants and pathological levels of 
cytosolic Ca2+, can Induce a rupture of mitochondria and release of caspase-activating 
proteins and alternative major initiators of the execution phase of apoptosis that have 
been suggested, including disruption of energy metabolism and export of superoxide 
anion (Og"). However, given that a fall In adenosine triphosphate (ATP) production is 
often seen late in the apoptotic process and that ATP appears to be a cofactor in the 
execution phase, disruption of electron transport and energy metabolism seems more 
likely to be an effect of the phenomenon rather than the cause. Similarly, given that some 
proapoptotic stimuli function in the absence or virtual absence of oxygen, production of 
superoxides may also be a consequence of the phenomenon rather than a sine qua non 
of apoptosis (Bossy-Wetzel. 1998; Bredesen, 1995; Eguchi, 1997; Green, 1998; 
Jacobson, 1995; Liu, X., 1996; Shimizu, 1995; Susin, 1996, 1997).
Once the apoptotic process has been initiated, members of the Bcl-2 family of proteins 
function as regulators, but it remains unclear If pro-survival Bcl-2 and Bcl-X[_ prevent 
apoptosis by inhibiting Ced-4-like molecules from activating the caspases, or if they 
operate by maintaining organelle integrity, particularly that of mitochondria.
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BcI-Xl can bind to Ced-4 and the Ced-4-like portion of its mammalian counterpart, Apaf-1. 
This interaction, which is illustrated in Figure 10, has been suggested to inhibit a further 
interaction between Apaf-1 and procaspase-9, leading to the letter's activation and the 
caspase cascade that effects the apoptotic dismantling of the cell. However, Bcl-2, which 
is located to the outer mitochondrial membrane by its transmembrane domain and has a 
potential pore-forming structure, prevents the release of cyt c, which appears to be an 
effector of the terminal stage of apoptosis in certain cell types. Cyt c also appears to be 
important in combination with deoxyadenosine triphosphate in facilitating the 
conformational change in Apaf-1 that allows it to activate procaspase-9. To confuse the 
issue further, Bcl-2 is apparently able to continue exerting its anti-apoptotic influence even 
after significant amounts of cyt c have been released, and the inability of cyt c to induce 
apoptosis in certain cell types in certain circumstances inevitably poses questions about 
the mechanism(s) by which Bcl-2-like proteins inhibit apoptosis. However, it is particularly 
interesting to note that the initiation of apoptosis through CD95 seems able to bypass the 
step controlled by Bcl-2-like proteins. Bcl-2's apparent inability to inhibit CD95-induced 
apoptosis may be explained by the fact that in lymphoid cells at least, CD95 initiates 
apoptosis through a pathway that activates caspase-8 rather than caspase-9 (Adams, 
1998; Ashkenazi, 1998; Green, 1998; Kroemer, 1997; Ii, P. 1997; Thornberry, 1998; 
Zamzami, 1998; Zou, 1997).
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Figure 10. Proposed model of regulation of Apaf-1 by Bcl-2 family proteins Reprinted, by
permission, from J M Adams & S. Cory, The Bcl-2 Family: Arbiters of Cell Survival, Science 281-1324 Figure 
4 (right) ©  The American Association for the Advancement of Science 1998
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4.4 The Permeability Transition Pore.
In regulating apoptosis, Bcl-2's association with the mitochondrial membrane where it is in 
contact with the inner membrane (Zamzami, 1998), and the protein's pore-forming 
potential cannot be overlooked. In both B- and T-cell subsets, the expression of Bcl-2 
correlates stoichiometrically with the peripheral benzodiazipine receptor (PBR). The 
location of the PBR in the outer mitochondrial membrane and its putative roie, along with 
other moiecuies such as porin, the adenine nucleotide transporter and the 
voltage-dependent anion channel, in forming the PT pore, suggests that Bcl-2 may 
associate with the PBR or an PBR-associated protein. Singie-channel measurements of 
excised mitochondrial patches and reconstituted purified ADP/ATP carrier (AAC), have 
suggested that when converted into a large unselective channel, the AAC is a key 
component of the PT pore. This channel is low cation selective, is pH sensitive, ciosing 
compietely at pH 5.2, and its conductance has muitipie subieveis varying from 300-600 pS 
(Brustovetsky, 1996; Carayon, 1996; Green, 1998). A number of studies suggest that 
Bcl-X[_, Bci-2 and Bax are capable of forming pores in lipid vesicles and planar lipid 
biiayers in experimental conditions, supporting the view that these proteins may function 
by forming/inhibiting pore formation in the intracellular membranes, particularly the 
mitochondrial membrane.
The ability of Bci-X[_ lacking a TM domain (ATM) to form pores in KCI-ioaded synthetic lipid 
vesicles is dependent upon vesicles consisting of at least 10% negatively charged lipids, 
implying that the ability of Bcl-Xi_ATM to permeabilise the vesicles relies on electrostatic 
interactions between it and membrane lipids. Channels formed by 
BcI-XlATM in planar lipid biiayers are pH-sensitive and formed at pHs as low as 4.0.
These channels display multiple discrete conductance states ranging from 80 - 301 pS 
depending on the electrolyte, or mixtures of electrolytes used. The predominant 
conductance state of 276 pS is induced by pH 7.2, with a 150:15 mM cis:trans KCi 
gradient with BcI-XlATM added to the cis side. The channels exhibited identical ion 
selectivity, but become cation-selective at physiological pH when the ion selectivity is K"*" = 
Na+ > Ca2+ > Cl" (Minn, 1997).
Bcl-2 ATM, as might be expected from the structural similarities between it and Bci-X|_, also 
forms conductance channels in lipid vesicles and planar lipid biiayers, having a similar 
requirement for acidic lipid membranes and low pH. The most frequent conductance 
observed using efflux of K"*" or Cl" was 18+2 pS in 0.5 M KCi at pH 7.4.
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On the basis of synthetic amphipathic helices that assemble into tetrameric four-helix 
bundles in membranes and create a channel with a conductance of -2 0  pS, this may 
result from a four-helix channel formed by a Bcl-2 dimer. Larger individual channel 
conductances of -40  pS and -90  pS were detected with progressively lesser frequency, 
suggesting that channels of progressively higher conductances may be formed by Bcl-2 
oligomers of progressively higher numbers of Bcl-2 monomers. The essential nature of 
Bcl-2's hydrophobic a-helices 5-6 for channel formation was confirmed by a Bcl-2ATM 
mutant lacking them, which failed to form conductance channels (Schendel, 1997).
Although both BaxATM and Bcl-2ATM can induce dye efflux from carboxy- 
fiuorescein-ioaded liposomes, they do not have the same effect on cellular integrity, and in 
contrast to Bci-2 ATM, Bax induces lysis in sympathetic neurons and sheep erythrocytes at 
concentrations between 5-10 pM at pH 7.4. This may be caused by conductance channel 
formation in the cells' membranes as indicated by these protein's release of dye from 
carboxyfiuorescein-loaded liposomes, with the different effects explained by the two 
proteins pH operating ranges. At pH 7.0, Bax ATM induces the release of carboxy- 
fluorescein from liposomes in a concentration-dependent manner with maximal effect at 
120 nM. In contrast Bcl-2 failed to trigger carboxyfiuorescein efflux in identical conditions 
at concentrations up to 360 nM. In common with Bcl-x^, release of carboxyfiuorescein 
triggered by Bax is pH-dependent and 8 times greater at pH 4.0 than at pH 7.5. Although 
Bcl-2 was as efficient at initiating carboxyfiuorescein release as Bax at pH 4.0, its 
optimum pH range is different, with its channel-forming properties diminished at pH 5.0 
and absent at pH 6.0. In keeping with its effect in protecting cells from apoptosis, 
Bcl-2ATM antagonises BaxATM-induced release of carboxyfiuorescein from liposomes at 
physiological pH. At a Bax:Bcl-2 ratio of 1:1 the efflux was reduced by 50% and at 1:10 
almost completely inhibited, in contrast to the effect of Bax alone. Conductance channels 
formed in planar lipid biiayers by BaxATM are both voltage- and pH-dependent, with 
conductances at pH 7.0 ranging from 5.6+0.2 pS to 2 nS, but with conductances of 26 pS, 
80 pS, 180 pS also detected. The progression to conductances of 2 nS was in multiples 
of -450 pS and was particularly evident with the passage of time and at higher voltages.
At pH 4.0 the Bax channel-forming activity was characterised by shorter-lived 
conductances about threefold lower than at pH 7.0 (Antonsson, 1997).
Comparison of the ion channel characteristics of Bax and Bci-2 using KCI-ioaded lipid 
vesicles, insertion of Bcl-2 and Bax into planar lipid biiayers, and the fusion of Bax- and 
Bcl-2-containing vesicles with planar lipid biiayers produced results both confirming and 
extending similar studies.
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As in the study by Antonsson, both BaxATM and Bci-2ATM were found to release ions 
from liposomes in a pH-dependent manner, but with Bax functioning within a broader pH 
spectrum than Bci-2. This phenomenon may be explained by the higher Bax a5-helix pi 
of 10.64, in comparison to 4.55 for the equivalent Bci-2 helix. Like Bcl-x^, channels 
formed by Bcl-2 exhibited a mild cation selectivity in contrast to Bax which displayed a 
constant anion selectivity. In planar lipid biiayers at low pH, the initial conductances 
detected for Bax- and Bcl-2-formed channels were 22 and 80 pS respectively. At pH 4.0 
the Bax channel progressed from the initial small Ci"-seiective channel with a 
conductance of 22 pS, through a transition phase with multiple conductance levels and 
moderate CL-seiectivity, and finally to an apparently stable channel of 0.731 nS that is 
continuously open and only mildly CI"-selective. In contrast, at pH 4.0 the Bcl-2-formed 
pore was K"*"-selective and progressed from a small channel with a conductance of -80 
pS that opened and closed spontaneously, to a large open stable pore with a conductance 
of -1.90 nS. Of note and difficult to reconcile with the observations by Antonsson et. al., 
shifting the pH from 4.0 to 7.0 in planar lipid biiayers alters the conductance and selectivity 
of Bax, but leaves Bcl-2 channels virtually unchanged (Schlesinger, 1997).
Whilst the conditions in vesicles and planar lipid biiayers may bear very little similarity to 
the conditions prevailing in the mitochondrial membranes at the contact sites between the 
inner and outer membranes where Bcl-2-family proteins are known to insert, the ability of 
Bci-2, Bc!-Xi_, and Bax to form conductance channels in these synthetic membranes offers 
the opportunity of speculating about the manner in which the Bci-2 family may adjust the 
apoptotic threshold of the ceil. In this respect it is particularly noteworthy that the ability of 
Bcl-2, BcI-Xl , and Bax to form conductance channels in synthetic membranes is linked to 
pH and voltage, that the channels they form are of different and varying conductance 
states, that they display a degree of ion-selectivity, that the a-helices 5 and 6 in Bcl-2 (and 
by inference their equivalents in the other family members that possess them) are 
particular important to pore forming function, that there is some suggestion of 
conductance being linked to oligomerisation of these proteins, and that Bci-2 appears to 
be capable of inhibiting the channel-forming activity of Bax in lipid vesicles.
4.5 Apoptosis execution.
Caspases are the protease executioners of apoptosis in the largely common degradation 
phase and are synthesised as precursors with little, if any. catalytic activity.
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They are usually converted to the active enzyme by autocatalysis or by another protease, 
e.g. caspase-9. Their specificity is conferred by an absolute requirement for cleavage 
after aspartic acid and recognition of at least four amino acids NHg-terminai to the 
cleavage site, which vary from caspase to caspase. Caspases function by cutting off the 
cell's contacts with adjacent cells, disassembling ceil structures, inactivating inhibitors of 
apoptosis, cleaving proteins involved in cytoskeleton regulation, inactivating or 
deregulating proteins involved in the repair and replication of DNA, destroying DNA, 
disrupting the nuclear structure, prompting the cell to display signals that single it out for 
phagocytosis, and causing the ceil to disintegrate into apoptotic bodies (Thornberry,
1998).
The three caspases which appear to initiate the execution phase of apoptosis are 
caspase-3, -8 and -9, but caspases-2 and -10 may have both initiator and effector 
potential. Caspase-3, -6, and -7 are activated by caspase-9 and involved in the down­
stream cascade which effects apoptosis. Caspase-9 has been shown to be involved in 
initiating the caspase cascade in cells treated with cytotoxic agents, whilst caspase-8 is 
particularly associated with CD95-induced apoptosis and activation may involve 
recruitment to the CD95(Fas) receptor complex. In contrast to the requirement of the 
apoptosome, consisting of Apaf-1, cyt c and deoxyadenosine triphosphate, for caspase-9 
activation, which was described in an earlier paragraph, activation of procaspase-8 
requires association with its cofactor FADD (Fas-associated protein with death domain 
aka M0RT1) via its death effector domain (Boldin, 1996; Deveraux, 1998; Muzio, 1996; 
Thornberry, 1998)
The targets for caspases include Bcl-2 which is cleaved at Asp34 by caspase-3 in in vitro 
apoptosis induced by CD95 ligation and IL-3 withdrawal. The carboxyl-terminal Bcl-2 
cleavage product Is itself apoptosis-inducing and accelerates Sindbis-virus-induced 
apoptosis. A similar mechanism is found in C. eiegans, where the Ced-3 caspase 
cleaves the C. elegans equivalent of Bci-2, Ced-9, at two separate sites, one of which is 
important to Ced-9's anti-apoptotic function (Cheng, 1997b; Xue, 1997). Other targets for 
caspases include the nuclear lamina which is involved in chromatin organisation and 
which consist of head-to-tail polymers of lamins. During apoptosis, these are cleaved at a 
single site, causing them to collapse and contributing to chromatin condensation (Orth, 
1996; Takahashi, 1996).
Proteins involved in cytoskeleton regulation are also targets for apoptotic caspases and 
include gelsolin, focal adhesion kinase and p21-activated kinase 2.
33
Gelsolin, a protein that severs actin filaments in a regulated manner, is changed to a 
constitutively active state by caspase cleavage. Focal adhesion kinase is Involved In the 
suppression of apoptosis In diverse cells types and is activated by interactions between 
integrins and the extracellular matrix. However, focal adhesion kinase appears to be 
cleaved early in apoptosis and may contribute to the cell's apoptotic disintegration. 
Similarly the caspase-mediated proteolytic cleavage of p21-activated kinase 2, generating 
a constitutively active protein fragment, may contribute to membrane and morphological 
changes observed in apoptotic Jurkat T-cells (Kothakota, 1997; Rudel, 1997; Wen, 1997).
Additionally, caspases attack the viability of the cell by inactivating proteins Involved in 
maintaining the integrity of DNA/RNA such as DNA-PK^g which is involved In DNA repair, 
U1-70K, which is involved in mRNA splicing, and replication factor C, which is involved in 
DNA replication. Precisely how these fit into the larger apoptotic picture is not yet 
understood, but clearly anything which makes a cell less able to resist the apoptotic 
process serves a purpose in these circumstances (Gryns, 1998; Rheaume, 1997).
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Figure 11. A generalised view of the apoptotic process.
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5 The bcl-2  family of genes/proteins.
5.1 Introduction.
bci-2 (B-cell lymphoma/leukaemia 2), the founding member of the bci-2 family of 
genes/proteins, is a proto-oncogene which was first identified in 1984 in follicular 
lymphoma cells using a probe obtained from an acute B-cell leukaemia cell line. The 
bci-2 gene is normally located at band q21.3 of chromosome 18, but a high proportion of 
cases of follicular lymphoma show a t(14;18)(q32;q21) translocation which juxtaposes the 
intact bcl-2 gene with an enhancer region in the Ig heavy chain locus on chromosome 14, 
leading to the constitutive expression of the protein (Bakshi, 1985; Cleary, 1985;
Pegoraro, 1984; Tsujimoto, 1984, 1985). The t(14;18) translocation is generally reported 
as being present in only -10%  of B-CLL cases examined using Southern blotting analysis 
(Merup, 1996; Schena, 1992), but more recent research using the fluorescence in situ 
hybridisation (FISH) technique, which does not rely on the production of metaphases, has 
suggested that the percentage of translocations may be higher than reported, as it 
appears to detect them in B-CLL cells where Southern blotting does not (Amiel, 1994; 
Lishner, 1995).
The human bcl-2 gene at 18q21.3 is an extremely large one due to a 225 kb intron and 
contains three exons (Cory, 1995; Silverman, 1990). Termination within the large intron 
results in an alternative transcript for jbc/-2p, which is identical to the predominant form, 
bcl-2a, except at the carboxy terminus. The predominant form, normally referred to 
without the suffix as bcl-2, encodes a protein of 239 amino acids with a molecular weight 
of 26 kDa (Tsujimoto, 1986). This has been extensively implicated in the suppression of 
apoptosis in B-CLL over the past 10^ years, although it is increasingly clear that 
apoptosis-resistance is not as simply related to cellular concentrations of Bci-2 as 
suggested by earlier in vitro studies (Panayiotidis, 1993, 1994) and that Bax may play a 
pivotal role along with other family members such as Mcl-1 (Kitada, 1998; Pepper, 1996, 
1998; Thomas, 1996).
X-ray and NMR analysis of the structure of Bci-X|_suggests that Bci-X|_ and Bci-2 in 
particular are composed of two central, primarily hydrophobic a-helices, surrounded by 5 
amphipathic a-heiices as illustrated in Figures 12 & 13. The arrangement of the a-helices 
is reminiscent of the membrane translocation domain of bacterial toxins such as 
diphtheria toxin and the colicins.
.'ÿ:
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Amino Acid Structure of Bcl-2 and BcI-Xl Showing Homology & a-Helix Structure
4 BH4 24
<    >
aaaaaa-al-aaaaaaBc 1-Xl 1 MS------ QSNRELWDFLSYKLSQKGYSWSQFSDVEEN 33Bcl-2 1 MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAP 39
Bc1-Xl 34 RTE^EGTESEMETPSAINGNPSWHLADSPAVNGATGHS 7 2Bcl-2 4 0 PGA^APGIFSSQPGHTPHPAASRDPVARTSPLQTPAAP 7 8
86 BH3 100
<-    >
aaaaaa-a2-aaaaa aaa-aS-aaBcl-x^ 7 3 SSL DAREVIP-MAAVKQALREAGDE FE LRYRRAFSDLT SQL 112Bcl-2 7 9 GAAAGPALS PV P PWHLTLRQAGDDFS RRYRRDFAEMS SQL 119
129 BHl 148
< >
aaaaa-a4-aaaa aaaaaaaa-a5-aaaaaaaa Bcl-x^ 113 HITPGTAYQSFEQWNELFRDGVISIWGRIVAFFSFGGALCVESVDK 157Bcl-2 120 HLTP FTARG RFAT WEELFRDGVNWGRIVAFFEFGGVMCVE SVNR 164
180 BH2 195
<-------------------------------»
aaaaaaaa6aaaaaaa aa6a aaaa7aaa Bcl-x^ 158 EMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNN 198Bcl-2 165 EMSPLVDNIALWMTEYLRRHLHTWIQDNGGWDAFVELYGPS 205
transmembrane domain
Bc1-Xl 199 AAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK 233
Bcl-2 206 MRPLFDFSWLSLKTLLSLAL-VGACITLGAYLGHK 239
Figure 12. Illustration of the homology between BcI-Xl and Bcl-2 relative to the Bcl-2 
homology domains, transmembrane domain and a-helices (Muchmore, 1996), who consider 
L, 1, F, V, M, and Y to be similar. N, D, K, R, Q, E, and H to be similar, with G, A, P, T, S, C,
and W having no equivalents, ana Indicates numbered Bcl-X|_ a-helices, <------- > indicates the
labelled Bcl-2 homology domain where the numbers refer to Bcl-x^ amino acid residues. 
Identical or similar amino acid residues are emboldened and underlined.
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If function follows form then Bcl-X^and Bcl-2 may act through pore forming/inhibiting 
activity and their location in the outer membrane of mitochondria, at the point where the 
outer and inner membranes are in contact, is certainly in keeping with such a theory (de 
Jong, 1994; Krajewski, 1993; Muchmore, 1996; Parker, 1993; Reed, 1997).
There appears to be no universal acceptance of what constitutes a member of the bcl-2 
family of genes/proteins. In the classic sense the family is defined by sequence homology 
in the bcl-2 homology region 1 (BHl) and BH2 domains (Boyd, 1995), but some groups 
define the Bcl-2 family by a requirement for 30% homology in the BH domains (Akahani,
1997). However, as the two further bcl-2 homology regions, BH3 and BH4, were 
discovered, the term bcl-2 family has been widened to apply to those genes/proteins 
which show sequence homology in the BHl, BH2, BH3, or BH4 regions and in the Bcl-2 
COOH-terminus membrane-spanning signal-anchor sequence. It is this latter wider 
definition that I have adopted. The locations of the Bcl-2 homology domains (Reed, 1997) 
are illustrated in Figure 13 and in Figures 14 & 15 following the descriptions of individual 
members. The bcl-2 homology domains have previously been referred to as BDs {bcl-2 
domains) or S homology regions, where BDA and SI refer to BH4 (aka A-box), BOB or 
82 refer to BHl and BDC or S3 refer to BH2 (Cory, 1995; Hanada, 1995; Wang, H-G. 
1996).
1 10 30 93 107 136 165 187 202 219 237 239
BH4 Loop BH3 BHl BH2 TM
a2 a3 a4 a5 a6 a7
Receptor domain
P m -IpBBWl
Figure 13. The structure of the human Bcl-2 protein. Adapted by permission from j.c. Reed, 
Double identity for proteins of the Bcl-2 family. Nature 387 -  775, © MacMillan Magazines 
Ltd. 1997.
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The bcl-2 family of genes is a highly conserved one as indicated by the range of 
organisms in which they are found and the degree of homoiogy between species. The 
Bcl-2 family of proteins consist of two subgroups, one of which is Involved in promoting 
cell survival and the other in promoting cell death. In the all-encompassing sense 
described above, the celi survival-promoting members include Bcl-2, BcI-Xl, BcI-w, Ced-9, 
Bhrf-1, Bfl-1, Grs, Al, Mc!-1, Brag-1, Orf16, Ksbcl-2, Gal-3, %b1, %bd1, and Nr-13. The 
cell-death promoting members include Bcl-Xg, Bok, Bad, Bak, Bax, Bik/Nbk, Bim^L., Hrk, 
Bar, and Bid. The homology of the Bcl-2 family is illustrated in Figures 14 and 15, 
following a brief description of the individual family members.
5.2 Bcl-2 family members.
The human form of Bcl-x was originally isolated using avian Bcl-x which had been 
isolated from chicken lymphoid cells using a murine bcl-2 cDNA probe. The bcl-x gene is 
situated on chromosome 20 (Gibson, 1996) and contains an open reading frame (ORF) 
encoding a protein of 233 amino acid residues. This Is designated Bcl-XL(large), has 
B H l-4 and transmembrane (TM) domains similar to Bcl-2, and a similar anti-apoptotic 
function. Alternative splicing gives rise to the apoptosis-inducing Bcl-Xg (small). This 170 
amino acid protein differs from Bcl-X|^by not possessing the 63 Bcl-X|_amlno acids from 
133-195 inclusive. BcI-Xq does not contain the Bcl-2 region of highest homology, 
containing BH l and BH2, but does contain BH3, BH4 and the TM region (Muchmore, 
1996). Bcl-Xg, unlike Bcl-X|_, is apoptosis-inducing. The highest levels of Bcl-x are found 
In the lymphoid and central nervous systems (Boise, 1993).
Bcl-w is a family member with particular sequence homology to Bcl-2 and Bcl-X|_, which 
has been isolated from both human and murine tissue and similarly can protect cells from 
apoptosis-inducing IL-3 withdrawal, y-irradiation and dexamethasone, but not from ligation 
of CD95 (APO-1/Fas) with MoAb. The locus of bcl-w  is in the central region of mouse 
chromosome 14 and at 14q11.2 In humans. It encodes a protein of 193 amino add 
residues with a molecular mass of -22  kDa. The protein shows clear sequence homology 
in all four domains and possesses a C-terminus TM domain. The authors have noted 
conserved sequences in the TM domain of Bcl-w, which has a similar cytoplasmic 
distribution to Bcl-2, and suggested that these may associate with a specific protein in the 
membranes in which they are found (Gibson, 1996).
ced-9 (cell death defective-9) is a nematode gene that was first isolated in C. elegans and 
maps to a bicistronic locus on the right arm of chromosome III.
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It was isolated as both a bicistronic 2.1 kb and a 1.3 kb ced-9 mRNA, the bicistronic 
mRNA aiso encoding the cyt-1 message which produces a protein similar to the 
cytochrome bggq of complex II of the mitochondrial respiratory chain. Ced-9 consists of 
280 amino acid residues with a predicted molecular weight of 32 kDa. Ced-9 is 
homologous to Bcl-2 with which it shows 23% sequence homology. It possesses a 
hydrophobic TM domain, but shows less homology in BH3 than in BH1, BH2 and BH4. 
Over expression of Ced-9 prevents the cell deaths that occur by apoptosis in C. elegans 
during normal development, a phenomenon that can also be produced by substituting 
Bcl-2 overexpression {Hengartner, 1994).
mcl-1 is an early induction gene that was isolated from the human ML-1 myeloid 
leukaemia cell line and which parallels the action of Bcl-2 in promoting cell viability. The 
isolated clones encoded a 350 amino acid residue protein with a predicted molecular 
mass of 37.3 kDa. Mcl-1 shows considerable sequence homology to other members of 
the family in all four BH domains pius a C-terminus TM domain {Kozopas, 1993; 
Muchmore, 1996).
a1 is an early-response gene that is transiently and rapidly induced in mouse BM by 
GM-CSF and lipopolysaccharide (IPS). A l expression is apparently limited to 
haematopoietic cells including T^-lymphocytes, macrophages and neutrophils, but was 
not found in the B-lymphoid, erythroid or nonhaematopoietic cell lines examined. The 
cloned gene of 729 bp with a terminal polyA sequence has an ORF that encodes a 
potential protein of 172 amino acid residues with an expected M  ^of 20,024 kDa. There is 
considerable sequence homology in domains B H l-3, but no obvious C-termina! TM 
domain (Cory, 1995; Lin, E. Y. 1993).
Bhrf-1, a viral homologue of Bcl-2, is a component of the restricted early antigen complex 
of the EBV lytic cycle. The bhrf-1 ORF is 675 bp in length and encodes a protein of 191 
amino acid residues with a molecular mass of 17 kDa. The main sequence homology 
between Bhrf-1 and other family members is in the BH1 and BH2 regions and like others 
possessing these conserved sequences, the protein confers anti-apoptotic properties on 
cells in which it is expressed. Bhrf-1 also possesses the C-terminal TM domain, but the 
cellular distribution of the protein varies from that of Bcl-2. Although a significant 
proportion localises to mitochondria with weaker staining of the endoplasmic reticulum 
(ER), strong staining is also observed in the perinuclear region of the celi (Khanim, 1997).
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orf16  (open reading frame 16) is a functional homologue of the bcl-2 gene encoded by 
the Herpesvirus Saimiri, whose expression inhibits apoptosis. orf16 encodes a protein of 
160 amino acid residues which shares sequence homology with bcl-2 family members in 
BH l and BH2, displays poor conservation in BH3, but possesses a COOH-terminus TM 
domain. Overall amino acid sequence identity varies between 17-26% with other family 
members (Nava, 1997).
ksbcl-2  (Kaposi sarcoma bcl-2) is a gene encoded by the Kaposi sarcoma-associated 
Herpesvirus aka human Herpesvirus 6 . The gene encodes a protein of 174 amino acid 
residues which is a homologue of Bcl-2, shows significant homology only in the BH1 and 
BH2 domains, and possesses a COOH-terminal TM domain. When transfected into cells 
Ksbcl-2 inhibits cell death at concentrations similar to Bcl-2 and Bcl-X[_, but shows greater 
amino acid identity to Bhrf-1 (19%) and Orf16 (20%), than to Bci-2 (16%) or Bcl-xJ17%) 
(Cheng, 1997a).
brag-1 (brain-related apoptosis gene) is a family member that was isolated from a human 
glioma. The gene is expressed as a 4.5 kb transcript in normal human brain tissue, but is 
expressed as a 1 . 8  kb message in the glioma suggesting it may have been rearranged. 
The 1. 8  kb message carries an ORF of 861 bp potentially encoding a protein of 286 
amino acid residues with a predicted molecular mass of 31 kDa. The protein shares 
significant sequence homology in BHl and BH2 and reacts with a Bcl-2 monoclonal 
antibody (MoAb) (Das, 1996).
bfl-1 {bcl-2 related gene expressed in foetal liver) was isolated from human foetal liver ( 2 2  
weeks gestation). It displays a particular degree of homology to A l and Grs in the B H l-2 
domains and to a lesser degree in BH3 and BH4. The cDNA includes an open reading 
frame encoding a protein of 175 amino acid residues with an M  ^of -20,000. Although the 
COOH-terminus TM domain contains 3 charged residues in addition to the hydrophobic 
residues, Bfl-1 appears to localise to subcellular membrane components with a 
distribution similar to Bcl-2. Bfl-1 appears to be highly expressed in bone marrow, in the 
Raji and HL60 haematopoietic cell lines, and expression was found to be dramatically 
increased in the metastatic and tumourous tissue of six patients with stomach cancer 
(Choi, 1995; D'Sa-Eipper, 1996).
grs  (Glasgow rearranged sequence) was first identified as a result of its rearrangement 
with the fibroblast growth factor 4 gene in a case of chronic myeloid leukaemia, but a 
cDNA clone was subsequently isolated from a human T-ceil library.
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The grs gene is located at 15q24-25 adjacent to the t(15;17) region of the translocation 
associated with acute promyelocytic leukaemia. The full-length cDNA contains a 528 bp 
coding region (103-630) encoding a 175 amino acid residue protein. Both the gene and 
the protein show a close similarity to a1 and bfl-1. grs shows a 77% nucleotide sequence 
identity to the murine haematopoietic-specific a l  and approximately 71% amino acid 
sequence identity to A l,  suggesting, particularly as grs appears to be selectively 
expressed in adults in haematopoietic tissues, that it may be the human equivalent of a l  
The amino acid residue sequence of Bfl-1 and Grs differ only at amino acids nos. 72 and 
107, suggesting that they may be the same protein (Kenny, 1997)
galectin-3  (a p-galactoside-binding protein) is a member of the family of 
p-Galactoside-binding lectins that is upregulated in proliferating cells and which also 
appears to be a member of the bcl-2 family of genes. The gene encodes an anti- 
apoptotic protein of 249 amino acid residues with a molecular mass of 31 kDa. The 
protein shows homology in BH l including the NWGR motif and possesses a COOH- 
terminal carbohydrate-binding domain. Galectin-3 shares 28% identity and 48% similarity 
in protein sequence with Bcl-2, in comparison to Bhrf-1 which, respectively, demonstrates 
only 24% and 41%. Galectin-3 has been implicated in neck, thyroid, gastric and coion 
cancer (Akahani, 1997; Barondes, 1994; Yang, 1996.)
%rl and are bcl-2 family members that were isolated from a Xenopus laevis stage 28- 
30 embryonic head library, respectively as 2.0 and 1.1 kb cDNA clones, and comparison 
of the predicted amino acid residue sequences showed significant sequence homology in 
the B H l, BH2 and COOH-terminus TM domains. Despite widespread expression of xd  
mRNA, its failure to translate In vitro casts doubt on its apoptosis-associated role, but the 
x rll ORF encodes a 204 amino acid residue protein of -22.5 kDa and rat fibroblasts 
transfected with sense cDNA demonstrated significant resistance to apoptosis induced by 
staurosporine, cycloheximide, serum deprivation and deregulation of c-myc expression 
(Cruz-Reyes, 1995).
nr-13 (neurotina-13) is an member of the bcl-2 family which is activated in avian (quail 
embryo) cells transformed by the Rous sarcoma virus. The nr-13 gene carries an ORF of 
531 bp encoding a protein of 177 amino acid residues with an estimated molecular mass 
of 18-19 kDa. This protein shares significant sequence homology with the Bcl-2 family in 
the BHl and BH2 domains and is thought to have an apoptosis-inhibiting effect on cells 
expressing it.
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Unlike other members of the Bcl-2 family. Nr-13 localises to the plasma membrane where 
the hydrophobic region from residues 159-177 may constitute a membrane-spanning 
domain and serve as a signal-anchor sequence. Nr-13 and chicken Bci-2 share 25% 
identity and 47% conservation in the amino acid residue sequence, in comparison to 
Nr-13 and Bax, where the respective figures are 28% and 54% (Gillet, 1995).
bak  {Bci-2-homoiogous antagonist/killer) is a primarily pro-apoptotic gene that was found 
to be present in significant quantities as a 2.4 kb mRNA transcript in a wide range of 
human tissues. The ORF encodes a protein of 211 amino acids and a of 23,400. The 
protein possesses a COOH-terminus TM domain and shows sequence homology in all 
four BH domains, especially in BHl and BH2 where it shares 53% sequence identity with 
Bcl-2. The bak gene spans 6  kb, contains at least three exons and is located on 
chromosome 6 . Copies of the gene also exist on chromosome 20 without introns and on 
chromosome 11 as a processed pseudogene (Kiefer. 1995).
bik/nbk  (Bcl-2 interacting killer) is a pro-apoptotic gene that was isolated from a human 
B-cell library as a 956 bp cDNA and is expressed in adult tissues and established cell 
lines as a 1 kb mRNA. The gene encodes a 160 amino acid protein with a caiculated 
molecular mass of 18 kDa, but in vitro translated Bik migrates at 26 kDa. Bik contains a 
COOH-terminus TM domain and shows clear sequence homology to other members of 
the family in BH3. The protein is localised around the nuclear envelope and cytoplasmic 
membrane structures with a similar distribution to Bcl-2, adenovirus E1b 19 kDa, Bhrf-1, 
and Nip1-3. It forms complexes with Bcl-2, Bcl-X|_, Bhrf-1, and adenovirus E lb  19 kDa 
(Boyd, 1995; Elangovan, 1997).
Bax (Bcl-2-associated X protein) was first identified in coimmunoprecipitation experiments 
using the human B-cell line RL-7, when it precipitated as a 21 kDa entity. Subsequent 
cloning and sequencing experiments identified an ORF of 576 bp encoding a 192 amino 
acid protein with a predicted molecular mass of 21.4 kDa. bax consists of 6  exons within 
a 4.5 kb region, all of which contribute to the amino acid sequence, but alternative splicing 
can produce a p species of 1.5 kb and 218 amino acids with a molecular mass of 24 kDa, 
or a y species of 1.0 kb, 41 amino acids and 4.5 kDa. The most highly conserved areas 
between Bax and Bcl-2 are in BH1 and BH2 and the protein possesses the COOH- 
terminus TM domain. Bax accelerates cell death and counters the effect of Bcl-2 
(Krajewski, 1994; Oltvai, 1993).
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Bad ()bc/-2-associated death promoter) was identified by screening a mouse embryo day 
14.5 cDNA fusion library. The gene encodes a protein of 204 amino acids with a 
predicted molecular mass of 22.1 kDa. It displays limited homology in the BH1 and BH2 
domains with other family members, but lacks a C-terminal TM domain. Bad selectively 
dimerises with Bcl-X|_ and Bcl-2, but it binds to Bcl-X|_with greater affinity and, unlike its 
action with Bcl-2, opposes the apoptosis-inhibiting activity of Bcl-xJYang, 1995).
bok (bcl-2- related ovarian killer) is a pro-apoptotic gene isolated initially from a rat 
ovarian fusion cDNA library, although high levels of a -1.5 kb transcript were found in the 
ovary, testis, uterus and the granulosa cells of ovarian follicles that undergo apoptosis 
during follicle degeneration. The bok ORF encodes a protein with 213 amino acid 
residues and a predicted molecular mass of 23.5 kDa, which shows extensive sequence 
homoiogy to other bc/-2 family members in the B H l-3 domains, possesses a COOH- 
terminus TM domain, but lacks the BH4 domain. In its homology it is particularly similar to 
Bax and Bak (Hsu, 1997).
bim  was originally identified from a murine T-lymphoma ceil line cDNA library as three 
isoforms designated bim^j_, , and biniQ. These appear to arise through alternative
splicing and encode respectively, proteins of 196, 140 and 110 amino acid residues. The 
human equivalents of bim^^ and bim[_ encode proteins of 198 and 138 amino acid 
residues which are respectively 89 and 85 % identical to their murine counterparts. The 
human and murine forms of Bim have sequence homology in the BH3 region, through 
which they appear to mediate their apoptosis-inducing function, and all possess a 
C-terminus TM domain. The Bim protein localises independently to intracytoplasmic 
membranes similar to the distribution reported for Bcl-2. In its role as an apoptosis- 
inducing protein Bim^ antagonises Bcl-2 more effectively than Bim^, with Bim^^the least 
effective (O'Connor, 1998).
Bid (BH3 interacting domain death agonist) was originally isolated from an expression 
library constructed from the murine T-ceil hybridoma line, 2B4, using both bcl-2 and bax 
probes, and only subsequently from human tissue. Both murine and human genes 
encode 195 amino acid residue proteins with predicted molecular weights of 21.95 kDa, 
which show extensive sequence conservation In the BH3 domain only. The protein also 
lacks the membrane-spanning TM domain. The protein interacts with Bcl-2, Bcl-X|_, and 
Bax and promotes cell death (Wang, K. 1996).
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hrk (hahkiri) is a cell death-inducing gene that was initially identified by screening a HeLa 
cDNA library and a 9-week old human embryo cDNA library. It is expressed as a 0.7 kb 
transcript encoding a 91 amino acid protein in adult human BM, spleen and pancreas.
The Hrk protein shows homoiogy to BH3 only in amino acids 37-44, but a region of 16 
amino acid residues including the BH3 domain is essential for its death-inducing function. 
Hrk has a region of 28 hydrophobic residues at its COOH-terminus that may act as a 
membrane-spanning domain and shows a granular and extranuclear distribution pattern 
consistent with being confined to membranes of intracellular organelles similar to Bcl-2 
and Bcl-X|_ (Inohara, 1997).
Although not a member of the Bcl-2 protein family, Bag-1 (Bcl-2-associated athanogene 
1) is worth inclusion because of its Bci-2 binding capacity and its ability to enhance cell 
survival. The bag-1 cDNA was isolated from a mouse embryo cDNA library and carries a 
630 bp coding region which encodes a 219 amino acid residue protein. Bag-Ts potential 
acidity, arising from multiple glutamic acid residues, may explain its migration at -29-30 
kD ^as opposed to the predicted -24.5 kDA. It has no sequence homology with Bci-2 
family members, but shows as much as 50% amino acid residue sequence identity in one 
region (residues (37-73) with several ubiquitin and ubiquitin-like proteins. 3TS fibroblasts 
and the human lymphoid cell line Jurkat showed increased resistance to induced 
apoptosis when transfected with Bag-1, but Jurkat in particular showed much greater 
resistance when transfected with both Bcl-2 and Bag-1 as opposed to when transfected 
with either of these proteins alone (Takayama, 1995).
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6 Bcl-2 Homology domains.
6.1 Introduction.
Any attempt to show the extent of sequence conservation amongst the members of the 
Bci-2 family of proteins, as illustrated in Figures 14 -15 , inevitably involves a number of 
arbitrary choices, e.g. the number and nature of the family members to be included in the 
calculations, the extent to which sequence conservation in the BH1, BH2, and BH4 
domains of anti-apoptotic members, where they appear to have greater significance, is 
allowed to influence the view of whole family-sequence conservation, the extent to which 
sequence conservation in the BH3 domain of pro-apoptotic family members is similarly 
allowed to influence the view of whole family-homology, and whether the same number of 
relatively rare residues, e.g. C, G, Q, S & Y (for amino acid key please see Figure 14), is 
required at a particular position before sequence conservation is assumed to have been 
preserved, as would be required for more commonly encountered residues, e g. A, E & L.
The purpose of Figures 14 and 15 is to give an accurate impression of sequence 
conservation rather than an absoiute picture and to this end a relatively strict convention 
of amino acid similarity has been applied. However, as the object of the exercise is to 
highlight areas of conservation that may be important, some fiexibility and overlap has 
been allowed. Where it appears that a particular residue is conserved as a charged 
residue, regardless of the type of charge, overlap has been allowed between negative and 
positive groups and the homology is indicated as being "similar". Similarly, where there is 
no clear conservation of a particular residue, but the residues are largely hydrophobic, the 
residues in that position are also shown as being "similar". Where the conserved residue 
is a relatively rarely encountered type, a smaller number of residues would generally be 
taken to indicate conservation, than would be the case for more common residues. No 
weighting is given to the contribution made to the homology of particular BH domains by 
either anti- or pro-apoptotic family members, except for BH4, where conservation is 
determined solely on the basis of the contribution made by anti-apoptotic family members. 
On the basis that its sequence is a duplicate of part of Bcl-x^, any contribution to 
homology from Bcl-Xg is ignored, but its sequence is included for completeness.
The analysis of conserved Bcl-2 sequence homology represented in Figures 14 and 15 
reveals a number of potentially significant features of conservation, which inciude:
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Conservation of sequence in the BH1-3 domains extends beyond the currently defined 
boundaries of these domains, particularly in the case of BH1. Conservation in the region 
of BH1 extends from Bcl-2 residues 130 to 164, conservation in the BH2 region extends 
from 185 to 203 and for BH3 the relevant residues extend from 93 to 109. Conversely 
when BH4 sequence conservation is analysed on the basis of the anti-apoptotic family 
members listed, conservation appears to encompass only the Bcl-2 residues from 12 to 
28.
BHl and BH2 are present and extensively conserved in ail of the anti- and a subset of 
pro-apoptotic family members, but there is a second group of pro-apoptotic family 
members (Bik, Bim^|_, Hrk and Bid) which show no conservation in B H l-2.
BH3 is extensively conserved in both types of family members including those with no 
conservation in B H l-2, and is the only conserved BH domain in some family members.
Ignoring Bcl-Xg on the basis that its sequence is a duplicate of part of the Bcl-x^ 
sequence, BH4 is only significantly conserved in anti-apoptotic family members.
The specific features of sequence conservation which appear to be particularly noteworthy 
include;
• The highly conserved V at Bcl-2 position 133 near BHl shows, on the basis of the 
family members listed, 81% sequence identity and 94% sequence similarity in anti- 
apoptotic proteins.
• Sequence homology near BH1 is especially conserved in the motifs F-DG, 
NWGRhydrophobicV, FG, LC, and the hydrophobic-polar-polar group at Bcl-2 positions 
162-164. These latter two highly conserved polar residues show 83% and 94% 
conservation, respectively.
• The extensively conserved BH2 motifs of W! followed by three positions with an 
exceptionally high number of the relatively rare hydrophilic Q and N residues and 
GGW.
• The conserved F at Bcl-2 position 198 in BH2, appears not to be conserved in pro- 
apoptotic family members.
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• The most highly conserved motif in BH4 is the Q-G motif starting at Bcl-2 position 25.
• The most highly conserved residues in the region of BH3 are the V at Bcl-2 position 
93, LR-AGDE from positions 97-103, RY at positions 107-8, F at position 112, the 
conserved hydrophobic residue at position 115 and the QL motif at positions 118-119,
If function follows form in the Bcl-2 family, then the clearly defined conserved sequence 
homology in the B H l-4 domains of all of the anti-apoptotic members of the Bcl-2 family, 
suggests that these domains play an important part in the apoptosis-inhibiting role of 
these proteins, as do the B H l-3 domains in the pro-apoptotic members. The absence of 
any significant conserved sequence homology in the BH4 domain of the pro-apoptotic 
proteins suggests that its function is restricted to apoptosis-inhibition. However, the 
absence of conservation in the BH1-2 domains of a group of pro-apoptotic Bcl-2 family 
members suggests that either these domains are not required for the pro-apoptotic 
function, or in apoptosis promotion there are at the very least, two variations on a theme.
Studies employing three different treeing methods, distance matrix, maximum likelihood 
and parsimony, suggest that the evolution of human Bax and Bci-2 diverged a 
considerable time ago (Evans, 1995). As Bax is one of the pro-apoptotic proteins in which 
BH1 and BH2 are particularly well conserved and conservation is unlikely to occur unless 
it serves a useful purpose, this would suggest that BHl and BH2 play significant roles in 
the function of Bax. However, given that other BH3-only members of the family can 
induce apoptosis it suggests quite clearly that there are two separate routes to do so. It is 
interesting to note that the GDE motif at residues 101-3 of BH3 in Bcl-2 is more highly 
conserved in pro-apoptotic family members, whilst the phenylalanine residue at position 
1 1 2  is more highly conserved in anti-apoptotic members, raising the possibility that this 
variation has a relevance to the potential pro- and anti-apoptotic function of this domain.
A wide range of studies have sought to determine the functions/importance of BH 
domains and conserved residues with regard to apoptosis and interaction between Bci-2 
family members. Given the wide range and nature of the techniques used to investigate 
the properties and functions of the Bcl-2 family, the range of viral, mammalian, and 
recombinant proteins members used, many of which have been modified, particularly by 
removal of the TM domain, no definitive picture of the functioning of these domains in 
humans and particularly in B-GLL has emerged.
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However, the role of these domains is becoming clearer and this is discussed by putative 
function rather than domain.
6.2 Homodlmerisation.
Studies concerned with the structural requirements of homodimerisation in members of 
the Bcl-2 family of proteins have concentrated mainly on Bcl-2, Bax and to a much lesser 
degree, Bel- X|_. These suggest that the structural requirements in terms of BH and TM 
domains varies significantly between Bcl-2/Bcl- Xl and Bax.
Use of Bcl-2 deletion mutants suggests that homodimerisation of the proteins involves two 
distinct regions. Bcl-2 deletion mutants consisting of residues 83-218, containing oniy 
B H l-3 and part of the TM domain, do not homodimerise with each other in a yeast two- 
hybrid system, but do homodimerise with another Bcl-2 mutant consisting of residues 1-81 
which contains the BH4 domain. These results suggest that Bcl-2's BH4 and BH1-3 
regions are involved in a complementary interaction in Bcl-2 homodimerisation. Serial 
deletions of BH l, BH2 and BH4 in a yeast two-hybrid assay confirm that these domains 
are not essential for homodimerisation with human Bcl-2, but that one Bcl-2 molecule 
must possess a functional BH4 domain and its partner, functional BHl and BH2 domains 
(Sato, 1994). Additionally, experiments using human Bcl-2p (1-205), which does not 
homodimerise with some deletion mutants that homodimerise with Bcl-2 (1-218), 
suggests that sequences located between BH2 and the TM domain also appear to be 
important for Bcl-2 homodimerisation (Hanada, 1995). In keeping with the reported need 
for only one partner to have a functional BH l domain for Bcl-2 homodimerisation, yeast 
two-hybrid studies indicate that the BHl substitutions in Bcl-2, W GR144-6AAA, 
WGR144-6WAR and WGR144-6WER, do not interfere with homodimerisation of mutant 
Bcl-2 and wt Bcl-2. (Sedlak, 1995). Similarly the BHl FRDG138-41 AAAA and G145E 
substitution mutants, along with the BH2 W188A and QDN190-2LAA substitution mutants, 
are found to homodimerise as strongly with unmutated Bcl-2 (Yin, 1994).
The extent to which BcI-Xl homodimerises is uncertain. In immunoprécipitation studies 
human Bcl-X|_ did not homodimerise with haemagglutinin-tagged Bcl-X|_ (Minn, 1996), and 
in a different series of similar studies a Bcl-x^^-derived BH3 peptide bound to Bcl-Xi_ with 
the lowest affinity of all of the BH3-derived peptides tested. I.e. a Bcl-X|^-derived BH3 
peptide bound to Bcl-x^ with an affinity of 325 pM in contrast to one derived from Bak 
which showed an affinity of 0.20 pM in binding to Bcl-x^ (Sattler, 1997).
51
In contrast, human Bcl-x^ is reported to homodimerise in a yeast two-hybrid assay, 
although the same report reported Bax as not homodimerising in the same system, in 
contrast to the numerous reports indicating it homodimerises readily (Zhang, 1995). 
However, it is also reported that Bcl-x^ homodimerises in plate binding assays. The 
authors acknowledge that binding to plastic may change the conformation of the protein, 
but the doubts about the legitimacy of the homodimerisation process does not entirely 
negate the fact that the study indicated that a 16 amino acid peptide derived from residues 
72-87 of the BH3 domain of Bak, GQVGRQLAIIGDDINR, and a 21 amino acid residue 
from residues 52-72 in BH3 of Bax, QDASTKKLSECLKRIGDELDS, are sufficient to inhibit 
the formation of both Bcl-2 and Bcl-x^ homodimers (Diaz, 1997).
The NWGR motif in BHl of human Bcl-2 seems to have particular significance for 
homodimerisation. Bcl-2 pairs in which only one partner possesses a functional BHl 
domain, cease to homodimerise when the NWGR motif is deleted. E.g. deletion of 
NWGR in Bcl-2 (83-218) abolishes homodimerisation activity with Bcl-2 (1-81) (Hanada,
1995).
In contrast to Bcl-2, homodimerisation in Bax appears to require a functional BH3 domain 
in one partner and BH l and BH3 in the other. The sufficiency of the BH3 domain alone in 
one partner in Bax homodimerisation is quite well established. Yeast two-hybrid studies 
show that In human Bax a region of 41 amino acids from 47-87, encompassing the BH3 
domain, is all that is required for Bax to interact with full length Bax. Furthermore, Bax 
truncations lacking the BH1-2 domains not only continue to interact with full length Bax, 
but do so more strongly, possibly reflecting the need for a conformational change in Bax 
that is necessary to effect homodimerisation of wild-type (wt) proteins (Simonen, 1997). 
Similarly, murine Bax proteins do not require the BH l, BH2, or the first 58 residues 
containing BH4 at the NH2 -terminus to form homodimers with wt murine Bax, and the 
region of Bax that is essential for homodimerisation mapped to the region containing BH3 
from residues 59-101. Deletion of this region abolishes the ability of Bax to homodimerise 
with wt Bax (Zha, H. 1996). The importance of BH3 to Bax homodimerisation is also 
confirmed by immunoprécipitation studies which indicate that substitution of GD67-8AA or 
deletion of residues 63-71 in BH3, prevent homodimerisation with wt Bax and that BH1 
and BH2 are unnecessary for homodimerisation with wt Bax. Substitution of G108A and 
deletion of residues 102-112 in BH l, as well as substitution of W 158A and deletion of 
residues 151-159, in BH2, failed to prevent Bax homodimerisation, although deletion of 
BH2 residues 151-159 reduced the ability of the protein to homodimerise (Simonian, 
1996b).
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The BH domains needed to complement a BH3-possessing Bax monomer are not so 
obvious. Bax truncation mutants in a yeast two-hybrid assay show that the minimal 
requirements for human Bax homodimerisation to a partner with the BH3 domain alone is 
minimally the possession of the BH1 and BH3 domains (Simonen, 1997). These findings 
are directly contradicted by studies using murine Bax in another yeast two-hybrid system. 
These confirmed that BH1 and BH2 are not needed for homodimerisation between mutant 
and wt Bax, but also found that Bax mutants with deletions of BHl or BH2 homodimerlsed 
successfully with themselves and each other, suggesting that BH1 and BH2 are 
unnecessary for Bax homodimerisation (Zha, H. 1996). Additionally, the need for BH3 in 
homodimerisation is supported by Bad which does not possess the BH3 domain and does 
not homodimerise (Zha, J. 1996). Of interest with respect to Bax homodimerisation in 
yeast two-hybrid studies is that although Bax heterodimerises with Bcl-2, the competing 
Bax homodimerisation reaction is stronger (Sedlak, 1995).
These results indicate that Bcl-2 requires BH l and BH2 in one homodimerisation partner 
and BH4 in the other, and support the view that Bcl-2 homodimerises in a head-to-tail 
fashion. However, the results are not as certain with regard to BH3 being essential for 
Bcl-2 homodimerisation. The study by Sato (1994) indicates that the B H l-3 region is 
necessary as an entity for homodimerisation without offering any specific evidence that 
BH3 is involved. Similarly, the study by Diaz (1996) which suggests that Bak- and 
Bax-derived BH3 peptides can prevent homodimerisation and heterodimerisatlon does not 
offer proof that BH3 is involved in the homodimerisation process, or that 
homodimerisation and heterodimerisatlon, as Diaz suggests, involve a common binding 
site that mediates heterodimerisatlon and homodimerisation of Bcl-2 family members. 
These BH3 peptides may bind to the same site, but Bcl-2 homodimerisation could just as 
easily be prevented by steric hindrance or a conformational change in one Bcl-2 partner 
induced by binding the peptide. A study in the nature of Sato's, that deletes the BH3 
domain in the partner that possesses the B H l-3 domains, would go some way to 
establishing the importance of BH3 to homodimerisation. The evidence for Bcl-x^ is 
tenuous to the point where it is not possible to draw any meaningful conclusions from it.
Whilst it is clear that BH3 is also essential in one partner in Bax homodimerisation, the 
requirements in the complementary partner are less clear and likely to remain so pending 
further studies.
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6.3 Heterodimerisatlon.
Heterodimerisation occurs essentially between the pro- and anti-apoptotic members of the 
Bcl-2 family, although exceptions to this rule include heterodimerisation between Mcl-1 
and Bcl-2 and Mcl-1 and Bcl-X|_ (Sato, 1994). The process appears to involve the BH3 
domain of the pro-apoptotic member binding to the BH l, BH2 and BH3 domains of the 
anti-apoptotic member. BH4 appears not to be required for heterodimerisation and 
deletion of BH4 in Bcl-2, either through deletion of residues 1-82 or deletion of residues 
11-33, has no discernible effect on heterodimerisation between Bcl-2 and Bax in vitro 
(Hanada, 1995).
X-ray and nuclear magnetic resonance (NMR) analysis of the structure of Bcl-X[_, and by 
inference the similarly-sequenced Bcl-2, suggests that in the quaternary structure of the 
proteins, BH1, BH2  and BH3 are in close spatial proximity to each other forming a 
hydrophobic cleft that provides a binding site for other members of the Bcl-2 family 
(Muchmore, 1996). A 16 amino acid residue peptide derived from the BH3 region of Bak 
consisting of residues 72-87 is the minimal region required to bind to Bci-X[_, and in 
solution this Bak peptide adopts an amphipathic a-helix form which binds to the cleft 
formed by the B H l-3 domains of Bcl-Xi_. In this relationship specific amino acids appear 
to be important. Substitution of L78A, D83A, or R76A in the Bak peptide reduces binding 
to BcI-Xl. D83 of Bak is thought to interact with R139 of Bcl-X|  ^and when the substitution 
R139Q is applied to Bcl-Xi_, its binding to Bax is inhibited. Interestingly the Bak-derived 
peptide binds to Bcl-X|_ with greater affinity than similar peptides derived from Bcl-2, Bax, 
Bik and Bcl-x^, and in keeping with Bcl-x^'s reported failure to homodimerise, the Bcl-x^- 
derived peptide bound to wt Bcl-x^^with the lowest affinity (Sattler, 1997). This relationship 
is also very much in keeping with sequence conservation amongst family members and is 
well supported by studies using a wide range of pro- and anti-apoptotic members, 
particularly the need for BH3 in the pro-apoptotic partner.
Peptides consisting of 16 and 21 amino acid residues derived, respectively, from residues 
72-87 of the BH3 domain of Bak and positions 52-72 of BH3 in Bax, are sufficient to inhibit 
the formation of Bcl-2/Bax and Bcl-Xi_/Bax heterodimers in plate binding assays, 
suggesting that this peptide occupies the site normally occupied by the pro-apoptotic 
partner (Diaz, 1997). Similarly, the limited sequence in Bax from residues 50-78 which 
encompasses BH3 is necessary and sufficient for heterodimerisation with E1B 19kDa 
(Han, J. 1995).
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Bax truncations show that a region of 41 amino acids from 47-87, also encompassing the 
BH3 domain, is all that is required for Bax to interact with full length Bax, Bcl-2, and BcI-Xl 
{Simonen, 1997), and a short sequence in Bad from 141-172 containing Bad's BH3 
domain (151-9), is both sufficient and essential for heterodimerisation with Bcl-2 (Zha, 
1997).
The importance of BH3 to heterodimerisation in pro-apoptotic Bci-2 family members is 
supported by both deletions of BH3 and other Bcl-2 homology domains. Deletion of the 
BH3 domain in Bax and B ipi indicate that it is critical for heterodimerising with both Bcl-2 
and Bcl-X|_ (Chittenden, 1995). For example, deletion of the sequence LRRIGELD, at 
residues 63-71 of Bax abolished Bax's ability to bind BcFxl (Simonian, 1996a), deletion of 
the BH3 domain residues in Bik from 61-69 (LACiGDEMD) suppresses interactions 
between Bik and the apoptosis-inhibiting members of the family (Boyd, 1995), and 
deletion of residues 59-101 containing the BH3 region of Bax abolishes the protein's 
ability to heterodimerise with Bcl-2 (Zha, H. 1996). In contrast, deletion of other homology 
domains appears to have no impact on the ability of pro-apoptotic family members to 
heterodimerise and emphasises the singular importance of BH3 in this respect. Deletion 
of residues 102-112 in BHl or deletion of residues 151-159 in BH2 in Bax did not prevent 
it from heterodimerising with Bcl-x^ (Simonian, 1996a). Likewise heterodimerisation 
between Bax and Bcl-2 occurs without the NH2 -terminus domain of Bax (Zha, H. 1996) 
and deletion of BH2 in Bad has virtually no effect on heterodimerisation with Bcl-2 and 
BcI-Xl (Zha, 1997).
Particular residues In BH3 appear important for heterodimerisation and offer a possible 
explanation of the greater affinity found between some family members. Substitutions in 
BH3 of Bad indicate that the heterodimerisation process varies between Bcl-2 and Bcl-x^. 
Bad L151A reduces binding to both Bci-2 and Bcl-X|_ by >90% and appears to be virtually 
unable to bind Bcl-x^, in contrast Bad G148A reduced binding to Bcl-2 by -50%, but had 
only a minimal effect on Bc!-Xi_. Additionally, in contrast to the other Bak and Bax BH3- 
derived peptides described earlier which prevented hetero-dimerisation between 
Bcl-2/Bax and Bcl-X[_/Bax, a BH3 derived peptide containing a G67R substitution failed to 
prevent heterodimerisation between Bcl-2, Bcl-x^ and Bax, suggesting that this particular 
residue has some significance in this respect (Diaz, 1997).
In line with Muchmore's (1996) and Battler's (1997) discoveries that the B H l-3 domains 
form a hydrophobic cleft in the tertiary structure of Bcl~X[_, BH1-3 appear to be of equal 
importance in the anti-apoptotic partner in heterodimerisation.
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For example, deletion of BH1 or BH2 in Bcl-2 removes the ability of the protein to 
heterodimerise with Bax (Hanada, 1995), but much of the evidence for the importance of 
these domains comes from substitution mutants.
Substitution of FRDG138-41 AAAA and WGR144-6AAA in BHl of human Bci-2 are 
reported to markedly reduce Bcl-2's ability to heterodimerise with Bax, in contrast to 
deletion of NWGR and substitution of WGR 144-6AAA, WGR144-6WAR, and 
WGR144-6WER in BH l, which are reported to prevent Bcl-2 heterodimerising with Bax 
(Hanada, 1995; Sedlak, 1995; Yin, 1994). Substitution of the highly conserved G145 
residue in BHl of Bcl-2 and the equivalent residue in other Bcl-2 homologues has 
significant, but variable effect. Substitution of G145A in BHl of Bcl-2 and substitution of 
G138A of BCL-Xl, completely abrogated the protein's ability to heterodimerise with Bax 
(Diaz, 1997; Yin, 1994). Similarly, substitution of G87A in BHl of E1B 19kDa prevents the 
protein heterodimerising with Bax (Han, 1995). The variable effect of this substitution is 
illustrated by substitutions in Bid and Bad, In vitro binding assays indicate that Bid forms 
heterodimers with both Bcl-2 and Bax, but this interaction is prevented when the 
substitutions G145A in BHl of Bcl-2 and G108A in BHl of Bax are applied (Wang, K.
1996). In contrast, substitution of G145A in BHl of Bcl-2 reduces heterodimerisation 
between Bcl-2 and Bad only slightly (Zha, 1997).
A conserved tryptophan residue at position 188 of Bcl-2 appears particularly important for 
heterodimerisation, and substitution of W188A in BH2 completely abrogated Bcl-2's ability 
to heterodimerise with Bax in one study and significantly reduced Bcl-2's ability to 
heterodimerise with Bad in another. Likewise substitution of QDN190-2LAA and E200A in 
BH2 of Bcl-2, markedly reduces its ability to heterodimerise with Bax (Yin, 1994; Zha,
1997).
This importance of BHl and BH2 in the anti-apoptotic heterodimerisation partner is 
underlined by the failure of Bcl-Xg, which lacks BHl and most of the BH2 region found in 
Bc1-Xl, to bind to Bax in the yeast two hybrid assay, in contrast to Bcl-2, Bcl-Xi_, and Mcl-1 
which do have BHl and BH2 domains (Sato, 1994). However, the need for BHl and 
BH2 in heterodimerisation may not be universal as Bcl-Xg forms heterodimers with Bik. In 
keeping with a form of heterodimerisation that clearly differs, for example, from the 
heterodimerisation between Bcl-2 and Bax, a yeast two-hybrid study suggested that the 
Bcl-2 residues from positions 43-48 and the homologous residues from positions 90-96 of 
E1B 19kDa are required for interaction between Bcl-2 and Bik (Boyd, 1995).
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Evidence for the importance of BH3 in the heterodimerisation function of the anti-apoptotic 
family members comes from the evolutionariiy diverse E1B 19kDa, Bcl-x^ and Bcl-2. 
Deletion of GDE at positions 94-6 of Bcl-x^ eliminated the protein's ability to bind Bak and 
the minimal region of E1B 19kDa necessary to interact with a sequence containing a BH3 
sequence from Bax maps to the conserved region including BH1-3. The importance of 
BH3 in this centrally conserved region is emphasised by the substitution of F51S in BH3 
of E1B 19kDa, which abrogates heterodimerisation with Bax. Similarly, 
heterodimerisation of Bci-2 and Bad is completely abolished when the L97A substitution is 
applied to the BH3 domain of Bcl-2 (Chittenden, 1995; Han, J. 1995; Zha, 1997).
Given the alternate splicing origin of the protein, heterodimerisations involving Bcl-Xg are 
clearly a special case. Bcl-Xg does not heterodimerise with Bax or with Bad (Sato, 1994; 
Sedlak, 1995; Yang, 1995), but it is found to heterodimerise with Bik in yeast two-hybrid 
studies (Boyd, 1995). Bcl-Xg's association with Bc1-Xl, Bcl-2 and Bax is not detected in 
vitro and in vivo Bcl-X[_ shows greater affinity for Bax by co-precipitating with Bax 
significantly better than Bcl-Xg. However, Bcl-Xg is found to heterodimerise with Bci-2 in 
the yeast two-hybrid assay (Zhang, 1995).
The general lack of action or lesser affinity between Bcl-Xg and other family members 
suggests that it reduces the cellular apoptotic threshold by a means that is different to 
other pro-apoptotic members with a wider range of binding ability. For Bcl-Xg to bind 
BcI-Xl the first 25 residues containing BH4 must be present in Bcl-Xg, but removal of the 
equivalent residues from Bcl-x^ enhances the binding affinity between the two proteins. 
Consistent with this, deletion of the NH2 -terminus of Bci-Xg prevents it from interacting 
with Bcl-X|_. The authors suggest that the NH2 -terminus of Bcl-x^ interacts with its own 
B H l-2 region during homodimerisation and that deletion of Bcl-X[_'s NH2 -terminus allows 
the same region of Bcl-Xg to react more readily with the B H l-2 region of Bcl-x^ (Minn, 
1996; Sato, 1994). In contrast, the BHl domain and the region containing the TM domain 
of Bcl-2 are required for heterodimerisation between Bcl-2 and Bcl-Xg, as are residues 24- 
78 of the NH2 -terminus of Bcl-Xg (Zhang, 1995).
The most widely observed form of dimérisation clearly involves the BH3 domain in the 
pro-apoptotic partner, binding to the B H l-3 domains of the anti-apoptotic partner, but 
clearly other forms of interaction are possible. The observed hetero-dimerisation between 
Bik whose conserved homology is in BH3 only, and Bci-Xg which lacks BHl and most of 
the BH2 domain, indicates other possibilities which may apply equally well to other family 
members.
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The heterodimerisation between Bcl-Xg and Bcl-X[_ shows distinct parallels with the head- 
to-tail Bcl-2 homodimerisation and may be explained In this way, but the 
heterodimerisation of Bcl-2 and Bcl-Xg shows nothing in common with other forms of 
heterodimerisation and hence serves only to emphasise that other possibilities may apply 
to other family members.
6.4 Apoptosis inhibition.
Extensive studies leave little room for doubt that the possession of the BH4, BH1 and BH2 
regions confer the ability to Inhibit apoptosis on the anti-apoptotic members of the Bcl-2 
family. Additionally some evidence attributes anti-apoptotic function to the TM domain 
and sequences between it and BH2.
Truncation and deletion mutations In murine Bcl-2 Indicate that BH1, BH2 and BH4 are 
essential to the suppression of nerve growth factor withdrawal-induced apoptosis in 
sympathetic neurons Isolated from the superior cervical ganglia of new-born rats.
Deletion of Bcl-2 residues 4-29 (BH4), residues 127-191 (BHl and part of BH2), residues 
187-207 (BH2) as well as any C-terminal truncation earlier than residue 196, abrogate the 
protein's anti-apoptotic function. Truncation of Bcl-2 at residue 196 reduces anti-apoptotic 
activity significantly, but truncations at 201, 202, 203 retain significant anti-apoptotic 
activity despite the absent TM domain. However the addition of a short hydrophobic 
peptide sequence to the truncation at residue 203 to produce Bcl-2(.,_203)+ HLEGPIL, 
produces an anti-apoptotic protein with significantly more effect that Bcl-2 (.,_2 0 3 ) alone.
This would suggest that the TM locating sequence of Bcl-2 is important, but has limited 
specificity to anti-apoptotic function (Borner, 1994).
Support for the importance of B H l-2, BH4 and sequences downstream of BH2 come from 
yeast two-hybrid, transient transfection studies and mutagenesis of the BH4 domain. Bcl- 
2 deletion mutants lacking BH4, BH l, BH2 or the NWGR motif are ineffective at blocking 
Bax-mediated apoptosis In yeast. Bcl-2p is also unable to block Bax-induced apoptosis, 
suggesting that sequences between BH2 and the TM domain are important for blocking 
Bax's function. Consistently, a Bcl-2 deletion mutant consisting only of residues 1-196 
also failed to prevent Bax-medlated apoptosis In yeast (Hanada, 1995). Similarly, 
transient transfection studies using staurosporine-induced apoptosis in fibroblasts and 
steroid-induced apoptosis in T-lymphoid cells, suggest that protection from apoptosis is 
dependent on both the region of Bcl-2 from residues 90-203 encompassing BHl and BH2 
and the region from 6-31 encompassing BH4 (Hunter, 1996).
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In particular, the BH4 region appears to be essential for Bcl-2's anti-apoptotic activity and 
systematic mutagenesis indicates that 5 hydrophobic and aromatic residues, 114, V I5,
Y18, 119 and L23, are critical to Its apoptosis-inhibiting function, and individuai mutation to 
glycine In any one of these residues profoundly Inhibits Bcl-2 activity in a transient 
transfection assay (Lee, 1996), Similar effects are found in studies in a series of Bcl-2 
deletion mutants used to challenge staurosporine-induced apoptosis in a transient 
transfection assay. Deletion of residues 6-31 encompassing the BH4 region imparted a 
negative phenotype to Bcl-2 which promoted rather than prevented apoptosis. Likewise 
deletion of BH4 in Bcl-2 converted the protein to a pro-apoptotic function in baby hamster 
kidney ceils (Hunter, 1996; Shibasaki, 1997).
Furthermore, substitution studies in human and murine Bcl-2 emphasise the importance 
of BH1 and BH2 to apoptosis. Substitution of FRDG 138-41 AAAA and WGR144-6AAA in 
the BHl domain of human Bcl-2, along with BH2 substitutions QDN190-2LAA and E200A, 
markedly reduced the apoptosis-inhibiting activity of the protein. In contrast, substitutions 
of G145A in BH l and W188A in BH2 completely abolished Bcl-2's ability to prevent 
lL-3-deprivation-, y-irradiation- and glucocorticoid-induced apoptosis (Yin, 1994). Likewise 
deletion of the XFXFG motif in BHl at residues 150-154 of murine Bcl-2 reduces the 
proteins anti-apoptotic effectiveness in counteracting the impact of nerve growth factor 
withdrawal-induced apoptosis in sympathetic neurons isolated from the superior cervical 
ganglia of new born rats (Borner, 1994).
Site-specific mutagenesis of Bcl-Xi_ supports the evidence gained from Bcl-2, indicating 
that BH1 and BH2 are essential to the anti-apoptotic function, but that residues critical to 
Bcl-Xi_ function are different from those required by Bcl-2. Substitution of VNW135-7AIL 
or GRI138-40ELN in BH l of human BcI-Xl abolishes its apoptosis-inhibiting activity in 
Sindbis virus-induced apoptosis in baby hamster kidney cells. Substitution of W  for any 
two Fs In the FFSFG motif of BH1 significantly reduces B c I-X l's  activity, in contrast to 
single and double substitutions between residues 129-134 of BHl which had only minimal 
effect. Substitution FRD131-3VRA also had very little effect on Bcl-X|_, in contrast to the 
same substitution in Bcl-2 which totally abrogated its anti-apoptotic activity in the same 
virus vector system. Single and double substitutions In BH2 of BcI-Xl have only very 
limited effects. Substitution of WD188-9GA reduced Bcl-Xi_'s activity by approximately 
half, but substituting the highly conserved tryptophan at position 181 had little effect 
(Cheng, 1996). This latter substitution is in direct contrast to the effect on Bcl-2, where 
substituting tryptophan 181 had a significant impact (Yin, 1994).
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Additionally, substitution of G159A in BH1 of Bcl-x^ abolished the protein's ability to 
repress apoptosis in FL5.12 cells deprived of IL-3 (Sedlak, 1995).
Evidence of the apparent biological universality of the need for the BH1 domain In Bcl-2 
homologues comes from substitution mutants of the E1B 19kDa protein and the African 
Swine fever virus protein A179L. Substitution of the E1B 19kDa conserved glycine 
residue G87A in BH l, abolishes the protein's ability to inhibit puromycin- or staurosporine- 
induced apoptosis (Chen, 1996) and substitution of G85A in BH l of A179L also abolishes 
its ability to protect K562 cells from apoptosis (Revilla, 1997).
6.4.7 Clearly the evidence supports not only the necessity of BH4, BH l and BH2 to Bcl-2 
and BcI-Xl's anti-apoptotic function, but also attributes some importance to the TM domain 
and a sequence between it and the BH2 domain in this respect, indeed on the basis of 
these studies there is significant justification for viewing BH4 as the anti-apoptotic domain. 
In particular the G145, NWGR motif generally, and the FRD motif In BHl of Bcl-2, as well 
as the W188 in BH2 of Bcl-2 and the VNWGRI motif and G159A in BHl of Bcl-X|_, seem 
to be particularly important to anti-apoptotic function. There is also some evidence to 
suggest that BH3 Is functionally important in apoptosis inhibition and an unspecified 
substitution of residues 97-98 abrogated Bcl-2's and BcI-Xl's anti-apoptotic function, and 
deletion of GDE at positions 94-6 of Bcl-x^, eliminated both Its ability to bind Bak and to 
suppress cell death (Chittenden, 1995).
6.5 Apoptosis induction.
BHl and BH2 appear to have no function in Inducing apoptosis In comparison to BH3. 
However, despite extensive studies using deletions and substitutions in a wide-range of 
pro-apoptotic Bcl-2 family members lending support to the proposition that BH3 is the pro- 
apoptotic domain, it remains unclear to what extent this is true.
A range of deletions and substitutions in BH l and BH2 of Bax, e.g. deletions of residues 
102-112 in BH1 and 151-159 in BH2, had no effect on the protein's ability to accelerate 
taxol-, vincristine-, cisplatin- or VP-16-induced apoptosis in FL5.12 cells (Simonian,
1996(1 & 2)). B H l-2 were found to be unnecessary to promote apoptosis, in contrast to 
BH3 which was found to be of central importance for Bak-promoted apoptosis in transient 
transfection assays in Rat-1 cells. Deletions in Bak identified the BH3-containlng residues 
67-94 as being uniquely important to accelerate apoptosis and truncated forms of Bak 
containing BH3 retain the protein's cytotoxic function.
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Support for the importance of BH3 cytotoxic function also comes from Bip1. This distant 
family member shows distinct similarity to BH3 of Bax and Bak in its amino acid sequence 
from 57-69, LALRLACIGDEMD, and deletion of the BH3 domain substantially impairs the 
protein’s ability to accelerate apoptosis in Rat-1 fibroblasts (Chittenden, 1995).
Similarly, BH3 appears to be the apoptosis-promoting domain in other pro-apoptotic 
proteins including Bik and Bax. Bik is an apoptosis-promoting member of the Bcl-2 family 
whose activities can be mitigated by the co-expression of Bcl-2, Bcl-x^, Bhrf-1 and E1B 
19kDa proteins, and deletion of the BH3 domain residues in Bik from 61-69 
(LACIGDEMD), suppresses the ability of the protein to induce apoptosis in Rat-1 
fibroblasts (Boyd, 1995).
Unfortunately the situation with Bax is not so cut and dried. Bax truncations containing 
only the BH3-encompassing 41 amino acids from residues 47-87, were as efficient as Bax 
truncations lacking only the TM domain at promoting apoptosis in REF52 rat fibroblasts 
(Simonen, 1997). However, the BH3 domain of murine Bax has been shown to be 
ultimately unnecessary to promote apoptosis in transfection studies using FL5.12 cells. 
Substitution of GD67-8AA and deletion of residues 63-71 in Bax did not abolish the 
protein's ability to promote apoptosis in FL5.12 cells and to counter the effects of Bcl-X|_ 
(Simonian, 1996(1 & 2)). Likewise deletion of the BH3 domain in Bax reduces but does 
not entirely eliminate the protein's ability to promote apoptosis in Rat-1 fibroblasts 
(Chittenden, 1995).
There seems little doubt that the BH3 domain is, as it were, the pro-apoptotic domain, but 
clearly the situation is not that simple with pro-apoptotic members of the Bcl-2 family able 
to promote apoptosis after the BH3 domain has been deleted or elements of it substituted. 
However, it remains unclear to what extent this is a genuine reflection of how the pro- 
apoptotic proteins perform in vivo. In particular it is unclear to what extent the common 
removal of the TM domain in studies affects the functioning of these proteins and it 
remains possible that the experimental conditions are so different from the conditions 
prevailing naturally in the cell as to call many of the conclusions derived from these 
experiments into question. In the context of BH3 it is interesting to note that deletion of 
murine Bcl-2 residues 4-29 that converts Bcl-2 into a BH3-possessing Bax lookaiike and 
deletion of residues 127-191 that converts Bcl-2 to a BH3-possessing 
Bcl-Xg-like form, does not confer Bax and Bcl-Xg's pro-apoptotic functions on either 
(Borner, 1994).
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6.6 Intracellular localisation of family members.
The majority of the antl-apoptotic and pro-apoptotic members of the Bcl-2 family possess 
a C-termina! membrane-spanning domain that appears to enhance function in both types 
of family member.
The TM domain of Bcl-2 appears to confer anti-apoptotic status on the protein and the 
Bcl-2p protein which arises from alternative splicing of the bcl~2 gene and is identical to 
Bcl-2a except that it lacks the letter's last 34 residues including the TM domain 
(Tsujimoto, 1986), is ineffective in prolonging the life of the lL-3-dependent 
haematopoietic cell line 32D in comparison to the full-length Bcl-2a. However, a 
chimaeric protein consisting of Bcl-2|3 and the TM and cytosolic domains of the IL-2 
receptor aprotein expressed in the 32D cell line resulted in the prolongation of cell life. 
When 32D cells were subsequently fractionated much of the Bcl-2p protein appeared to 
reside in the cystol, in comparison to the chimaeric protein which was found in fractions 
associated with the mitochondrial enzyme F1-p-ATPase {Tanaka, 1993). Such results 
would appear to suggest that localisation to mitochondria via a TM domain is important to 
Bcl-2 anti-apoptotic function, but that specific conservation of sequence in the Bcl-2 family 
TM domain is not.
In contrast to these findings other studies suggest that only some anti-apoptotic activity is 
vested in the TM domain. Bcl-2a truncation mutants lacking the normal TM domain as a 
result of truncation after residues 196, 201, 202 and 203, continue to inhibit the induction 
of apoptosis in sympathetic neurons by removal of nerve growth factor. Confocai 
microscopy indicates that the Bcl-2a truncation mutant (1-203) is located in the 
extremities of neurites in neurons and filopodias in fibroblasts, suggesting that the normal 
membrane localisation of Bcl-2 is unnecessary to enable it to perform its anti-apoptotic 
function. However, fusion of a truncation mutant consisting of Bcl-2a residues 1-203 to a 
peptide sequence consisting of HLEGPIL restored full wt Bcl-2 anti-apoptotic activity in 
L929 fibroblasts as well as sympathetic neurons, confirming the apparent non-specific 
nature of the Bcl-2 TM domain (Borner, 1994). This latter study is supported by transient 
transfection studies using staurosporine-induced apoptosis in fibroblasts and steroid- 
induced apoptosis in T-lymphoid cells, which suggest that protection from apoptosis is 
only partially reduced after deletion of the Bcl-2 TM domain, and indeed a Bcl-2 155- 
residue lacking also most of the region from residues 30-91 and the TM domain, exhibited 
a significant protective effect (Hunter, 1996).
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The TM domain also appears to have functional significance in pro-apoptotic family 
members. Microinjection of the pcDNAS expression vector, into which full-length Bax has 
been cloned, into REF52 rat fibroblasts, induced apoptosis in 33% of them within 24 hrs.
In contrast, cloning a version of Bax from which the TM domain coding has been deleted 
into the same expression vector, results in apoptosis being induced in only 8 % of the cells 
after the same time (Simonen, 1997), suggesting that localisation to intracellular 
membranes via the TM plays a significant role in inducing apoptosis. These results are 
supported by similar results which tested the ability of Bak mutants to induce apoptosis in 
transient transfection assays in Rat-1 cells. Bak mutants lacking the carboxy-terminal 
hydrophobic TM domain had a diminished cytotoxic function (Chittenden, 1995). Of 
particular interest is the fact that at high levels of expression, haemagglutinin-tagged Bax 
possessing a TM domain shows a diffuse cytoplasmic and nuclear distribution in baby 
hamster kidney cells, in contrast to the normal membrane distribution found at low levels 
of expression. However, this changes dramatically In response to co-expression of Bcl-2, 
when it localises to the cytoplasmic membranes with a staining pattern similar to Bcl-2 
(Shibasaki, 1997). These results appear to suggest that in some circumstances at least, 
Bax is targeted to the mitochondrial, ER and perinuclear membranes by Bcl-2 and not by 
its own TM domain.
Not enough studies have been carried out to form a definitive conclusion, but the evidence 
points to the TM domain as enhancing the function of both anti- and pro-apoptotic family 
members, which inevitably casts doubt over the results obtained from the many studies in 
which the TM domain of Bcl-2 family members have been removed as part of the 
experimental procedures.
6.7 Interaction between family members.
The model proposed by Oltvai, Korsmeyer, and Milliman ( Korsmeyer, 1995; Oltvai, 1993; 
Oltvai & Korsmeyer, 1994) envisages that the apoptotic fate of the cell is determined by 
the equilibrium between the anti-apoptotic Bcl-2 and the pro-apoptotic Bax, with the 
former acting to raise the apoptotic threshold of the cell and the latter acting to lower it. 
This paradigm has grown to incorporate other family members, e.g. Bcl-x^, and Bak, but it 
remains unclear if the pro-apoptotic Bcl-2 family members are the active entities regulated 
by the anti-apoptotic members or vice versa. However, it is proposed that family 
members with opposing functions regulate each other by heterodimerising and 
neutralising the opposing function. Additionally, it is thought that as part of their function 
both pro- and anti-apoptotic members of the Bcl-2 family may need to homodimerise.
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Evidence in support of this model comes mainly from studies showing a correlation 
between the expression of pro- and anti-apoptotic members and the cell's fate, with 
supporting evidence indicating that substitutions which affect the ability of the two family 
subtypes to bind to each other also affect apoptosis induction or inhibition. However, the 
evidence is not entirely one-sided and significant evidence exists to suggest that pro- 
apoptotic proteins especially can induce apoptosis without binding opposing family 
members, and that monomeric forms of pro-apoptotic proteins can promote apoptosis.
The FRDG138-41AAAA, WGR144-6AAA, QDN190-2LAA, and E200A substitutions in 
human Bcl-2 markedly reduce, and the G145A and W188A substitutions completely 
abrogate, Bcl-2's ability to prevent IL-3-deprivation-, y-irradiation- and glucocorticoid- 
induced apoptosis accelerated by Bax. These mutations show a striking correlation 
between Bcl-2's ability to repress apoptosis and its ability to bind Bax, with those 
mutations which bind Bax less avidly also being less effective at apoptosis inhibition, and 
those substitutions which abrogate Bcl-2/Bax heterodimerisation also abrogating Bcl-2's 
apoptosis-inhibiting function (Yin, 1994). This study suggests that both BH1 and BH2 are 
Involved in heterodimerising with Bax and offers support to the model envisaging that 
Bcl-2 must bind to Bax to exert its death-repressing function.
Likewise, studies using yeast two-hybrid assays with human Bcl-2 and mouse Bax, 
indicate that deletions in Bcl-2 that abolish or lessen the protein's ability to inhibit 
apoptosis, similarly affect Bcl-2's ability to bind Bax (Hanada, 1995). These findings are 
further supported by a study showing that the adenovirus Bcl-2 homologue, E1B 19kDa, 
confers protection against apoptosis in Chinese hamster ovary cells that is virtually 
indistinguishable from the protection conferred by Bcl-2. When a G87A substitution is 
applied to BH1 of E1B 19kDa, the protein loses its ability to inhibit puromycin- and 
staurosporine-induced apoptosis in a manner that directly corresponds to the proteins 
ability to bind Bax (Chen, 1996).
Studies which create substitution mutants in the pro-apoptotic family members Bik, Bax, 
and Bak, also suggest that apoptosis induction or inhibition is associated with molecular 
interactions, include those involving Bcl-2 and BcI-Xl. The apoptosis-promoting function of 
Bik is opposed by the co-expression of Bcl-2, Bcl-X|_, Bhrf-1 and E1B 19kDa proteins, and 
deletion of residues 61-69 (LACIGDEMD) in BH3 of Bik simultaneously suppresses both 
apoptosis-induction and interactions between Bik and the apoptosis-inhibiting members of 
the family (Boyd, 1995).
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The BH3 domain seems to be of particular importance in this respect and substitution and 
deletion of residues in this domain in both pro- and anti-apoptotic members highlights the 
parallel function of binding and inhibition of apoptosis. A series of deletion mutants in Bak 
indicate that both the interaction with Bcl-x^ and the protein's apoptosis-inducing function 
depend on the residues 73-94 encompassing BH3. Similarly, BH3 appears to be 
functionally important in BcI-Xl with deletion of GDE at positions 94-6 of Bcl-X[_ eliminating
..ÿboth its ability to bind Bak and suppress cell death. Furthermore, deletion of the BH3
domain in Bax confirms that it is critical to the ability of the protein to promote apoptosis 
and to bind to both Bcl-2 and Bel- X|_ (Chittenden, 1995).
A particularly convincing demonstration of the association between apoptosis inhibition by
.iBcl-2 and heterodimerisation was contrived using a substitution mutant of Bcl-2 and a j
truncation mutant of Bax. Bcl-2 G145A does not bind wt Bax and does not protect 
mammalian 293 cells from Bax-induced apoptosis. However, Bcl-2 G 145A does bind to a 
version of Bax truncated at the C-terminus (BaxAC) which retains its pro-apoptotic 
function. When Bcl-2 G145A is co-transfected with BaxAC the Bcl-2 mutant is as 
effective at inhibiting apoptosis as wt Bcl-2, suggesting that Bcl-2 exerts its protective 
effect via heterodimerisation with Bax (Ottilie, 1997; Yin, 1994). Studies involving chicken 
embryo neurotrophic factor-deprived neurons also offer some support for Oltvai,
Korsmeyer and Milliman's model, although here the normally accepted role of Bax may 
apparently be reversed. When either a Bcl-2 or Bax expression vector was injected to 
produce a Bcl-2:Bax ratio of >2:1 or <1:2, many more neurons were protected from 
apoptosis in comparison to control cultures. However, when expression vectors were 
injected to produce equal concentrations of Bcl-2 and Bax, the number of surviving 
neurons was no greater than control injected neurons. Although this study raises 
questions about the anomalous role of Bax when its concentration is at least twice that of 
Bcl-2, the results are consistent with Bcl-2 and Bax expressing a mutual antagonism 
through heterodimerisation (Middleton, 1996).
There is also evidence to suggest that binding of the pro-and anti-apoptotic family 
members is not essential to the promotion or inhibition of apoptosis. Results from 
substitution mutations involving both BH1 and BH2 domains suggest that Bcl-x^ does not 
have to bind Bax to inhibit apoptosis. Substitution of FRD131-3VRA or G148E and 
G187A in Bcl-X|_ abolishes the interaction between Bcl-x^ and Bax, whilst preserving 70- 
80% of B c I-X l 's  wt activity in inhibiting Sindbis virus-induced apoptosis (Cheng, 1996).
Likewise, deletion of residues 63-71 (LRRIGELD) in BH3 in Bax abrogated its ability to 
bind BcI-Xl, but not its ability to counter the effects of BcI-Xl (Simonian, 1996a).
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Studies using Vaccinia virus-induced transient transfection assays and in vitro binding 
assays indicate that Bid heterodimerises with BcI-Xl and Bcl-2 via its BH3 domain. Bid 
promotes apoptosis without a specific apoptotic stimulus, but different Bid BH3 mutants 
can be generated which bind Bcl-2 without countering its anti-apoptotic effect and which 
do not bind Bcl-2 but which still retain an ability to promote apoptosis (Wang, K. 1996), 
Interestingly as well as heterodimerisation being unnecessary in some studies, 
homodimerisation of pro-apoptotic proteins also appears unnecessary for promotion of 
apoptosis. Bax proteins retain their ability to accelerate the rate of taxol- and vincristine- 
induced apoptosis in FL5.12 cells after deletion of residues 63-71 in BH3 although this 
deletion disrupted Bax homodimerisation, indicating that monomeric forms of Bax remain 
active in inducing apoptosis (Simonian, 1996b).
Although the weight of evidence appears to be balanced in favour of heterodimerisation 
between pro- and anti-apoptotic members being necessary to induce/inhibit apoptosis, it 
does not seem possible to form any definitive conclusion about the coupling between 
heterodimerisation and induction or inhibition of apoptosis, when evidence exists to the 
contrary. However, it has to be borne in mind that the majority of testing methods bear 
very little resemblance to the circumstances that prevail naturally in the cell. In particular 
many of the Bcl-2 family members have their TM domains removed before testing and/or 
are bound to expression vectors in a manner that may affect their conformation. This 
compares with the situation thought to prevail in the cell where many of these proteins are 
thought to function embedded in mitochondrial, endoplasmic reticular, or perinuclear 
membranes. This difference between the natural and testing methods may offer some 
explanation for the contradictory nature of these results, but it may also be that control of 
apoptosis by the Bcl-2 family is not as simple as originally envisaged. Support for the 
view that the results of many Bcl-2 family interaction studies should be viewed with 
caution comes from a study involving Bcl-2, Bcl-x^, and Bax. This suggested that Bax 
homo- and heterodimerisation may be determined by detergent-induced conformations in 
Bax, that vary depending on the detergent used (Hsu, 1998). The ability of pro-apoptotic 
Bax to protect cells from apoptosis when expressed in excess (Middleton, 1996) also 
suggests that control of apoptosis by the Bcl-2 family requires a more detailed model. 
Furthermore, Bad heterodimerises with both Bcl-X|_ and Bcl-2, binding more strongly to the 
former in mammalian cells, but countering only the anti-apoptotic activity of BcI-Xl. In 
heterodimerising with BcI-Xl, Bad appears to displace Bax and when approximately half of 
the cellular Bax is heterodimerised, apoptosis is inhibited (Yang, 1995).
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This suggests that the control of apoptosis by the Bcl-2 family may be a multi-layered 
system of greater complexity than that envisaged by the Oltvai, Korsmeyer and Milliman
paradigm. |
i
6.8 interactions with Bcl-2 family-associated proteins.
It is clear that the Bcl-2 family does not exert its control over apoptosis in isolation from 
other non-family molecules. Bcl-2 associates with two specific molecules, Bag-1 and 
Raf-1, which in turn also interact with each other. Both Bag-1 and Raf-1 have been 
shown to interact with Bcl-2 in an apparently synergistic relationship which confers a 
greater survival advantage in the variety of cells in which they have been transgenically 
expressed. However, whilst a certain amount of information has emerged about the 
individual interactions, the mechanism (s) by which this trinity of Bcl-2, Bag-1 and Raf-1 
exerts its effect, remains essentially unclear.
The Bag-1 protein shows no homology with Bcl-2 family members, but binds to Bcl-2 and 
the synergistic effect has been demonstrated in several cell types. For example, co­
expression by gene transfer of Bag-1 and Bcl-2 in the human lymphoid cell line Jurkat, 
markedly increases the protection offered from apoptosis induced by a range of apoptotic 
stimuli, in comparison to the degree of protection offered when levels of Bag- 1  or Bcl-2 
were elevated in isolation from each other (Takayama, 1995). Similar results were 
obtained using hybridoma 2E3-0 cells transfected with bcl~2 and bag-1.
Despite being investigated over a considerable number of years, the precise function of 
the Bcl-2 homology domains remains to be defined and many of the anomalies that the 
studies have raised remain to be resolved. However, a general picture is beginning to
Memerge that is largely in keeping with the conservation of sequence homology observed in |
family members. This appears to indicate that the BH4 domain is the anti-apoptosis 
domain, BH3 is the pro-apoptotic domain, the major role of BH1 and BH2 may be in
C:
interactions between family members and Bcl-2 family-associated proteins, and that the 
role of the TM domain includes functionally essential location of family members to the |
appropriate intracellular membranes as well as apparently having an essential role in the 
interactions of some family members. The heterodimerisation and homodimerisation 
functions seem to be radically different, with Bcl-2 and Bcl-X|_ homodimers adopting a 
head-to-tail interaction while heterodimers appear to adopt a tail-to-tail conformation.
:9:
67
These exhibited improved survival over a longer period when treated with thymidine in 
excess (30 mM) or when subjected to nutritional limitation, in comparison to mock 
transfectant cells or cells transfected with bcl-2 alone (Terada, 1997). Likewise, co­
expression of Bcl-2 and Bag-1 in neuronally differentiated PCI 2 cells, which are subject to 
synchronous apoptosis when deprived of nerve growth factor, are protected more by the 
expression of Bcl-2 and Bag-1 than by Bcl-2 alone (Schulz, 1997). These results are 
further supported by a study where the overexpression of Bag-1 in the IL-3-dependent 
B-cell line Ba/F3, generated an lL-3-independent culture with minimal apoptosis observed 
in the absence of the cytokine (Clevenger, 1997).
Bcl-2 has also be shown to interact with Raf-1. Bcl-2 co-immunoprecipitates with Raf-1 in 
a mammalian haematopoietic cell line 32D.3, a diploid murine myeloid cell clone that is 
IL-3 dependent, and when Bcl-2 and Raf-1 are expressed in Sf9 insect cells using 
recombinant baculoviruses. When expressed together, Bcl-2 and Raf-1 also exhibit a 
functional synergy in 32D.3 cells in protecting the cells from apoptosis induced by means 
of IL-3 deprivation. Bcl-2 binds to a both the wild-type Raf-1 and to a truncated form 
containing the catalytic domain. However, Raf-1 does not appear to phosphorylate Bcl-2 
in either 32D.3 or Sf9 insect cells, suggesting that the relationship is not one of enzyme 
and substrate (Wang, H-G., 1994).
Bcl-2, in binding to Raf-1, appears to target the protein kinase to mitochondria. Bcl-2 and 
Raf-1 interact via the BH4 domain of the former and the catalytic domain of the latter, as 
indicated by its reaction with the BH4-containing Bcl-Xg, and its failure to react with Bax in 
which BH4 is absent. Furthermore, only wild-type Bcl-2 possessing BH4 targets Raf-1 
fused to a green fluorescent protein to mitochondria in a punctate fashion, in contrast to a 
deletion mutant of Bcl-2 lacking BH4, which produces a diffuse cellular distribution 
pattern. Raf-1 targeted to mitochondria via Bcl-2 enhances the ability of 32D.3 cells to 
resist apoptosis induced by IL-3 withdrawal and staurosporine, whereas interfering with 
the action of endogenous Raf-1 at mitochondria by mutating the functionally essential 
lysine 375 to tryptophan, has precisely the opposite effect Whereas Raf-1 does not 
appear to phosphorylate Bcl-2, BcI-Xl, Bcl-Xg, Mcl-1, Bax, or Bak, it does appear to 
phosphorylate Bad. This phosphorylation of Bad was detected both in vitro and in vivo, in 
cells expressing Raf-1 targeted at mitochondria but not Raf-1 targeted at the plasma 
membrane (Wang, H-G., 1996a). The authors speculate that phosphorylating Bad may 
displace it from Bcl-2, allowing Bcl-2 to fulfil its anti-apoptotic function.
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Bag-1 also binds and activates the serine/threonine specific kinase, Raf-1, although in this 
particular study the Raf-1 protein was not purified creating the possibility that the 
activation of the enzyme occurrs via an intermediary. However, in in vitro binding assays 
and yeast two-hybrid assays, Bag-1 was found to interact with Raf-1 via its catalytic 
domain in the C-terminal portion of the protein and to increase its kinase activity ~3-5-fold 
without phosphorylating the Bag-1 protein. Interestingly, Bag-1, Raf-1 and Bcl-2 formed 
tri-molecular complexes, although the stoichiometry was only ~1% and probably too low to 
represent an active part of the anti-apoptotic mechanism (Wang, H-G., 1996b).
According to studies using the haematopoietic cell line, BAF-B03 F7, Bag-1 expression 
can be modulated by IL-2. When BAF-B03 F7 cells expressing the gene 
transfer-mediated IL-2Ra chain, are exposed to in vitro IL-2, Bag-1 expression is 
upregulated (Adachi, 1996). However, any attempt to understand Bag-1's role In the 
apoptotic process is confused by its interaction with other cellular entitles. Gene 
transfer-mediated expression of Bag-1 in the MKN74 human gastric cancer cell line 
results, apparently by means of Bag-1's association with cytokeratin and actin filaments, in 
increased cell migration through increased cell motility (Nashiro, 1999).
Bag-1 also appears to be a cofactor of the heat shock cognate Hsc70 protein, where it is 
apparently involved in regulating its chaperone function. Bag-1 binds to the ATPase 
domain of the Hsc70 protein and is instrumental in substantially accelerating the release 
of ADP from Hsc70, by stimulating ATP hydrolysis (Hohfeld, 1997, 1998), However, 
whether Bag-Ts involvement in the cellular chaperone machinery and in cell motility 
reflects the complexity of the apoptotic pathways or the extent of Bag-Ts multiple 
functions, remains to be seen.
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7 Levels of expression of Bcl-2 family members in B-CLL and correlation with 
sensitivity to induced apoptosis.
7.1 Introduction.
The founding member of the bcl-2 family of genes, bcl-2, is a proto-oncogene which was 
first identified in 1984 in follicular lymphoma cells using a probe obtained from an acute 
B-cell leukaemia cell line. The bcl-2 gene is normally located at band q21,3 of 
chromosome 18, but a high proportion of cases of follicular lymphoma show a 
t{14;18){q32:q21) translocation which juxtaposes the intact bcl-2 gene with an enhancer 
region in the Ig H-chain locus on chromosome 14, leading to the constitutive expression of 
the protein (Bakshi, 1985; Cleary, 1985; Pegoraro, 1984; Tsujimoto, 1984, 1985).
Attempts to detect and quantify the involvement of the bcl-2 family of genes in B-CLL have 
concentrated largely on bcl-2, but expression of mcl-1, bak, bag-1, bax, bd-Xi, and bcZ-Xg 
have also been detected in the disease in varying amounts (Aguilar-Santiteses, 1996; 
Gottardi, 1996; Kitada, 1998). Bcl-2 is therefore not the only family member that may play 
a role in the pathogenesis of the disease by influencing the life span of B-CLL leukaemic 
cells, but abnormal expression of the bcl-2 gene, and its very close homologue bc/-x^ in 
particular, has been detected too consistently in the disease for there not to be a 
presumption that their expression plays some part in the B-CLL neoplastic process. For 
example, in an analysis of peripheral blood cells from 58 previously untreated B-CLL 
patients, Bcl-2, Mcl-1, Bag-1, Bax, and Bak were commonly but variably found using 
immunoblot assays and MoAbs specific for each protein. On the basis of densitometry 
scores, these proteins were found to be expressed in quantities equal to or greater than 
the amount of Bcl-2 expressed by the RS11846 t(14;18)-containing non-Hodgkins 
lymphoma cell line. Bcl-2 was expressed in quantity in 34/57 cases (60%), Mcl-1 in 24/55 
(44%), Bax in 27/57 (47%), Bak in 27/51 (53%), and Bag-1 in 7/51 (14%). The authors do 
not give specific figures for the extent of the overlap of different Bcl-2 family members in 
individual patients, but both the above statistics and one of the authors' illustrations 
(Figure 1) indicates that both Bcl-2 and Mcl-1 are jointly expressed in the B-CLL cells of 
some patients. However, no clear correlation could be drawn between the expression of 
these family members and in vitro chemosensitivity to fludarabine-induced apoptosis. In 
contrast to those listed above, Bcl-X|_, and Bad proteins were not present at detectable 
levels in any of the samples tested (Kitada, 1998).
These findings are strongly supported by a study of CD5'*’ B-cells from 23 B-CLL patients.
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Two further small studies confirm that the rate of expression of Bcl-2 in B-CLL is 
commonly higher than normal, with one of them being out-of-step by suggesting that there 
is a link between Bcl-2 levels and in vitro survival. When the expression of bcl-2 in cells 
from 9 B-CLL patients was investigated, bcl-2 mRNA transcripts were detected in 9/9 
samples analysed, with the high molecular weight 8.5 kb transcript being the most 
abundant transcript detected. Expression was heterogeneous, with levels comparable to 
those found in the Karpass 422 cell line carrying a bcl-2 rearrangement.
This investigation showed not only high levels of Bcl-2 and bcl-2 mRNA, but also strong 
expression of Bax and, in contrast to the findings reported by Kitada, strong expression of 
BcI-Xl (although only trace quantities of Bcl-Xg were detected). Northern blotting and
't:fluorescence-activated cell sorting (FACS) using an anti-Bcl-2 monoclonal antibody, 
respectively revealed both high levels of bcl-2 mRNA and Bcl-2 in all 23 of the B-CLL 
samples studied. Likewise, reverse transcriptase polymerase chain reaction (RT-PCR) 
confirmed by FACS, showed strong expression of bax mRNA in 20/23 cases studied.
RT-PCR also showed that high levels of bd-Xi_ mRNA was present in 16/23 of the 
samples tested, although bcl-x^ mRNA was detectable in only trace amounts in 13/23.
No relationship was observed between the expression of these family members or the 
clinical stage of the disease, but there appears to be a clear overlap in the expression of 
the anti-apoptotic proteins Bcl-2 and Bcl-Xj_ in the cells of some patients. Bcl-2 and bcl-2 
mRNA were found in all 23 samples tested so there must be an overlap in expression in 
the 16 samples in which bcl-Xi_ mRNA was also detected (Gottardi, 1996).
"iAlthough the levels of expression did not appear to be as high as the levels reported by |
Kitada e t a i, and referred to in a previous paragraph, a study aimed at linking Bcl-2, Bax 
and P53 expression to in vitro survival and clinical progression, similarly suggests that 
bcl-2 mRNA is aberrantly expressed in B-CLL. A study of 38 B-CLL patients defined as 
having progressive or non-progressive disease showed significantly higher levels of bcl-2 
mRNA, as measured by competitive polymerase chain reaction (PCR), in comparison to 
normal values. mRNA values expressed as moles per mole of glucose-3-phosphate 
dehydrogenase mRNA ranged from 0.01 to 9.00 and this degree of variability was 
reflected in protein levels. When measured as specific mean fluorescence intensity, Bcl-2 
levels were found to vary from 0.79 to 31.73 with a mean of 17.20 compared to 0.11 for a 
control nult-bc/-2 Daudi cell line and 67.46 for the t(14;18)-containing RL-7 cell line.
However, again no obvious relationship between Bcl-2 levels and disease progression 
could be detected (Aguilar-Santileses, 1996).
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However, no rearrangement was detected in any of the 9 samples using either a major 
cluster region (mcr) or a 5' breakpoint region probe to explain the higher rate of 
expression of bcl~2 mRNA, In contrast bcl-2 mRNA was not detected in the normal 
B-cells with which B-CLL cells were compared and the level of bcl-2 mRNA in the 
neoplastic cells showed no apparent relationship to either the patients' clinical stage or 
white blood cell count (Schena, 1992). Similarly a more recent study measured Bcl-2 
levels in the leukaemic B-cells from 8 B-CLL patients using a flow cytometer calibrated 
using fluorescein isothiocyanate (FITC)-labelled micro-beads and an FITC-labelled mouse 
anti-human-Bcl-2 mononclonal antibody on permeabilised cells. More than 90% of the 
cells from all 8 patients expressed Bcl-2 at high levels measured as 39+10 x 10^ mean 
equivalent of soluble fluorochrome (MESF) units before culture. This fell to 26+4 x 10^ 
after 7 days culture in medium alone, but with the percentage of Bcl-2'*' cells remaining 
constant. However, when B-CLL cells were cultured on a layer of BM stromal cells the 
MESF was measured as 44+9 after 7 days, suggesting that the Bcl-2 levels are 
maintained or enhanced in the presence of BM stromal cells (Lagneaux, 1998).
Although many of the studies do not involve the size of cohort that might resolve the 
question at a stroke, the extent to which anti-apoptotic proteins, particularly Bcl-2, are so 
consistently expressed in an apparently aberrant manner at both message and protein 
level, lends considerable weight to the belief that Bcl-2 and other anti-apoptotic family 
members are involved in the pathogenesis of B-CLL. Similarly and although the evidence 
is not unanimous, it is clear that there is no simple cause and effect relationship between 
absolute levels of Bcl-2 and disease progression, or clinical stage. However, perhaps the 
most interesting fact to emerge from the studies referred to in the preceding paragraphs, 
is the extent of the overlapping over expression of anti-apoptotic members of the family 
which was detected, i.e. Bcl-2 and Mcl-1 in one investigation, and Bcl-2 and Bcl-x jn  
another.
7.2 Bcl-2 levels and sensitivity of B-CLL cells to apoptosis.
The apparently inconsistent pattern of Bcl-2 expression in B-CLL in relation to clinical 
stage or disease progression, is reflected in a similar inconsistency between the Bcl-2 
levels detected and the degree of sensitivity of B-CLL cells to induced or spontaneous 
apoptosis in vitro.
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investigations that have suggested a link between Bcl-2 levels and the apoptotic threshold 
of B-CLL cells include simple observations of the link between Bcl-2 and spontaneous 
apoptosis, those which link stimulated expression of Bcl-2 to reduced rates of apoptosis, 
and those where apoptosis induced by cytotoxic agents has been shown to be mediated 
by reduced levels of Bcl-2.
An example of the former suggests that when B-CLL cells are cultured in vitro, the rate of 
spontaneous apoptosis is influenced by Bcl-2 levels, in a study of cells from 5 B-CLL 
patients, >85% of the cells were found to express Bcl-2 using an anti-Bcl-2 antibody and 
FITC-conjugated sheep anti-mouse Ig. During in vitro culture the mean fluorescence of 
the Bcl-2-expressing cells was downregulated, resulting in the appearance of cells with a 
Bcl-2 i°w phenotype after 48 hours. The percentage of cells down regulating Bcl-2 
expression continued to increase so that after 8 days of culture the majority of cells 
displayed a Bcl-2'°^ phenotype. The reduction in expression of Bci-2 was found to 
correlate with the rate of apoptosis, insofar as the percentage of Bcl-2h'9h cells was similar 
at all time points to the remaining percentage of viable cells for all 5 cell populations 
(Tangye, 1996).
In keeping with these results, culture of B-CLL cells with IFN-a, IL-4, bFGF, 
CDw32-transfected cells, or BM stromal cells, appears to reduce the extent of in vitro 
apoptosis in a manner that is linked to increased or preserved Bcl-2 levels. For example, 
during in vitro culture, Bcl-2 levels were measured by Western blotting and found to be 
preserved in those cells resistant to apoptosis and reduced in susceptible cells, but 
exposure to IFN-a and IL-4 appears to increase survival of B-CLL cells by preserving 
Bcl-2 levels. In an analysis of the cells from 8 B-CLL patients, Bcl-2 levels were found to 
be preserved in cells from 4 patients resistant to apoptosis for up to 30 days of culture in 
medium alone, but levels of Bcl-2 were rapidly reduced in cells from 4 patients sensitive to 
apoptosis. However, the rate of in vitro apoptosis could be reduced by culturing the cells 
with both IFN-a and IL-4 (which is discussed in greater detail in a subsequent chapter 
concerned with the modulation of levels of Bcl-2 family members), both of which reduced 
the rate of apoptosis in a manner that appeared to be associated with preservation of 
pre-existing Bcl-2 levels (Panayiotidis, 1993, 1994).
IL-4 has also been shown to increase the survival of B-CLL cells through Bcl-2 levels in a 
series of tests on B-CLL cells from 17 previously untreated patients. In comparison to 
control cultures, there was a 56% reduction in the number of cells undergoing apoptosis in 
B-CLL cells cultured with IL-4 for 4 days.
73
In the three samples of B-CLL cells tested, the prolongation of survival was accompanied 
by a partial preservation of Bcl-2 levels (Buske, 1997). Additionally, IL-4 has been shown 
to improve viability in B-CLL cells treated with hydrocortisone (HC) through its influence on 
Bcl-2 levels. B-CLL cells isolated from 12 patients were assessed for viability In the 
presence of medium alone, medium plus rlL-4 at 10ng/ml, medium supplemented with HC 
at 10“  ^M, or medium and rlL-4 at lOng/ml plus HC at 10'^ M. Cells cultured with HC 
showed the highest level of apoptosis, and cells cultured in medium plus rlL-4 showed a 
greater degree of viability than those cultured in medium alone. However, cells cultured 
with HC plus rlL-4 showed lower rates of apoptosis than cells cultured in medium alone. 
This lower rate of apoptosis appeared to be associated with Bcl-2 expression, with 
IL-4-treated cells expressing significantly more Bcl-2 than unstimulated, HC-treated, or 
freshly isolated B-CLL cells. Furthermore, the in vitro effect of IL-4 was found in vivo in 1 
patient, with subcutaneous administration of IL-4 at lOOpg/m^ increasing Bcl-2 expression 
in B-CLL cells (Danescu, 1992).
bFGF also appears to exert its influence on B-CLL cells by modulating Bcl-2 levels and at 
a concentration of 100 pM, was found to protect cells from the EBV-transformed cell line, 
183CLL, from apoptosis induced by 100 pM fludarabine. Compared to control cultures, 
addition of bFGF to the culture conditions resulted in both a delay in the onset of, and 
reduction in the percentage of cells undergoing apoptosis. Protection from apoptosis 
appears to be associated with upregulation of bcl-2 mRNA expression and the 183CLL 
cell line, which expresses low amounts of steady-state bcl-2 mRNA, showed a significant 
upregulation of the 8.5 kb transcript after stimulation with 10 ng/ml bFGF. A significant 
accumulation of the transcript was detected after 2 hours, with maximal response at 24 
hours, and increased expression of Bcl-2 was detected in 183CLL cells with densitometric 
analysis of protein bands indicating that bFGF had induced a 1.7-fold increase in Bcl-2 
levels (Konig, 1997b).
Evidence in support of the view that in vitro viability of B-CLL cells is linked to expression 
of Bcl-2 comes from studies in which Bcl-2 levels were manipulated using culture with BM 
stromal cells and CDw32-transfected murine fibroblasts. Cells from 8 B-CLL patients 
cultured with medium alone were 22+3% apoptotic after 48 hours, in contrast to cells 
cultured on a layer of human BM stromal cells which were only 8+2%. Bcl-2 levels in the 
B-cells from 8 B-CLL patients, measured using flow cytometry and an FITC-labelled 
mouse anti-human-Bcl-2 monoclonal antibody on permeabilised cells, showed more than 
90% of the cells from all patients expressing Bcl-2 at high levels, measured as 39+10 x 
10^ mean equivalent of soluble fluorochrome (MESF) units.
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At this level of fluorescence the rate of in vitro apoptosis was very low, but after 7 days' 
culture in medium alone, the level of Bcl-2 had been downregulated to 26±4 x 10^ MESF 
units, with the percentage of Bcl-2 positive cells remaining constant. This downregulation 
of Bcl-2 levels showed significant correlation with the increased rate of apoptosis in these 
cultured cells. In contrast, B-CLL cells cultured on BM stromal cells showed improved 
viability with the level of Bcl-2 measured after 7 days as 44±9 x 10^ MESF units 
(Lagneaux, 1998).
Similarly, when BM- and peripheral blood-derived B-CLL cells from 17 previously 
untreated patients were analysed for survival and apoptosis in relation to Bcl-2 expression 
after culture with various soluble ligands, the most efficient stimulus to in vitro survival was 
co-cuitivation with CDw32-transfected murine fibroblasts with fibroblasts in direct contact
'.
with the leukaemic cells, in comparison to control cultures there was a reduction in the |
number of cells undergoing apoptosis of 90% as assessed by trypan blue exclusion. The 
prolongation of survival by CDw32-transfected murine fibroblasts was accompanied by a 
reduction in apoptosis which was associated with the partial prevention of the loss of Bcl-2 
(Buske, 1997).
As increased viability of B-CLL cells appears to be mediated by increased expression of 
bci-2, Induction of in vitro apoptosis by cytotoxic agents appears to be mediated by 
reduced Bcl-2 levels. In a study using melarsoprol, an organic arsenical used in the 
treatment of trypanosomiasis, the compound was found to induce apoptosis in the 
non-EBV-transformed B-CLL cell line, WSU-CLL and the EBV-transformed B-CLL cell 
line, 183CLL, as well as lymphocytes from 5 B-CLL patients in a dose- and 
time-dependent manner. Of particular interest was the concentration-dependent 
downregulation of bcl-2 mRNA and reduced expression of Bcl-2 protein that was 
observed in both the WSU-CLL and 183CLL cell lines, which accompanied the decreased 
viability of these cell lines after 24 hours exposure to melarsoprol (KOnig, 1997a).
The results of these studies suggest that Bcl-2 levels and the rate of apoptosis appear to 
be inversely related, but unfortunately a significant number of other studies have produced 
quite contradictory results. In contrast to the results obtained using CDw32-transfected 
murine fibroblasts and IL-4, neither cultivation with soluble recombinant human CD40 nor 
cultivation with two different anti-CD40 antibodies, were found to prolong cell survival.
Bci-2 was found to be highest in freshly isolated cells and culture with soluble CD40 ligand 
resulted in the highest Bcl-2 levels being maintained.
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However, this occurred without any detectable increase in survival rate, suggesting that 
survival is not simply a matter of maintaining Bcl-2 levels (Buske, 1997).
A number of recent studies have also contradicted the mechanism by which IL-4 
increases the cell viability of B-CLL cells (Buske, 1997; Danescu, 1992; Panayiotidis,
1993, 1994). Comparison of the response of B-CLL celis from 11 previously treated 
patients (chlorambucil, prednisone, fludarabine, vincristine and cytoxan), with the cells 
from 14 untreated patients, showed that IL-4 protected the cells from previously treated 
patients against apoptosis more effectively that cells from the untreated patients.
However, when the IL-4-sensitive cells from 5 treated patients were analysed using 
anti-Bcl-2 MoAb indirect immunofluorescence staining, FITC-labelled anti-mouse Ig, and 
flow cytometry, no difference was detected between the Bcl-2 levels of cells cultured with 
or without IL-4 (Frankfurt, 1997),
Likewise, IL-4, with an optimal concentration of 50 U/ml, was found to significantly 
enhance the viability of B-CLL cells in culture for periods up to 96 hours independently of 
Bcl-2 levels, in comparison to control cultures. Furthermore, given the consistent 
observation that IL-4 enhances cell viability in culture, it was paradoxically found to 
increase the sensitivity of B-CLL cells to melphalan (L-phenylalanine mustard)-induced 
apoptosis. The increased rate of apoptosis was accompanied by interstrand-DNA 
cross-linking in B-CLL cells following short term exposure to the compound (Pu. 1997).
The effect of IL-4 on Bcl-2 levels has also been called into question indirectly by a study 
that shows IL-5 is able to increase the rate of spontaneous apoptosis in B-CLL cells 
independently of Bcl-2 levels, but which can be antagonised by IL-4. When the cells from 
13 B-CLL patients were incubated in medium supplemented with 20 U/ml of IL-5, 
spontaneous apoptosis increased by a mean percentage of 53% after 2 days of culture 
and by 37% after 3 days, in contrast to culture in medium alone. The apoptotic activity of 
IL-5 was dose-dependent and in half the cases studied the Increase in apoptosis was as 
great as that induced by dexamethasone at 25 pM/L. Bcl-2 expression was quantified 
using unlabelled mouse anti-human Bci-2 MoAb, FITC-labelled F(ab) ’ 2  fragments of rabbit 
anti-mouse Ig, and the cell-associated fluorescence with an FITC-labelled 
microbead-calibrated flow cytometer. In the five cases examined, Bcl-2 expression was 
not found to be significantly different in cells incubated with IL-5 compared to those 
incubated in medium alone. However, in all of these cases, IL-4 partially protected cells 
against IL-5-induced apoptosis in a manner that could be inhibited by anti-IL-4 MoAb 
(Mainou-Fowler, 1994).
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lL-10 has also been shown to Improve the in vitro cell viability of B-CLL cells 
independently of Bci-2 levels. Further-unpurified peripheral blood mononuclear cells 
(PBMC) from 4 B-CLL patients, purified by Ficoll/Hypaque density gradient centrifugation 
(only 3 of which were CD5'*’), incubated with IL-10 at concentrations between 1.0-50 ng/ml 
for between 10-21 days, were found to reduce the degree of apoptosis. However, when 
Bcl-2 expression was examined by flow cytometry and Western blotting, no difference 
was detected in its expression in the PBMC cultured with and without IL-10 (Kitabayashi,
1995). The absence of further purification of PBMC may raise doubts about the effect of 
IL-10, but does not change the fact that survival was improved independently of Bcl-2.
Many of the studies quoted involve questionably small cohorts, but a larger than average 
investigation of 42 B-CLL patients, although confirming previous observations that the 
propensity of B-CLL cells to undergo apoptotic death is greater in cells isolated from 
patients with untreated early stage disease, failed to detect any connection between Bci-2 
levels and cell survival. Bcl-2 expression was detected in 42/42 samples of leukaemic 
ceils from B-CLL patients by Western blotting, with levels ranging from 0.07 to 3.34 
arbitrary units when normalised to a t(14;18)-containing lymphoma cell line (Johnson).
9/42 samples showed higher levels of Bcl-2 expression than that found in the Johnson cell 
line and a further 19/42 had Bcl-2 levels < levels found in B-cells from normal peripheral 
blood. However, no correlation between the level of Bcl-2 and clinical stage, prior 
treatment status, or refractory disease was detected. In particular, there was no 
correlation between Bcl-2 levels and spontaneous or fludarabine-induced apoptosis, as 
measured by DNA fragmentation. Similarly, assessment of B-CLL cell viability over 72 
hours using a trypan blue assay did not appear to correlate with Bcl-2 expression 
(Robertson, 1996).
Whilst Bcl-2 levels do appear to have some bearing on the fate of B-CLL cells in vitro, the 
contradictory nature of the evidence available makes it is difficult to accept that the 
sensitivity of B-CLL cells to apoptosis is determined by Bcl-2 levels alone. In such 
circumstances, the cellular levels of pro-apoptotic Bcl-2 family members, particularly in 
relation to Bcl-2 levels, need to be considered.
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7.3 Bc!-2:Bax ratios.
Although once again the evidence is not entirely unanimous, some explanation for the 
absence of any apparent correlation between Bcl-2 or BcI-Xl levels in B-CLL and either 
disease progression or in vitro survival rates, may be offered by differences in the cellular 
Bcl-2;Bax and Bcl-X|_:Bax ratios. Higher levels of these appear to be related to 
progressive disease, previous treatment status, and relative insensitivity to the induction 
of apoptosis in a way that absolute levels of Bcl-2 cannot be linked.
For example, the study involving cells from 38 patients with B-CLL, referred to in a 
previous paragraph, showed no relationship between Bcl-2 levels and disease 
progression or in vitro survival, but higher levels of bax^ were detected in the non- 
progressive patients resulting in significantly lower bcl~2:bax^ mRNA ratios compared to
cells from patients with progressive disease (Aguilar-Santileses, 1996). This is certainly in 
keeping with the relationship between Bcl-2:Bax ratios which Oltvai, Korsmeyer, and 
Milliman (1993, 1994) have suggested is a determining factor in regulating apoptosis, and 
is well-supported by other studies which have looked at the ratio of pro- and anti-apoptotic 
members of the Bcl-2 family in the context of in vitro life span, disease progression, and 
resistance to chemotherapeutic treatment.
These studies include a study of B-cell isolates from 24 B-CLL patients. Comparison of 
the 4/24 patient isolates which subsequently proved most sensitive to in vitro apoptosis 
induction with methylprednisolone or fludarabine plus mitoxantrone, with the 4/24 least 
sensitive, revealed that Bcl-2 levels were four-fold higher in the latter and were 
accompanied by only a modest increase in Bax. When isolates from all groups were 
incubated in vitro, Bcl-2 expression fell in comparison to freshly isolated controls, while 
Bax fell in only the apoptosis-resistant samples. This supports the theory that Bcl-2:Bax 
ratios are more important than absolute Bcl-2 levels in protecting the leukaemic cells from 
apoptosis, but of particular interest is the difference in endogenous endonuclease activity 
between the apoptosis-resistant and apoptosis-sensitive isolates. Nuclei from apoptosis- 
sensitive B-CLL cells expressed abundant levels of endogenous endonuclease activity, in 
comparison to the apoptosis-resistant cells, where endonuclease activity was not 
detected. This study involves a very small sample, but if it proved eventually to be 
representative of B-CLL cells with lower Bcl-2:Bax ratios, it would suggest that they are 
primed and ready for the apoptotic cascade (McConkey, 1996).
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The Bcl-2:Bax ratio also appeared to correlate with previous cytotoxic treatment status 
when the leukaemic cells from 22 patients with B-CLL were assessed by quantitative 
immunofluorescence analysis using flow cytometry to determine Bcl-2 and Bax 
expression. Increased Bcl-2:Bax ratios were observed in all 22 samples compared to 
those detected in normal peripheral blood B lymphocytes used as controls, and previously 
untreated patients had lower Bcl-2:Bax ratios than previously treated patients. Additionally 
the higher Bcl-2:Bax ratios were particularly pronounced in those previously treated 
patients who were found to be clinically unresponsive to therapy. The in vitro response to 
chlorambucil-induced apoptosis correlates with the Bcl-2:Bax ratio and there appears to 
be a trend towards an apoptosis-resistant phenotype with treatment (Pepper, 1996, 1997). 
This apoptosis-resistant phenotype may be due to a degree of variation in the Bcl-2:Bax 
ratio within the clone and the selection of a resistant population with higher Bcl-2:Bax 
ratios, but the possibility that it involves the induction of drug resistance cannot be 
excluded.
Similarly, Western blot analysis and quantification using laser densitometry of Bcl-2 and 
Bax expression revealed a correlation between 9-amino-20(s)-campothecin- and 
fludarabine-induced apoptosis and the endogenous ratios of Bcl-2:Bax. B-CLL cells from 
21 patients with low Bcl-2:Bax ratios were generally found to be drug-sensitive, compared 
to those with intermediate-high Bcl-2:Bax ratios, which were resistant to the induction of 
apoptosis in vitro. Prior to the induction of apoptosis, Bax was found to migrate as a 
single 21 kDa species, but expression was upregulated after drug-induced apoptosis 
when Bax migrated as complexes of 36-42 kDa. These were disrupted using two- 
dimensional gel electrophoresis in reducing conditions to reveal that they were comprised 
of Bax monomers of 18 and 21 kDa. The need for reducing conditions would suggest that 
disulphide bonds were involved in the formation of the dimers, but the significance of this 
de novo appearance of an 18 kDa Bax species and its increased expression in B-CLL 
cells undergoing drug-induced apoptosis, remains unclear (Thomas, 1996).
Particularly compelling evidence for the role of the Bci-2:Bax ratio in determining the cell’s 
sensitivity to apoptosis comes from an analysis of cells from a total of 26 B-CLL patients 
using antagonistic monoclonal antibodies, the anti-CD6 MoAb, I0R-T1, and anti-lgM.
Cells from 10 patients showed a significant increase in the rate of in vitro apoptosis from a 
mean of 13.2% to 39.7% when cultured with anti-lgM MoAb, but the rate of apoptosis was 
reduced in 8/10 populations co-cultured with anti-lgM and 10R-T1. The induction of 
apoptosis by anti-lgM in B-CLL cells and the protection offered against it by I0R-T1 
appears to be mediated by changes in bcl-2 and bax mRNA levels.
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in 5 cultures anti-lgM was found to reduce the bcl-2/bax^mRHA  ratio through a reduction 
in bcl-2 mRNA and particularly by an upregulation of bax^ mRNA. Simultaneous culture 
with anti-lgM and IOR-T1 in 4 cases resulted in a significant reduction in baxq, mRNA 
without any change in bcl-2 mRNA, raising the bc/-2/bax^ mRNA ratio in a manner that 
correlated with 10R-T1-mediated protection of anti-lgM-treated cells. In B-CLL cells from 
3 patients co-cultured with anti-lgM and I0R-T1, the unchanged bcl-2 mRNA and reduced 
baXg, mRNA levels were reflected in unchanged Bcl-2 and reduced Bax^  ^ levels, in two 
further cell cultures, Bax^  ^ levels were higher after culture with anti-lgM than after culture 
with medium alone (Osorio, 1997).
Further support for the view that Bcl-2:Bax ratios determine the fate of B-CLL cells, comes 
from studies using B-1 cells derived from New Zealand bald (NZB) mice which serve as a 
murine model for studying B-CLL. NZB mice cell lines show close parallels to B-CLL in an 
age-dependant onset of the clonal expansion of malignant B-1 cells, the indolent disease 
course, increased numbers of lymphocytes and smudge (smear) cells in peripheral blood, 
chromosomal abnormalities, and a similar pathology with neoplastic cells infiltrating 
spleen, lymph nodes and peritoneum. Although the B-1 cell line used, LNC, was resistant 
to the in vitro induction of apoptosis with fludarabine at concentrations up to 48 |.iM, an 
increase in apoptosis, detected by propidium iodide staining and DNA fragmentation gel 
electrophoresis, was induced by the mitotic spindle inhibitors colcemid and nocodazole.
In the case of colcemid this was preceded by arrest at G2-M phase of the cell cycle. A 
reduction in the amount of B-cell-specific-activator-protein (BSAP) mRNA (which is 
constitutively expressed in malignant B-1 cells), accompanied unchanged constitutive 
expression of bcl-2 mRNA, but increased levels of expression of bax mRNA. This 
suggests that colcemid- and nocodazole-induced apoptosis is also executed by changing 
the balance between Bcl-2 and Bax, but the significance of the G2-M arrest and BSAP 
remains unclear (Zhang, 1998).
Unfortunately not all of the results are consistent with the Oltvai, Milliman and Korsmeyer 
paradigm. An investigation of 41 cases of B-CLL based on densitometry immunoblot 
scores, showed that the Bcl-2:Bax ratios were skewed very clearly to ratios of 1 and 
above and failed to correspond with rates of in vitro spontaneous apoptosis. Additionally 
when the samples were separated into high and low Bcl-2:Bax ratio groups, an 
unexpected correlation between lower ratios and a failure to achieve complete remission 
was observed (Kitada, 1998).
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If the life span of B-CLL cells is determined by a relatively simple mechanism involving the 
relationship between the apoptosis-inhibiting Bcl-2 and the apoptosis-inducing Bax, then 
precisely the opposite relationship might be expected.
However, on balance the evidence is very strongly supportive of the view that higher 
Bcl-2:Bax ratios are related to progressive disease, previous treatment status, and relative 
insensitivity to the induction of apoptosis in a way that offers a highly plausible explanation 
for the difficulty in linking these variables to Bcl-2 levels alone.
8 Causes of the higher level of expression of bcl-2  mRNA and Bcl-2 in B-CLL.
Aside from attempts to explain the often higher expression of Bcl-2 in B-CLL through 
stimulation of the cells, attempts to explain the higher level of expression of both bcl-2 
mRNA and Bcl-2 in B-CLL have concentrated most entirely on detecting deregulating 
translocations of the bcl-2 gene. The fact that levels of Bcl-2 are clearly modulated in 
normal cells, e.g. during B-lymphopoiesis, and that a malfunctioning of any of the 
modulatory mechanisms could just as easily result in pathological expression of the 
protein, has been largely ignored, as has overexpression of many other Bcl-2 family 
members. However, although the sample was very small and involved cells from only 
four patients in which a translocation had been detected, interestingly one study showed 
that expression of Bcl-2 was stronger in those cells with a translocation, than in those 
without {Merup, 1996). The commonest technique used to detect translocations is 
Southern blotting and investigations of the incidence of translocation of the bcl-2 gene in 
B-CLL using it have produced contradictory results. A variable degree of rearrangement 
involving the immunoglobulin heavy chain locus, and light chain k  and 1 loci, ranging from 
0-12% has been detected, but the extent and importance of translocation in B-CLL 
remains unclear.
A large study investigated CDS'*", CD19'*' and CD23'*' neoplastic B-cells from 100 B-CLL 
patients in Rai stages 0-IV for oncogene rearrangements including bcl-2. Probes were 
used for the three known bc/-2 translocation clusters {Cleary, 1986; Tsujimoto, 1985), the 
major cluster region (mcr), the minor breakpoint region (mbr) and the cluster region 
located in, and adjacent to, the 5’ region of the gene. Using the probes pFL-1 and pFL-2 
on BamHl digests and pB16 on Hind\\\ digests, no translocations of the bcl-2 gene were 
detected, although in view of the possible connection between Bcl-2:Bax ratios and p53, it 
is interesting to note that p53 mutations were detected in 10/100 samples representing all 
stages of disease (Gaidano, 1994; Miyashita, 1994).
Several other studies have also failed to detect rearrangements of the bcl-2 gene in 
B-CLL. Two separate studies, in which pB3 and p i 8-4 probes aimed at the mcr and 
pFL-2 probes aimed at the mbr were used, failed to detect any occurrences of the t(14;18) 
translocation typical of follicular lymphoma in samples of neoplastic cells from a total of 48 
(32+16) B-CLL patients (Adachi, 1990, Hanada, 1993). In another series of experiments 
the cells from 4 B-CLL patients, in which Bcl-2 levels were found to be preserved and 
which were resistant to in vitro apoptosis, were compared with the cells from 4 patients in 
which levels of Bcl-2 were rapidly reduced and which were sensitive to in vitro apoptosis.
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Southern blotting analysis failed to detect any rearrangement of the major breakpoint 
cluster region in either group. Furthermore, analysis using PCR amplification failed to 
detect any evidence of rearrangement of the major or minor breakpoint cluster regions 
(Panayiotidis, 1994). Similarly an earlier study of 38 B-CLL patients also failed to identify 
any rearrangements of the bcl-2 gene (Rechavi, 1989).
In keeping with the absence of the t(14;18) translocation in B-CLL shown in the studies 
referred to above, investigations using Southern blotting which have demonstrated 
evidence of bcl-2 rearrangements, have shown only a relatively low incidence ranging 
from <2%-4%. Analysis of 44 patients with B-CLL using probes for the Ig genes, as well 
as probes for the mbr, mcr and 5' breakpoint regions associated with the bcl-2 gene, 
showed a t(14;18)(q32:q21) rate of 1/44 (-2% ) (Raghoebier, 1991). Likewise a very large 
study of the cells from 170 patients with B-CLL, showed a rate of 3/170 (~2%) with 
translocation of the bcl-2 gene to the H-chain locus on chromosome 14, where all three 
cases had breakpoints in the 3' region of bcl-2 mapping to the region between the mbr 
and mcr (Dyer, 1994). The highest detected rate for the t(14;18) translocation using a 1.5 
kb pFL-1 probe for the mcr, detected rearrangements in 3/71 (4%) of the B-CLL cells 
tested, although in 2/3 of these a rearrangement was also detected in the variant cluster 
region (vcr) flanking the 5’ end of the bcl-2 gene using the 1.2 kb probe pB16 (Merup,
1996).
Higher rates of rearrangement of the bcl-2 gene are found in relation to the 5' vcr region, 
which is particularly associated with the t(18;22)(q21.3;q11) and t(2;18)(p11;q21.3) 
translocations, which translocate the bcl-2 gene to the IgA. and IgK loci, respectively. The 
pB16 probe obtained from the first exon of bcl-2 detected reciprocal translocations 
between the bcl-2 gene and the immunoglobulin light chain loci in 3 of the 32 samples 
(-10% ) obtained from B-CLL patients (although there is a question mark over this statistic 
as it appears that one of the samples was known to carry the IgA. translocation before the 
study was carried out, so a more representative occurrence would be 2/31 or -6%). In 
two cases the reciprocal translocation involved the Ig A locus and in the third case the Ig k 
locus, with the bcl-2 gene transposed in a head-to-head configuration. In all three cases 
the breakpoints on chromosome 18 were clustered in the region flanking the 5' of the 
bc!-2 gene between 1100-2200 bp upstream, suggesting the existence of a hotspot for 
rearrangements in B-CLL in this region (Adachi, 1989a, 1989b, 1990). A slightly higher 
percentage of rearrangement was detected with the pB16 probe in a larger than average 
study, involving a total of 96 patients with B-CLL.
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Of the 67 patients tested, 8 showed a rearrangement with this vcr probe (12%), including 
four who showed rearrangement associated with the Ig k gene (4%) (Merup, 1996). 
Similarly, probes for the Ig genes and 5' vcr regions, showed gene alteration events in the 
cells 2/44 (5%) B-CLL patients, with rearrangements of the bcl-2 5'-breakpoint region 
without translocation to the Ig light gene loci (Raghoebier, 1991). Additionally, both 5‘ and 
3' region bcl-2 probes showed one example of each of the t(18;22)(q21.3;q11) and 
t(2;18)(p11;q21.3) translocations in 2/170 cases of B-CLL (1%) (Dyer, 1994). Not all 
studies aimed at the vcr adjacent to the 5' end of the gene show rearrangement of this 
part of chromosome 18 and a 3.85 kb p i 8-21H probe failed to demonstrate any evidence 
of this particular rearrangement in a study of the cells from 16 B-CLL patients (Hanada, 
1993).
On the basis of Southern blotting these studies suggest that the incidence of bcl-2 
rearrangement in B-CLL is much lower than that encountered in follicular lymphoma, with 
a preferential translocation to the Ig L-chain loci, rather than the Ig H-chain locus.
However, other techniques such as pulsed-field gel electrophoresis (PFGE) and 
fluorescence in situ hybridisation (FISH) suggest that these results may not reflect the true 
incidence or nature of bcl-2 translocation in B-CLL.
In particular, one investigation found a 100% incidence rate of rearrangements of the bcl- 
2 gene in neoplastic cells from 9 B-CLL patients and 2 cell lines, using PFGE to probe 
fragments varying in length from >50 to 10,000 kb, where no rearrangements had been 
discovered using Southern blotting. In all 11 samples the 1.6 kb pB16 probe, an EcoRI 
fragment containing the bcl-2 cDNA that corresponds to the 3’ part of the 5' end of the 
bcl-2 gene, failed to detect any rearrangement of the bcl-2 gene in AV/ndl 11-digested DNA 
from the B-CLL patients' neoplastic cells using Southern blotting. The same probe also 
failed to detect any rearrangement in B-CLL cell lines, or lymphoblastoid cell lines (LCLs) 
established from the B-CLL patients' normal peripheral blood lymphocytes. In contrast, 
when the pB16 cDNA was used in PGFE to probe large fragments of DNA produced by 
KspI or Sa/I digestion, it showed bcl-2 rearrangements in fragments of DNA 245-600 kb in 
length from all 9 of the neoplastic cell samples from the B-CLL patients, as well as the two 
B-CLL cell lines. Only the normal germ line pattern was detected in KspI- or Sa/I-digested 
DNA from normal controls or the paired normal LCLs of the B-CLL patients, thereby 
excluding restriction fragment length polymorphisms as the cause of these results 
(Laytragoon-Lewin, 1998).
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Additionally, a study using FISH to detect rearrangement of the bcl-1, bcl-2, and bcl-3 
genes, along with trisomy 12, showed a higher rate of rearrangement of the bcl-2 gene 
with translocation to the Ig heavy chain locus in B-CLL cells, than had been detected by 
other means. Using a 3.5 kb EcoRI, Hind\\\ fragment in a pYT13 plasmid as a probe for 
the JH region, a 4.2 kb Hind\\\ fragment in a pYT13 plasmid as a probe for bcl-2, and a 
-satellite D12Z3 as a probe for trisomy 12, showed an incidence of 3/20 (15%) in B-CLL 
cells for the t(14;18)(q32;q21) translocation, where two of the translocations were also 
accompanied by trisomy 12 (Lishner, 1995).
Given the restricted ability of Southern blotting to detect gene rearrangements over long 
distances and the difficulty in obtaining adequate numbers of metaphases from the many 
clones of B-CLL cells that are un reactive to polyclonal activators such as SAC strain 1 
plus IL-2 and TPA, it is not unreasonable to question the ability of this technique to detect 
all bcl-2 rearrangements in B-CLL. For example, in a study involving the cells from 30 
B-CLL patients, SAC and IL-2 were found to cause proliferation in only the B-CLL cells 
from the 15 patients with progressive disease and had only a marginal proliferative effect 
on 1 of 15 patients with non-progressive disease (Aguilar-Santileses, 1994). The ability of 
Southern blotting to detect bcl-2 rearrangements is indirectly called into question by the 
results obtained using FISH (Lishner, 1995), and particularly the results obtained in 
detecting bcl-2 rearrangements using PFGE (Laytagoon-Lewin, 1998). The 15% 
incidence of the t(14;18) translocation demonstrated by FISH is the highest reported 
occurrence of this translocation in B-CLL. Although the study by Lishner et al did not 
apparently attempt to detect any of 3 /201(14;18) translocations by Southern blotting, their 
demonstration that bcl-1 rearrangements that could not be detected by Southern blotting 
could be detected by FISH, lends credence to their claim that FISH is a more sensitive 
technique for detecting this translocation in B-CLL and that, by inference. Southern 
blotting underestimates the rate of rearrangement of the bcl-2 gene in B-CLL. This 
suggestion is particularly well supported by the study by Laytragoon-Lewin et al 
demonstrating bcl-2 gene rearrangement in 11 B-CLL samples where Southern blotting 
had failed to detect rearrangements. That PFGE is well-suited to detect bcl-2 gene 
rearrangements is also supported by a study using this technique to detect the t(14;18) 
translocation In follicular and diffuse lymphoma. Using PFGE, Southern blotting, 
polymerase chain reaction, and cytogenetic analysis, this study showed that this technique 
was the most effective at detecting the bcl-2 rearrangement in follicular lymphoma in a 
series of 40 patients, being the only technique to detect this translocation in one case.
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In addition, in a series of seven cases with progression from follicular to diffuse 
lymphoma, PFGE detected the translocation in all seven cases compared to a detection 
rate of only 3/7 for Southern blotting (Zelenetz, 1991).
The impression given by studies using Southern blotting, that the bcl-2 gene 
rearrangement occurs in only a very small minority of cases of B-CLL and that where it 
occurs, the bcl-2 gene is preferentially rearranged to the IgK and IgA loci, appears 
uncertain at best and further large scale studies using the range of techniques available 
would be needed to resolve the issue. It remains possible that the bcl-2 gene is 
rearranged in a much greater number of cases of B-CLL than previously thought and that 
the rearrangement may not necessarily involve translocation to another chromosome, but 
a study showing that expression of bcl-2 can be modulated in B-CLL lines is a reminder 
that Bcl-2 overexpression in B-CLL may not be entirely due to translocation.
The investigation in question explored the growth- and differentiation-associated 
expression of bcl-2 in two B-CLL cell lines, 173 and 183, using different activation 
protocols. When 173 B-CLL cells were advanced from Ggto G., by TPA and 
differentiated into IgM-secreting lymphoblasts and plasmablasts, in the absence of DNA 
synthesis, the steady-state level of bcl-2 mRNA was rapidly downregulated. Reductions in 
bcl-2 mRNA levels were observed within an hour of treatment with maximal response 
after 3 hours in comparison to steady-state levels. Levels fell to -35%  of control levels, 
before rebounding to 4-fold control levels at 12 and 72 hours post treatment. Similarly, 
when the 183B-CLL cell line was subjected to mitogenic protocols including treatment with 
various combinations of TPA, SAC, IL-2, TNF-a, IL-4 and B-cell stimulatory factor from 
the T-cell hybridoma, MPG, (BSF-MP6), reductions in both bcl-2 mRNA and Bcl-2 were 
observed. This was particularly true where high DNA synthesis was observed, suggesting 
that bcl-2 expression was inversely related to proliferation in this 183 cell line (Schena, 
1992). It is difficult to envisage how a rearranged bcl-2 gene could be modulated in this 
way during growth or differentiation, suggesting that in some B-CLL cells at least, a 
mechanism other than deregulation of the gene as a result of rearrangement may be 
responsible for the aberrant expression of bcl-2.
One mechanism suggested to explain the high levels of expression of Bcl-2 in B-CLL 
without apparent rearrangement of the gene, involves its hypomethylation. This was 
investigated in a study that analysed the structure, méthylation status, and expression of 
the bcl-2 gene in 20 patients with a lymphoproliferative neoplastic disease, including 17 
diagnosed as having B-CLL.
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Twelve of the cases of B-CLL showed expression of p26-Bct-2 protein that was roughly 
equal to, or greater than the level of Bcl-2 protein expressed by the t(14;18)“Containing 
RS11846 B-lymphoma cell line. There was no evidence in any of the 17 B-CLL samples 
of rearrangement of the bcl-2 gene using a 3.85 kb Xho\ to Hind\\\ fragment from p i 8-21H 
for the 5' breakpoint region, a 4.4 kb Hind\\\ fragment from p i 8-4 for the S' mcr, a 4,5 
EcoRI fragment from pFL-2 for the mbr, or a 2.8 kb Mbo\ fragment from pKB-Mbol 2.8 for 
human mitochondrial DNA. However, investigation of the méthylation status of the bcl-2 
gene using a probe corresponding to the first exon of the gene and the isoschizomers, 
Msp I and Hpa II, demonstrated a complete absence of méthylation in the region of the 
bcl-2 gene corresponding to the 2.4 kb Msp I fragment. This applied to all 20 samples 
including the cells from the 17 B-CLL patients. In contrast, the results from 6/6 cells from 
B-cell lines that display a t(14;18) translocation suggested hypomethylation of only one 
allele and neither copy of the bcl-2 allele was hypomethylated in the region corresponding 
to Msp I in 5/5 lymphoid cell lines that lack the t{14;18) translocation (Hanada, 1993). 
Whilst such results are not conclusive they do open up the possibility of trans-acting 
mechanisms causing elevated levels of transcription of the gene through a mechanism 
that involves hypomethylation, as opposed to the cis-regulating mechanisms that are 
thought to apply in bcl-2 gene rearrangements.
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9 Modulation of the level of Bcl-2 family members by extra- and intracellular 
influences. 
9.1 Introduction.
When the cells from B-CLL patients are cultured in vitro, they are generally found to die 
apoptotically (Collins, 1989; Buschle, 1993), suggesting that culture systems lack 
essential survival factors that are present in vivo. Over a significant number of years the 
factors that have been shown to influence the life span of B-CLL cells in vitro include 
soluble and cell membrane bound factors as well as P53. These include the cytokines 
IL-4, IL-5, IL-8, IL-10, IFN-a, IFN-y, and bFGF, as well as CDw32, BM stromal cells, 
CD95/APO-1/Fas, CD40, and CD6.
9.2 IL-4
IL-4 in particular appears very effective in protecting B-CLL cells from in vitro apoptosis, 
but not all studies agree as to its effect or that it does so by modulating the level of Bcl-2. 
For example, B-CLL cells isolated from 12 patients and assessed for apoptosis by trypan 
blue exclusion, were found to be protected from spontaneous and hydrocortisone-induced 
apoptosis when rlL-4 at 10 ng/ml was added to the culture conditions. A measure of the 
degree of protection is indicated by the fact that cells cultured with HC showed the highest 
rates of apoptosis, but culture with HC and rlL-4 produced lower rates of apoptosis than 
when B-CLL cells were cultured in medium alone. The rate of apoptosis appears to be 
associated with Bci-2 expression, which is upregulated in those cells treated with rlL-4, 
with treated cells expressing significantly more protein than unstimulated, HC-treated or 
freshly isolated B-CLL cells. Furthermore the effect of rlL-4 is supported by an 
experiment in 1 patient where subcutaneous administration of IL-4 at lOOpg/m^ increased 
Bcl-2 expression in B-CLL cells in vivo (Danescu, 1992).
Support for the view that IL-4 improves viability of B-CLL cells in vitro by increasing Bcl-2 
levels, comes from a study involving 24 B-CLL patients. B-CLL cells were -33%  apoptotic 
after 26-30 hours in in vitro culture, which increased to 90-100% after 8-10 days. At 
concentrations of 0.5-5 ng/ml, human recombinant IL-4 reduced the rate of apoptosis 
without stimulating cell proliferation and viable cells could be maintained in culture for up 
to 3 weeks, e.g., at 5 ng/ml, IL-4 reduced apoptotic DNA fragmentation to a mean of 
14.9% after 26-30 hours.
All 11 patients analysed by Western blotting showed expression of Bcl-2, but during 
culture this was only preserved in cells resistant to apoptosis and reduced in susceptible 
cells. Bcl-2 loss was inhibited in cells cultured with IL-4, suggesting once more that this 
cytokine may play a part In the extended survival of B-CLL cells (Panayiotidis, 1993).
Although theophylline and chlorambucil apparently induce in vitro apoptosis in B-CLL cells 
by different pathways/mechanisms, they appear to do so by reducing expression of bcl-2 
mRNA and Bcl-2, which can be reversed by culturing the ceils with IL-4. Theophylline 
-induced apoptosis involves an accumulation of cyclic adenosine monophosphate, in 
contrast to the Ca^"  ^mobilisation and influx induced by chlorambucil. However, both 
compounds induce apoptosis and their actions are synergistic allowing fourfold lower 
concentrations to be used in combination. Significant amounts of bcl-2 mRNA and Bcl-2 
were expressed in the 15 B-CLL patients tested and incubation with theophylline and/or 
chlorambucil reduced expression of bcl-2 mRNA and Bcl-2. However, the effect of these 
cytotoxic drugs on bcl-2 expression is partially reversed by IL-4 at 10 ng/ml (Mentz, 1996).
The effect of IL-4 on the rate of apoptosis in B-CLL cells appears to be in keeping with the 
expression of IL-4 receptors. Using flow cytometry, expression of IL-4 receptors on cells 
from 4 B-CLL patients was found to be uniform and significantly increased over 
background fluorescence, in comparison to IL-4 expression in 3 samples of normal 
CD19+ peripheral blood B-celis, where fluorescence was minimal. In keeping with this 
difference in IL-4 receptor expression, culturing B-CLL cells with 10 ng/ml of IL-4 
significantly reduced the amount of apoptosis in 9/11 samples after culture for 48 hours 
from -34%  in medium alone to -10% . In contrast, IL-4 at 10 ng/ml had only a marginal 
effect on normal cells, reducing apoptosis from a mean of 24+4% to 18+3% in the 7 
samples tested (Douglas, 1997).
Evidence for IL-4 exerting its anti-apoptotic effect via Bcl-2 is not unanimous. As might be 
expected, given that treatment appears to induce an apoptosis-resistant phenotype or 
drug resistance (Pepper, 1996, 1997), IL-4 at 0.01, 0.1 and 1.0 ng/ml protected B-CLL 
cells from 11 patients who had previously been treated with cytotoxic drugs, e.g. 
chlorambucil, from apoptosis more effectively than B-CLL cells from 14 untreated 
patients. Rates of in vitro apoptosis were comparable in the two groups cultured in 
medium alone, but IL-4 concentration had to be increased from 0.01 ng/ml in the treated 
patients to near 1.0 ng/ml in untreated patients to achieve the same protection.
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In this study IL-4 did not appear to modulate sensitivity to apoptosis through Bcl-2 levels. 
Bcl-2 levels measured by indirect immunofluorescence staining using an anti-Bcl-2 MoAb, 
FITC-labelled anti-mouse Ig, and flow cytometry in 5 patients whose B-CLL cells were 
sensitive to the anti-apoptotic effect of IL-4, showed no difference when cells were 
cultured in the presence or absence of IL-4 (Frankfurt, 1997).
Paradoxically, IL-4 has been associated with an increase in chemically-induced apoptosis 
in one study, where IL-4 was found to significantly enhance the viability of B-CLL cells in 
culture for periods up to 96 hours compared to control cultures, with an optimal 
concentration of 50 U/ml. However, it was found to increase the sensitivity of B-CLL cells 
to melphalan (L-phenylalanine mustard)-induced apoptosis. The increased rate of 
apoptosis was accompanied by interstrand-DNA cross-linking in B-CLL cells following 
short term exposure to the compound. It remains unclear if this suggests that IL-4 does 
not modulate Bcl-2 levels or whether, by a separate pathway, apoptosis can be induced 
independently of Bcl-2 levels (Pu, 1997). The separate pathway explanation is certainly 
plausible as apoptosis induced in B-lymphoid cell lines through CD95 ligation and the 
FADD/caspase-8 pathway appears to be relatively immune to the expression of Bcl-2 
(Adams, 1998), but it remains to be seen if melphalan induces this pathway.
A study to determine the effect of IL-5 on the rate of in vitro apoptosis in B-CLL cell 
cultures, casts further doubt on whether IL-4 exerts its anti-apoptotic effect on B-CLL cells 
through a simple variance of Bcl-2 levels, since IL-5 was found to increase the rate of 
apoptosis in B-CLL cells in a manner that does not Involve modulation of the Bcl-2 level, 
but which is partially reversible by IL-4. When purified B-CLL cells from 13 patients were 
incubated in medium supplemented with 20 U/ml of IL-5, spontaneous apoptosis 
increased by 53% after 2 days of culture and 37% after 3 days in comparison to cells 
cultured in medium alone. In half the cases studied the increase in apoptosis, which was 
dose-dependent, was as great as that induced by dexamethasone of 25 pM. In the five 
cases examined, Bcl-2 expression quantified by flow cytometry was not found to be 
significantly influenced by incubation with IL-5. IL-4 partially protected cells against 
ÎL-5-induced apoptosis in a manner that could be inhibited by anti-IL-4 MoAb, and such 
protection suggests that IL-4's protection of B-CLL cells is not via a simple link with Bcl-2 
levels (Mainou-Fowler, 1994).
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9.3 IL-8
IL-8 also appears to be capable of prolonging the in vitro life of B-CLL cells and to do so in 
an autocrine fashion. When the leukaemic cells fronn 16 B-CLL patients were cultured 
with IL-8 at concentrations of 5 & 50 ng/ml. 11/16 showed a reduced rate of apoptosis as 
measured by propidium iodide staining and flow cytometry. Simultaneous incubation with 
an anti-IL-8 MoAb reversed the apoptosis-inhibiting effect of the cytokine. In the 
remaining 5 cases the percentage of surviving cells was so spontaneously high (90.6%) 
after 2 days that the effect of IL-8 could not be tested. Incubation of the cells from these 5 
patients for 2 days with 10-^ mol/L of hydrocortisone reduced the percentage of surviving 
cells to 55%, but addition of IL-8 at 5 ng/ml to the culture conditions was able to effect a 
significant rescue of the cells. IL-8 failed to induce any in vitro proliferative effect as 
measured by ^H-thymidine (^H-TdR) incorporation and there appeared to be no synergy 
between IL-8 and IL-4 or IFN-a in preventing apoptosis. Of particular interest, all of the 9 
B-CLL samples tested constitutively expressed IL-8 mRNA and released between 0.3 and
6.5 ng/ml. The presence of the 439 bp IL-8 receptor mRNA was detected in 7/9 cases 
and B-CLL cells maintained stable expression of this after 2-3 days of culture.
Additionally, the presence of the IL-8 receptor on the cell surface was found to be positive 
on 10/10 samples tested over 6 days of culture, using cytofluorometric detection of 
phycoerythrin-conjugated IL-8. Perhaps most interesting of all was the increase in 
cellular IL-8 mRNA in 10/12 B-CLL samples when the cells were cultured in 5 ng/ml of 
IL-8. Constitutive expression of bcl-2 mRNA was detected in 7/7 cases tested using 
RT-PCR and incubation of the cells with IL-8 resulted in an increase in both bcl-2 mRNA 
and Bcl-2 protein (Francia di Celle, 1996). Given that the dose range of IL-8 capable of 
producing the prolonged survival of B-CLL cells is comparable with the levels of IL-8 
released constitutively by these cells, it appears possible that IL-8 may play a significant 
role in prolonging the life span of B-CLL cells in an autocrine fashion and may do so by 
increasing levels of Bcl-2.
9.4 lL-10
The effect of culturing of B-CLL cells with IL-10 is unclear, with studies showing widely 
conflicting results. For example, culture of 5 B-CLL samples with IL-10 increased the rate 
at which cells were lost in a dose-dependent manner, with all samples showing a 2- to 
4-fold increase in apoptotic cells, measured using Hoechst 33342, propidium iodide and 
flow cytometry. After 1 week B-CLL populations cultured with IL-10 were lost, whilst those 
cultured without it survived.
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Treatment with IL-10 also Inhibits spontaneous DNA synthesis in B-CLL cells. In the 4/12 
cells that spontaneously incorporated significant amounts of ^H-TdR (2,800-5,700 cpm), 
incorporation was reduced by 54-96% after 3 days of culture in a dose-dependent 
manner. The lL-10-lnduced increase in apoptosis appears to correlate with Bcl-2 levels, 
which freshly isolated B-CLL cells were found to express at high levels in a unimodal 
fashion. After four days of culture in medium this changed to a bimodal pattern, with 74% 
of the cells continuing to express Bcl-2 at high levels and 26% expressing low levels. A 
culture repeated with medium plus IL-10 resulted in a decrease in Bcl-2 expression, with 
83% of cells expressing low levels and only 17% expressing high levels. The addition of 
a neutralising anti-IL-10 monoclonal antibody, IL-2, IL-4, IFN-y and anti-CD40 monoclonal 
antibody, was able to counteract the apoptosis-inducing effect of IL-10 (Fluckiger, 1994).
However, further experiments failed to support these findings. B-CLL cells from 9 patients 
were found to express between 47-127 IL-10 receptor sites per cell, whose binding 
specificity of IL-10 was reflected in a dissociation constant estimated as ranging from 
168-426 X 10'’'2 mol/L. Binding of IL-10 to its receptor on B-CLL cells results in a pattern 
of phosphorylation of signal transducer and activators of transcription 1 (STAT1 ) and 
STAT3 proteins that is identical to that seen in normal T-cells and monocytes and similar 
to IFN-a (STAT1 & 3) and IFN-y (STAT1) receptor activation in B-CLL. Interestingly, at 
concentrations above 10 ng/ml, IL-10 consistently and significantly inhibited, in a 
dose-dependent manner, TPA-induced proliferation of B-CLL cells as measured by 
^H-TdR incorporation (cells from 5 patients cultured for 7 days). IL-10 had the opposite 
effect on the differentiation of B-CLL cells from 10 patients. Incubation of B-CLL cells in 
the presence of IL-10 and TPA was shown to significantly enhance the production of IgM 
compared to those cells incubated with TPA alone. However, in contrast to the study by 
Fluckinger, which suggested that IL-10 induces apoptosis in B-CLL cells associated with a 
reduction in cellular Bcl-2 levels, no increase in the rate of apoptosis was detected in 
those cells cultured with the cytokine. When cells from 7 B-CLL cases were cultured in 25 
ng/ml of IL-10 for 24 hours there was no increase in apoptosis detected compared with 
cells cultured in medium alone. Similar results were obtained when culture was extended 
in 3 cases from 24 to 72 hours. There was no statistically significant increase in the rate 
of apoptosis in 6 cell samples cultured with IL-10, but there appeared to be a trend 
towards Improved survival and in individual cases cell survival was clearly higher. 
Furthermore, IL-10 induced an increased rate of cell survival comparable to that of IFN-y, 
when used at 25 ng/ml to counteract the effect of HC at a concentration of 5 x 10'^ mol/L.
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As one might expect in a study showing no statistically significant improvement or loss of 
cell viability, no change in Bcl-2 levels was induced by IL-10. The authors suggest that 
the contrast between their study and that of Fluckinger is explained by the different 
methods of cell selection and cryopreservation, the latter being reported to induce a 
substantial reduction in IL-10 binding specificity compared to freshly isolated cells 
(Jurlander, 1997).
Furthermore, a third study suggests that IL-10 increases B-CLL cell viability in vitro. In an 
investigation using cells from 4 B-CLL patients, only 3 of which were CDS'*", blood was 
obtained and PBMC were isolated by Ficoll/Hypaque density gradient centrifugation. No 
further purification was undertaken on the basis that in all four cases the leukaemic cells 
accounted for >90% of the blood lymphocyte population. In comparison to in vitro culture 
of PBMC from B-CLL patients in medium alone, and the culture of PBMC cells from 
normal individuals with IL-10, which showed no improvement in survival, culture of PBMC 
from B-CLL patients with IL-10 at 1.0-50 ng/ml for between 10-21 days offered statistically 
significant increased survival, suggesting that IL-10 offers protection from apoptosis. In 
culture, the PBMC from B-CLL patients were found to spontaneously produce IL-10 using 
ELISA, in comparison to the sera from normal individuals in which IL-10 was 
undetectable. The authors suggest that this is evidence of the autocrine involvement of 
IL-10 in extending the life span of B-CLL cells in vitro, but given the absence of any 
attempt to further purify the PBMC there can be no certainty that IL-10 is being produced 
by B-CLL cells. Bcl-2 expression was examined by flow cytometry and Western blotting 
without detecting any difference in its expression in PBMC cultured with and without IL-10 
(Kitabayashi, 1995).
Doubts about IL-10's ability to increase the rate of in vitro apoptosis observed in B-CLL 
cells are also raised by a study attempting to determine the effect of BM stromal cells on 
the survival of B-CLL cells. In a study of cells from 9 B-CLL patients, where apoptosis 
was shown to be increased from -22%  to 42±5% when cells were cultured in BM stromal 
celt conditioned medium, the use of an anti-IL-10 antibody failed to prevent the increase, 
suggesting that IL-10 was not instrumental in mediating it (Lagneaux, 1998).
Given the small sample size of some of these studies, the limited degree of cell 
purification in one study, the conflicting evidence of the effect of IL-10 on cell viability and 
particularly its effect on Bcl-2 levels, it is difficult to draw any clear conclusions from the 
results, but on balance IL-10 appears not to reduce the viability of B-CLL cells in vitro.
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However, although no attempt was made to relate IL-10 to the expression of Bcl-2 family 
proteins, a further series of studies of the effect of IL-10 on B-CLL cells, throws these 
inconsistencies into even sharper contrast.
A study of the B-CLL cells from 35 patients which sought to relate the expression of IL-10 
mRNA to disease progression, came to the conclusion that the expression of IL-10 mRNA 
was inversely related to disease progression in an autocrine fashion. Transcripts of the 
gene were detected by RT-PCR in 11/20 patients with non-progressive disease, but in 
only 2/15 with progressive disease. Disease progression being defined by a progression 
in the previous 3 months of disease-related anaemia (haemoglobin <100 g/l), 
thrombocytopenia (platelets < 100 x 10^/i), enlargement of spleen/liver/lymph nodes >
25%, doubling of blood lymphocyte counts, and/or the appearance of constitutional 
symptoms (Sjoberg, 1996). Although the authors suggest that "effective autocrine loops 
may be generated by intracellular cycling of cytokines", no attempt was made to 
demonstrate production of IL-10 by these cells, to determine the serum levels of IL-10 in 
these patients, or to show the in vitro effect of IL-10 on these neoplastic cells, and the 
results are called into question by two other studies. In contrast a study of 123 serum 
samples from 97 B-CLL patients showed no correlation between disease progression 
(which the authors failed to define) and IL-10 serum levels. However, a correlation was 
noted between IL-10 serum levels and the Rai stage, with higher levels detected in the 
sera of patients with Rai stage 3-4, compared to levels in Rai stage 0-2 (Egle, 1996). 
Notwithstanding the failure of this study to detect a statistical correlation between disease 
progression and IL-10 sera levels, at face value the detection of higher levels of IL-10 in 
the cells from patients with B-CLL Rai stage 3-4 rests very uneasily with the lower levels 
of IL-10 mRNA found in patients with progressive disease reported by Sjoberg et. al. 
Furthermore, another study comparing the serum IL-10 levels from 55 HIV-negative 
B-CLL patients with those of 48 healthy donors, was unable detect any statistically 
significant difference in the B-CLL group when analysed by Binet stage or between the 
two groups (Knauf, 1995).
9.6 IFN-a
Studies investigating the effect of IFN-a on Bcl-2 levels in, and the rate of in vitro 
apoptosis of B-CLL cells, have also produced inconsistent results. Despite having been 
used at one time as a treatment for B-CLL, IFN-a has also been shown to reduce the level 
of apoptosis in B-CLL cells and to preserve the ex vivo levels of Bcl-2.
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Apoptosis was observed in 9/16 samples of B-CLL cells after 30 hours of in vitro culture, 
but this was reduced from a mean of 36.8% apoptotic cells to 16.8% when the cells were 
cultured in medium containing 10^ U/ml IFN-a. Additionally, culture of the cells with IFN-a 
protected the leukaemic cells from hydrocortisone-induced apoptosis. Bcl-2 levels were 
found to be preserved in cells from patients resistant to apoptosis for up to 30 days of 
culture in medium alone, but levels of Bcl-2 were rapidly reduced in cells sensitive to 
apoptosis. The loss of Bcl-2 was inhibited by culture with IFN-a (Panayiotidis, 1994).
These results were confirmed by a study of 12 B-CLL patients, none of whom showed any 
evidence of a t(14;18) translocation, which indicated that IFN-a increases cellular levels of 
Bcl-2 in vitro and in vivo and protects cells from apoptosis in vitro. Cells from 10 patients 
with different stages of disease were incubated in medium alone and with IFN-a for 18 
hours, before being analysed for Bcl-2 using indirect immunofluorescence and flow 
cytometry. Cells incubated in medium alone were 79.7+8.4% positive for Bcl-2 with a 
mean cell fluorescence of 24.8+6.2. Cells incubated with 500 U/ml of IFN-a showed 
significant increases in Bcl-2 as indicated by 94.6+3.2% being Bcl-2-positive with a mean 
cell fluorescence of 49.6+5.8. The IFN-a-induced increase in Bcl-2 was accompanied by 
reduced rates of apoptosis, including that induced by incubation with 10'^ M of HC and 
exposure to 1500 rads of y-radiation before incubation. The rates of a DNA fragmentation 
after 18 hours, as quantified by a modified diphenylamine reaction in which the DNA in the 
supernatant was calculated as a % of the total DNA in the supernatant and pellet, was 
35.6+10.3% in medium alone, 63.9+12.6% in medium plus HC and 80.0±2.9% when pre-y 
-irradiated. These rates were reduced respectively to 6.6+5.8%, 10.8+4.5% and 5.4+ 
1.6%, when IFN-a was introduced to the culture conditions. However, the use of IFN-a to 
treat B-CLL suggests that any relationship between IFN-a, Bcl-2 levels and sensitivity to 
apoptosis is not a simple one. Anomalously, and in contrast to the reduction in white 
blood cell counts that are detected when the disease is treated with IFN-a, 8 B-CLL 
patients receiving 3 megaunits of IFN-a subcutaneously 3 times weekly for 3-6 weeks, 
showed an increase in Bcl-2 levels in cells isolated after treatment compared to those 
detected before administration of IFN-a, (Jewell, 1994).
Although IFN-a was found to reduce the B-CLL cell burden when used to treat one patient 
(3 X 10® 3 times weekly), it was also found to protect B-CLL cells from in vitro apoptosis in 
6/8 patients. 16% of cells cultured for 96 hours with the 2b isoform of IFN-a exhibited 
signs of apoptosis measured by propidium iodide labelling in flow cytometric analysis and 
DNA fragmentation assays, compared to to 70% in control cultures.
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The results were not dependent on type and the 2a isoform of IFN-a produced similar 
results. However, in disagreement with the two other studies quoted, no link was detected 
between the IFN-a-induced lower rates of apoptosis and maintained or increased levels of 
Bcl-2. indeed lower basal levels of Bcl-2 were detected after 24, 48 and 72 hours of 
incubation with IFN-a (Chaouchi, 1994).
9.6 bFGF
Basic fibroblast growth factor (BFGF) also protects cells from B-CLL celt lines from 
fludarabine-induced apoptosis in a manner that appears to involve the upregulation of 
bcl-2 mRNA and Bcl-2. Cells from the EBV-transformed cell line 183CLL and cells from 
the EBV-negative WSU-CLL were incubated with 100 pM fludarabine alone or fludarabine 
and bFGF at 100 ng/ml. Incubation with fludarabine alone resulted in a reduction in cell 
viability as measured by trypan blue exclusion compared to control cultures. Addition of 
bFGF to the culture conditions resulted in both a delay in the onset of, and reduction in the 
percentage of celis undergoing apoptosis. Protection from apoptosis appears to be 
associated with upregulation of bcl-2 mRNA expression and the 183CLL cell line, which 
expresses low amounts of steady-state bcl-2 mRNA, showed a significant upregulation of 
the 8,5 kb transcript after stimulation with 10 ng/ml bFGF. A significant accumulation of 
the transcript was detected after 2 hours, with maximal response at 24 hours. No 
difference in the half-life of bcl-2 mRNA from bFGF-stimulated and unstimulated 183CLL 
cells was detected. Similarly, increased expression of Bcl-2 was detected in 183CLL 
cells, WSU-CLL cells and cells from three B-CLL patients purified by Ficoll-Hypaque 
density gradient centrifugation only, after exposure to bFGF. Densitometric analysis of 
protein bands indicated that bFGF induced a 1.5- to 2.3-fold inorease in Bcl-2 levels 
(Konig, 1997b),
9.7 p 5 3 .
Significant evidence exists to suggest that the Bcl-2:Bax ratio can be modulated either 
directly or indirectly by the p53 gene product, but the evidence for its involvement in the 
pathogenesis of B-CLL is unfortunately both limited and contradictory. For example, 
evidence in support of p53's influence on Bcl-2:Bax ratios comes from studies using M l 
myeloid leukaemia cells and mice. Induction of a temperature-sensitive form of the 
tumour suppressor p53 gene in transfected M l cells, a murine myeloblastic leukaemia 
cell line that contains no P53 protein, reduces bcl-2 mRNA to less than 10% of normal 
levels after 19 hours.
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In contrast the level of bax mRNA is rapidly increased after 4 hours. However, the actual 
impact of induction of this gene may be underestimated, as the semi-quantitative RT-PCR 
method used to measure bcl-2 mRNA levels and the Northern blotting analysis of bax 
mRNA take no account of the many cells with low Bcl-2:Bax ratios that may have 
undergone apoptosis before analysis. Measurement of the levels of Bcl-2 and Bax in 
p53-deficient mice homozygous for p53 gene disruptions {-/-) indicate that the loss of p53 
appears insufficient to cause elevations of Bcl-2 and reductions in Bax in all tissues In 
vivo, but it appears to exert an influence in several tissues including lymph nodes, spleen, 
epithelial cells of the prostate, several neuronal cell populations, and thymocytes. For 
example, in the thymus Bcl-2 and Bax expression was largely confined to medullary cells 
with little staining of cortical thymocytes observed in either p53-deficient or normal mice. 
However, in the p53-deficient mice, Bcl-2 immunostaining of medullary thymocytes was 
significantly stronger whilst that of Bax was weaker. The absence of any effect on Bcl-2 
levels in certain murine tissues such as liver, heart, and skeletal indicates that p53 Is not 
the only determinant of Bcl-2 and Bax levels in certain tissues, but such limitations do not 
negate the findings of this study (Miyashita, 1994).
Further evidence in support of the p53 gene's ability to influence the Bcl-2:Bax ratio 
comes from an investigation using M l myeloid leukaemia cells. These were stably 
transfected with a plasmid to establish an M1p53 cell line which expresses wild-type (wt) 
p53 under the control of a temperature-sensitive transgene, the effect of which was 
compared to untransfected M l myeloid leukaemia cells exposed to TG Fpi. Activation of 
the wt p53 function at the permissive temperature of 32.5®c resulted in the apoptotic death 
of the entire population of 0.15 x 10® within 24 hours. Treatment of M l cells with 10 ng/ml 
of TG Fpi also resulted in apoptotic death, but the process was much slower than with 
induction of apoptosis via the temperature-sensitive p53, and was incomplete after 5 days. 
Bcl-2 expression was rapidly downregulated in M1 cells following induction of apoptosis 
with both the temperature-sensitive p53 and TGFp1. However, the rapid 20-fold increase 
in the level of bax mRNA seen in the presence of the protein synthesis inhibitor 
cycloheximide, and the 10-fold increase in the level of Bax, seen in response to p53 
activation, is not detected with TG Fpi. Ectopic expression of Bcl-2, using recombinant 
plasmids constructed and packaged as infectious amphotrophic retroviruses, blocks 
apoptosis in M l cells induced by TG Fpi, but only delays apoptosis induced by 
temperature-activated p53. This would appear to suggest that Bax is an immediate early 
response target gene for P53 and assum ing that the mechanism functions similarly in 
B-CLL cells, adds weight to the view that their fate is determined by the balance between 
inducible Bcl-2 and Bax {Selvakumaran, 1994).
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Although no attempt was made to measure the relative levels of Bcl-2 and Bax, support 
for the theory that p53 induces apoptosis through manipulation of the relative Bcl-2 and 
Bax levels comes from a study indicating that p53-induced apoptosis can be overcome by 
overproduction of Bcl-2. About 90% of cells from a V-myc-induced T-cell lymphoma cell 
line died apoptotically within 3 days of the induction of a transfected and 
temperature-sensitive wt p53 gene. However, in two double transfectant clones 
containing also a retrovirally-driven bct~2 construct, Bcl-2 was expressed at high levels 
and apoptosis was almost completely inhibited. A further clone expressing Bcl-2 at lower 
levels partially protected the T-cell lymphoma cell line from p53-induced apoptosis (Wang, 
1993). This response is certainly compatible with p53 causing apoptosis through its effect 
on Bcl-2 and Bax, but unfortunately the evidence for its involvement in B-CLL in this 
manner is both scanty and contradictory.
Circumstantial evidence in support of p53's involvement in the control of apoptosis in 
B-CLL comes from a study involving 30 B-CLL patients. 15 of these, who were defined as 
having non-progressive disease and 15 having progressive disease, showed a clear 
correlation between progressive B-CLL and aberrant expression of p53 protein using both 
enzyme-linked immunosorbent assay (ELISA) and FACS. In contrast, the leukaemic cells 
from 15/15 non-progressive patients, normal resting B-cells and activated B-cells, were all 
found to be negative for p53 protein using the PAb260 monoclonal antibody. However, 
9/15 samples from progressive B-CLL patients were found to be positive for this antibody 
which recognises a conformational alteration which Is normally characteristic of mutant 
p53 protein. The levels of p53 mRNA were similar in both groups, so it remains possible 
that the aberrant expression of PAb260-recognised P53 protein arises from post- 
transcriptional modifications that induce functional and conformational changes.
However, this does not entirely negate the fact that an apparently abnormal form of P53 
was expressed in the B-CLL cells from patients with progressive disease 
(Aguilar-Santileses, 1994).
The influence of the p53 gene in B-CLL is contradicted by a further two studies which 
failed to find a connection between Bcl-2:Bax ratios and p53 mutations, or between levels 
of p53 mRNA detected and bax mRNA levels, bcl-2:bax mRNA ratios, or disease 
progression. When the neoplastic cells from 21 B-CLL patients were studied to determine 
if there was any connection between the mutant form of P53 and Bcl-2/Bax levels and 
sensitivity to 9-amino-20(s)-campothecin- or fludarabine-induced apoptosis, none could 
be detected. The 7/21 patients with a detected p53 mutation displayed highly variable 
levels of Bcl-2/Bax, as did the 14/21 with wt P53.
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A relationship between high Bcl-2:Bax ratios and resistance to 
9-amino-20(s)-campothecin- or fludarabine-induced apoptosis was detected in 7/8 
samples, but the resistance to induced apoptosis was unrelated to P53 status (Thomas, 
1996) Similarly, when the levels of p53 mRNA in B-CLL cells from 38 patients were 
analysed by competitive PCR, there was no obvious relationship between the absolute 
p53 mRNA values and bax mRNA levels, bcl-2:bax mRNA ratios, or between leukaemic 
cells from patients with progressive and non-progressive disease (Aguilar-Santileses, 
1996).
Some explanation for these contradictory results may come from a study which found that 
the leukaemic cells from 15 B-CLL patients expressed significant amounts of bd-2  mRNA 
and Bcl-2 on isolation, but after incubation with theophylline, chlorambucil and particularly 
theophylline and chlorambucil in combination, this was reduced and accompanied by 
significant increases in apoptosis. However, theophylline and chlorambucil have opposite 
effects on P53 expression. Incubation with theophylline reduced expression of P53 by a 
mean of 68%, in contrast to incubation with chlorambucil and to a lesser extent 
theophylline and chlorambucil, which increased levels of P53 by a mean of 45% and 20% 
respectively. Although no attempt was made to relate P53 levels to the Bcl-2:Bax ratio, 
the theophylline-induced reduced expression of P53 and Bcl-2, combined with the 
chlorambucil-induced increased level of P53 and reduced level of Bcl-2, suggests that 
there may be P53-dependent and P53-independent pathways to influence the Bcl-2:Bax 
ratio (Mentz, 1996). Such a phenomenon would offer a possible explanation for the 
contradictory results from the other studies referred to in previous paragraphs.
The evidence available is too contradictory to enable any meaningful conclusions to be 
formed, but given that p53 is reported involved in over 50% of all neoplasias, the matter is 
clearly of such potential importance in the pathogenesis of B-CLL as to warrant more 
definitive and exhaustive investigation.
9.8 BM stromal cells
Culturing cells from B-CLL patients with human BM stromal cells reduces the rate of 
apoptosis in vitro in a manner that correlates with maintenance of Bci-2 levels. When 
B-CLL cells were cultured in medium alone they were 22±3% and 21 ±6% apoptotic after 
48 hours in two separate tests, but when cultured directly on normal BM stromal cells 
apoptosis was reduced to 8±2% and Bcl-2 expression was preserved.
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In contrast when a microporous membrane was used to separate the B-CLL and stromal 
cells, the rate of apoptosis increased from -22%  to 38+7%. The rate of apoptosis was 
similarly increased to 42+5% in B-CLL cells cultured in stromal cell conditioned medium. 
These results suggest that culture on BM stromal cells inhibits apoptosis, but that BM 
stromal cells release a soluble factor which promotes apoptosis. Use of antibodies 
subsequently excluded the possibility of this soluble factor being IL-6, IL-10 or TGF-p.
Use of antibodies similarly showed that adhesion of neoplastic B-CLL cells to stromal cells 
is partially mediated by the (31 and (32 integrins acting simultaneously, In particular 
CD18/CD1 la  and CD49d, and that the lower survival rate of umbilical cord blood B-cells 
cultured on BM stromal cells could be explained by a lower rate of adhesion. Similarly the 
(31/ (32 integrin ligands on stromal cells, ICAM-1 (CD54) and VCAM-1 (CD106), are 
simultaneously involved, but the fact that the complete blocking of adhesion of B-CLL 
cells to stromal cells could not be achieved by targeting these CDs with antibodies, 
suggests that other mechanisms are involved in the adhesion process (Lagneaux, 1998). 
A study described in detail para 9.12.2 suggests that IL-7 may mediate apoptosis 
reduction caused by ligation of the (32 integrin.
Given the propensity of B-CLL to invade the BM it is particularly interesting that BM 
stromal ceils may play an Important role in the survival and accumulation of neoplastic 
B-CLL cells. Although no attempt was made to relate survival to Bcl-2 levels, the ability of 
BM stromal cells to promote cell survival is further supported by a study of cells from 10 
patients. In 10 B-CLL cell cultures using medium alone, only a mean of 14.7% of the cells 
remained viable after 10 days of culture and all cells were dead after 30 days. In 
comparison, a mean of 47% of the B-CLL cells cultured on BM stromal cells obtained 
from normal BM donors were alive after 10 days of culture and after 30 days of culture 
between 12-65% of the cells from 7/10 cultures remained viable. Adherence to BM 
stromal cells again appeared critical for the anti-apoptotic effect and separation of the 
B-CLL cells from the BM stromal cells with a 0.45 pM culture filter resulted in the 
anti-apoptotic effect being lost. Culture on BM stromal cells offers similar protection from 
HC-induced apoptosis. In medium plus HC, a mean of only 2.4% of the cells were alive 
after 10 days of culture and all were dead after 30 days. In comparison a mean of 20.5% 
and 5.8% respectively were alive when cultured directly on BM stromal cells plus HC 
(Panayiotidis, 1996).
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9.9 CD95/APO-1/Fas and CD40.
Although ligation of CD95 appears to induce apoptosis by a Bcl-2-independent route in 
lymphoid celis, the effect of Bcl-2 family members on CD95-lnduced apoptosis in B-CLL 
cells remains very unclear with studies showing widely differing results. However, the 
connection between Bcl-2 family members and CD95-induced apoptosis is of particular 
interest, as a means of inducing apoptosis in Bci-2-expressing B-CLL cells that is 
independent of Bcl-2, is at least as interesting as one that is not.
A series of studies using lymphoid cells from mice and investigating CD95-induced 
apoptosis via the FADD/caspase-8 apoptotic pathway, suggests that Bcl-2 does not inhibit 
CD95-induced apoptosis. In CD95-induced apoptosis in B-lymphoid cell lines, 
thymocytes, and activated T-cells, Bcl-2 expression is not downregulated, Bax and Bcl-Xg 
are not upregulated, and Bcl-2 offers very little protection from apoptosis. In contrast 
expression of the cowpox virus caspase-inhibiting cytokine response modifier A (crmA), 
blocks apoptosis induced by CD95 ligation, but not that induced by y-irradiation, 
corticosteroids or serum deprivation, which are blocked by Bcl-2. Furthermore, 
transgenically expressed Bcl-2 markedly augments the survival and abnormal 
accumulation of lymphocytes in CD95-deficient Ipr mice (Green, 1998; Newton, 1998; 
Smith, 1996; Strasser, 1995; Thornberry, 1998), These studies suggest that CD95 and 
Bcl-2 are involved in regulating different apoptotic pathways, but on the basis of the 
evidence available it remains unclear what connection if any there is between CD95- 
induced apoptosis and Bcl-2 levels in B-CLL.
A study involving a total of 21 B-CLL patients suggests that Bcl-2 can inhibit CD95- 
induced apoptosis. When analysed, the cells from 10 patients were found to be weakly 
positive for CD95 using a specific IgM MoAb, with a mean of 15.6% of the cells (range 
5-41%) expressing the antigen. CD95 expression was not changed during spontaneous 
or HC-induced apoptosis, and culture with medium alone, IL-4, IL-10, or PMA did not 
modulate its expression. However, culture of CD95- B-CLL cells with IFN-a upregulated 
CD95 expression in 15/19 samples and CD95 mRNA expression in 5/7. Similarly, culture 
with IFN-y increased CD95 expression in 21/21 and CD95 mRNA expression in 7/7. 
Culture with an anti-CD95 MoAb failed to induce apoptosis in B-CLL cells in which 
expression of CD95 had been increased by cuiture with IFN-y, in contrast to its effect on 
CDOS"*" Jurkat cells and four CD95"^ lymphoblastoid cell lines, where the anti-CD95 MoAb 
induced apoptosis. This may be due to higher levels of Bcl-2 expressed in the cells.
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The cells from 4 B-CLL patients analysed for Bcl-2 expression using anti-Bcl-2 MoAb, 
FITC-conjugated rabbit anti-mouse Ig, and FACS, were found to be 90-96% positive for 
Bcl-2 (Panayiotidis, 1995).
A further study has linked downregulation of bcl-2 expression very tenuously with 
CD95-induced apoptosis in B-CLL cells. The neoplastic cells from a total of 9 B-CLL 
patients were analysed for bcl-2 levels and the extent of apoptosis, in relation to exposure 
to SAC, IL-2, and anti-CD95. The study purports to show that treatment of B-CLL cells 
with SAC and IL-2 results in an increased expression of surface CD95 and a greater 
sensitivity to CD95-induced apoptosis through a downregulation in the expression of bcl-2. 
However, it has to be noted that of the total of 9 patients, the cells from only 2 were 
analysed for CD95 expression before and after activation with SAC, IL-2 or a combination 
of the two, and only one of the second pair had been included in the first analysis.
Although 5 patients showed downregulation of bcl-2 mRNA in response to activation with 
SAC and IL-2, and in 3 patients activation with SAC and IL-2 led to an increase in 
CD95-induced apoptosis, the cells from none of the patients were subjected to all of the 
analyses. Furthermore, only the cells from 1 patient were subjected to 3/4 analyses. 
Treatment with SAC plus IL-2 bears very little relationship to the conditions prevailing 
naturally In vivo and given the very small sample sizes, the study offers very little other 
than what may be an insight into the idiosyncrasies of the cells of a single case of B-CLL. 
The value of this Insight is emphasised very strongly by the cells from a further B-CLL 
patient, which had a high constitutive expression of CD95 before activation and a CD95 
epitope density simiiar to the other tested cells after activation with SAC and IL-2. After 
incubation with SAC, IL-2, and anti-CD95, the cells reacted in a directly opposite manner 
by high ®H-TdR incorporation and low apoptosis (Mapara, 1993).
Very limited support for the results obtained in murine lymphoid cells comes from a study 
attempting to determine the relative effects of CD40 and CD95 on apoptosis in B-CLL 
ceils. Analysis of the leukaemic cells from B-CLL patients indicated that an average of 
85.5% of the cells from 10/10 patients cells were positive for CD40 with a range of 
54-97%. Similarly all 10 samples expressed Bcl-2 with a mean of 86.8% of the cells being 
positive (range 42-100%). Fewer of the cells and patients were positive for CD95. Only 
4/10 samples had >10% of the cells CD95‘^ , with a mean of 9.4% overall. However, 
incubation of the cells from 10/10 patients with NIH3T3 cells stably expressing the human 
CD40 ligand (CD40L) increased the CD95"^ cells very significantly to a mean of 74.0% 
(range 18-95%) and also increased the mean fluorescence intensity from 0.58 arbitrary 
units to 3.27.
102
Incubation with anti-CD95 MoAb did not increase the rate of apoptosis in unactivated 
B-CLL ceils and CD40 triggering did not significantly Inhibit apoptosis. However, ligation 
of CD95 significantly increased the rate of apoptosis in 2/10 cells in which CD95 had been 
upregulated by ligation of CD40. No differences in Bcl-2 levels in B-CLL cells were 
detected before and after in vitro culture and no correlation between Bcl-2 levels and 
sensitivity to CD95-induced apoptosis was detected (Wang, 1997).
However, a subsequent study contrasts sharply with the findings of the investigation by 
Wang et. al. Exogenous CD40 ligand (CD40L) rescues B-CLL cells from spontaneous, 
soluble CD95 ligand- and fludarabine-induced in vitro apoptosis in a dose- dependent 
manner at ooncentrations between 0.10-1.0 ng/ml. Incubation of B-CLL cells for 24 hours 
with medium alone resulted in 21.42+4.6% becoming apoptotic and incubation with 
medium plus CD95 ligand resulted in 46.2+8.6% becoming apoptotic. Addition of CD40L 
at 1 ng/ml to the culture conditions reduced the percentage of apoptotic cells to 5.3+1.4% 
and 21.0+6.1% respectively, suggesting that CD40 antagonises almost exactly the effect 
of CD95. Similarly CD40L rescued B-CLL cells cultured with fludarabine from in vitro 
apoptosis. Interestingly the sera of B-CLL patients appears to contain higher levels of 
active soluble CD40L than the sera from normal healthy donors. The sera from 51 B-CLL 
patients was found to contain a mean value of 0.80 ng/ml of CD40L in comparison to that 
from 55 healthy donors, where the mean level was 0.29 ng/ml. Incubation of B-CLL with 
varying concentrations of autologous plasma showed that those with the highest 
concentrations of CD40L had the highest percentage of surviving cells after 24 hours, a 
phenomenon that could be reversed by anti-CD40L antibody at 25 pg/ml. Although it had 
no apparent effect on the expression of bd-Xg or bcl~2 mRNA, incubation of B-CLL cells 
with CD40L upregulated bc/-x^ mRNA and CD95 receptor expression in 6 samples within 
3-6 hours (Younes, 1998). Whilst confirming the effect of CD40 ligation on CD95 
expression, this study raises questions about the effect of CD40 ligation on apoptosis in 
B-CLL, and on the role that Bcl-Xi_ might play in countering CD95-induced apoptosis in 
B-CLL.
Overall the results of these attempts to determine what role CD40 and particularly CD95 
might play in the pathogenesis of B-CLL have produced results that are too Inconsistent 
for conclusions to be drawn from them. However, the advantage presented by a means 
of inducing Bcl-2-independent apoptosis in B-CLL is of such potential therapeutic interest 
as to warrant further clarification of how CD40 and CD95 function and oppose each other.
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9.10 CD6
An explanation for the frequently inconsistent and contradictory results from attempts to 
link external stimulation to the rate of apoptosis and Bcl-2 levels, comes from a study 
investigating the role of IgM and CD6 in B-CLL. CD6 (activated leukocyte cell adhesion 
molecule) expression on B-CLL cells from 26 patients was found to be higher than that 
expressed on normal tonsillar B-cells, but not associated with disease progression.
Levels were very variable, with cells from 22/26 patients positive for CD6 and the cells 
from 20/26 >75% CD6'*'. In the 3 cases assessed for CD6 expression using indirect 
immuno-fluorescence with the anti-CD6 MoAb I0R-T1, CD6 expression increased after 3 
days in vitro incubation with SAC + IL-2, or TPA. However, B-CLL cells reacted variably to 
stimulation with various combinations of SAC, IL-2, TPA, or I0R-T1, which had no 
consistent proliferative effect. In vitro, cells from 10 patients showed a significant 
increase in the number with apoptotic nuclei observed with uv microscopy, from a mean of 
13.2% to 39.7% when cultured with anti-IgM MoAb. The degree of apoptosis in these 
circumstances correlates with cell surface IgM expression, but the percentage of 
apoptotic cells was reduced in 8/10 populations co-cultured with anti-IgM and the 
anti-CD6 MoAb I0R-T1. The induction of apoptosis by anti-IgM in B-CLL cells and the 
protection offered against anti-lgM-induced apoptosis by I0R-T1 appears to be mediated 
by changes in bcl-2 and bax^ mRNA levels. In 5 cultures anti-IgM was found to reduce 
the bcl-2/bax^ mRNA ratio by a reduction in bcl-2 mRNA and particularly by an 
upregulation of bax^ mRNA. Simultaneous culture with IgM and anti-CD6 MoAb lOR-T 1 
in 4 cases resulted in a significant reduction in bax^ mRNA without any change in bcl-2 
mRNA, raising the bcl-2/bax^ mRNA ratio in a manner that correlated with I0R-T1- 
mediated protection of anti-lgM-treated cells. Changes at the mRNA level appear to 
translate into similar changes at the protein level and in B-CLL cells from 3 patients 
co-cultured with anti-IgM and I0R-T1, the unchanged bcl-2 mRNA and reduced bax^ 
mRNA levels were reflected in unchanged Bcl-2 and reduced Bax^  ^ levels. In two further 
cell cultures Bax^  ^protein levels were higher after culture with anti-IgM than after culture 
with medium alone. In the circumstances it appears that it may be the Bcl-2/Bax ratio that 
is modulated through CD6 in B-CLL cells, where appropriately CD6 expression appears to 
be higher than on normal tonsillar B-cells (Osorio, 1997).
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9.11 CDw32
When BM- and peripheral blood-derived B-CLL cells from 17 previously untreated patients 
were analysed for survival and apoptosis in relation to Bcl-2 expression with a number of 
soluble and membrane-bound factors, the most efficient stimulus to in vitro survival was 
co-cultivation with CDw32-transfected murine fibroblasts where direct contact between the 
fibroblasts and leukaemic cells was permitted. In comparison to control cultures there 
was a reduction in the number of cells undergoing apoptosis of 90% as assessed by 
trypan blue exclusion. The prolongation of survival by CDw32-transfected murine 
fibroblasts was accompanied by a reduction in apoptosis which was associated with the 
partial prevention of the loss of Bcl-2. The association between CDw32, the reduced rate 
of apoptosis, and preservation of Bcl-2 levels is given added weight by a further 
co-cultivation using a murine fibroblast cell line C58 which was not transfected with 
CDw32 and which failed to prevent the loss of Bcl-2 or to offer any similar protection from 
apoptosis {Buske, 1997).
9.12 Others
Other studies have implicated other cytokines in the control of apoptosis in B-CLL cells, 
although in many cases the sample numbers are small and function has not been related 
to the Bcl-2 family. A study using the leukaemic cells from 6 patients suggested that as 
well as IL-4 which is discussed in earlier paragraphs, the cytokines IFN-y, IL-2, IL-6, IL-13 
and TNF-a were also capable of suppressing spontaneous in vitro apoptosis. In 
comparison to cells cultured in medium alone, culture with IL-4 and IFN-y increased in 
vitro viability by 15-40% in respectively 6/6 and 5/6 cell populations. Culture with IL-2 and 
IL-6 increased the viability of the same 4/6 cell populations by 15-30%, where the ability of 
IL-2 to suppress apoptosis in these cells generally correlated with surface expression of 
the low-affinity IL-2 receptor, CD25. The effect of TNF-a was to increase cell viability in 
4/6 populations by between 5-20% and IL-13 significantly increased viability in 1/6 
populations by 29.0%. When Bcl-2 levels were measured in 4 of 6 cell populations using 
flow cytometry at various intervals between 4-7 days, all of these cytokines appeared to 
sustain rather than upregulate Bcl-2 expression (Tangye, 1997). Although Bcl-2 levels 
were not assessed, the suggestion that IL-13 protects B-CLL cells from spontaneous 
apoptosis, is supported by a further study using cells from 12 patients. IL-13 is effective 
at reducing the rate of apoptosis in culture at 100-200 ng/ml, with the number of B-CLL 
cells with apoptotic nuclei reduced from 68+24% to 32+12% after 4 days culture at the 
higher concentration, in comparison to culture in medium alone (Chaouchi, 1996)
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IL-7 has also been tenuously connected to the prevention of apoptosis in B-CLL cells, but 
without any attempt to relate its effect to Bcl-2 family members. Apoptosis was inhibited 
when B-CLL cells were cultured in vitro on a monolayer of EA.hy926 human umbilical cord 
endothelial hybrid cells, with the coincident kinetics of IL-7 mRNA down- regulation and 
the reduced rate of apoptosis, suggesting that prevention of apoptosis is linked to the 
retention of IL-7 mRNA. In contrast, the rate of apoptosis was higher and IL-7 mRNA was 
downregulated in B-CLL cells cultured on a monolayer of A549/8 carcinoma cells, the 
fusion partner used to generate the EA.hy926 hybrid cells, and those cultured in the 
absence of other cells. As appeared also to be the case with BM stromal cells (para 
9.8.1), the effect of monoclonal antibodies directed against the j32-integrin, CD11b/CD18, 
on B-CLL cells, suggests that it is involved in mediating the interaction between B-CLL 
and EA.hy926 hybrid cells (Long, 1995). However, the anti-apoptotic effect of IL-7 is 
called into question to some extent by a series of in vitro experiments involving the B-CLL 
oells from 10 patients. This suggested that IL-1 and IL-7, and in contrast to the results 
obtained by Tangye ef. a/., IL-2 and IL-6, failed to inhibit apoptosis as assessed by 
morphology and DNA fragmentation. If this study is correct, then IL-7 must improve in 
vitro B-CLL cell viability in an intracellular autocrine fashion (Buschle, 1993).
IFN-y also appears to extend the life span of B-CLL cells in an autocrine fashion that 
shows parallels with the effects of other cytokines, but unfortunately no attempt was made 
to determine if this Involves Bcl-2. In vitro culture of B-CLL cells from 10 patients in 
medium alone resulted in the recovery of 56+6.1 % viable cells after 5 days, with 5-20% of 
the cells showing morphologic evidence of apoptosis, and DNA fragmentation into 
multiples of 180 bp after 16 hours. In contrast, culture with 100 U/ml of IFN-y increased 
viability to 94+3.6% after 5 days without any evidence of cell proliferation. Concentrations 
of IFN-y as low as 25 U/ml were effective, with maximum inhibition of apoptosis achieved 
at IFN-y concentrations between 100-1000 U/ml. The sera of 7/10 B-CLL patients 
contained IFN-y at concentrations between 60-200 pg/ml, in contrast to the sera from 10 
healthy donors where IFN-y concentrations were undetectable (<20 pg/ml). Production of 
IFN-y mRNA was found to be at high levels in the cells from 3 B-CLL patients activated 
with TPA and calcium ionophore and, in the 2 cases tested, 74% and 82% of the 
leukaemic cells were found to synthesise IFN-y transcripts, suggesting that IFN-y may play 
a part in increasing the life span of B-CLL cells in an autocrine fashion (Buschle, 1993).
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10 Conclusions.
The conclusions that can be drawn from the involvement of the Bcl-2 family in the 
pathogenesis of B-CLL particularly include, that the life span of B-CLL cells appears to be 
extended in vitro by higher ratios of Bcl-2 to Bax rather than absolute levels of Bcl-2, that 
involvement extends beyond Bcl-2 and Bax and may involve the expression of multiple 
family members, that the deregulated expression of Bcl-2 caused by genetic translocation 
may be greater than initial studies suggested, that Bcl-2 and Bax levels in B-CLL cells 
may be subject to deregulation and control by a wide range of largely extra-cellular 
influences, and that B-CLL cells may conform to the general apoptotic paradigm with 
Bcl-2 family members regulating cell survival through pore-forming/inhibiting activity in 
intracellular membranes.
Given the large number of studies which have linked expression of members of the Bcl-2 
family to the neoplastic process in B-CLL, the link with the Bcl-2 family is now beyond 
doubt and, if the studies by Gottardi (1996), Kitada (1998) et. al. are representative, 
aberrant and overlapping expression of members of the Bcl-2 family is common in B-CLL. 
Unfortunately, only limited information is available about the causes and extent of the 
inappropriate expression of these proteins in B-CLL, the number of patients in which Bcl-2 
family members may play a significant role in the neoplastic process, the extent to which 
expression may vary within the clone and provide the setting for the chemotherapeutic 
selection of refractory clones, the extent to which expression of more than one 
pro-survival member of the family may contribute to the neoplasm, and particularly very 
little to relate the nature of abnormal expression of Bcl-2 family members to the highly 
variable clinical outcome.
There appears to be no simple correlation between Bcl-2 levels and the clinical 
progression or stage of the disease. Likewise, attempts to show an inverse relationship 
between the sensitivity of B-CLL cells to in wfro-induced apoptosis and absolute levels of 
Bcl-2, and by inference extended life span in vivo, have produced conflicting results in a 
large number of studies. However, the absence of any clear relationship between Bcl-2 
levels and disease progression, and the contradictory findings of studies trying to link the 
in vitro survival times of B-CLL cells and Bci-2 levels, are explained by the co-expression 
of pro-apoptotic family members such as Bax. Higher Bcl-2:Bax ratios correlate with 
progressive disease, lack of response to therapy, and resistance to the in vitro apoptosis 
induced by a wide range of cytotoxic agents.
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In contrast lower Bcl-2:Bax ratios correlated with non-progressive disease, lack of 
previous treatment, and increased sensitivity to the induction of apoptosis using cytotoxic 
agents in vitro.
The relationship between higher Bcl-2:Bax ratios and progressive disease, lack of 
response to therapy, and resistance to the induction of in vitro apoptosis, is very much in
'■li
keeping with clinical observations of an often relentless accumulation of neoplastic B-CLL 
cells accompanied by an acquired tolerance of cytotoxic drugs. In particular the effect of 
higher Bcl-2:Bax ratios in B-CLL appears to conform to the Oltvai, Korsmeyer and 
Milliman paradigm, allowing speculation that the interaction of the pro- and anti-apoptotic 
members of the Bcl-2 family in B-CLL cells corresponds to a common cellular 
mechanism. The wider evidence confirms the role of the BH3 domain as the
pro-apoptotic domain, with BH1-4 apparently essential for anti-apoptotic function, although 
fundamental questions about the way in which the BH3-only pro-apoptotic members 
function in comparison to the BH1-3 pro-apoptotic members, remain unanswered. A wide 
range of experiments suggest that homo- and heterogenous interactions between family 
members are essential to apoptotic function. Unfortunately the experimental conditions 
frequently bear too little resemblance to conditions prevailing naturally in the cell for 
meaningful conclusions to be drawn from them and the mechanics of apoptosis remain 
essentially unclear. It is difficult to infer anything significant from experimental conditions 
that involve, for example, the removal of the hydrophobic TM domain from family 
members when it is thought to play an essential role in locating these proteins to 
intracellular membranes and when some studies have suggested it to be important to 
Bcl-2's anti-apoptotic function. The fact that these proteins apparently continue to fulfil 
their proposed function without a TM domain does not necessarily indicate that the TM 
domain is unnecessary to function. They may be targeting a protein with which they 
interact before it has reached its normal site and interference with function in such an 
abnormal manner says very little about normal function. Tagging of family members such 
as Bcl-2, Bcl-X|_ and Bax with haemagglutin and FLAG epitopes is also common in 
experimental procedures, as are plate binding assays. It remains possible that these 
modifications, as well as the removal of the TM domain, may induce their observed 
effects via changes in the protein's conformation or by steric hindrance, and again may 
say very little about the function of the family members in a more natural setting.
What is especially intriguing and remains largely unexplored and unexplained, is the 
apparently pore-forming structure of various members of the famiiy, particularly Bcl-2 and 
Bc1-Xl, and their location in mitochondrial membranes.
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Unless this is an occasion where form does not follow function, nothing has been 
discovered to exclude the possibility that their putative pore-forming structure plays an 
essential role in the mitochondrial control of apoptosis.
Whilst the conditions in vesicles and planar lipid bilayers may bear very little similarity to
the conditions prevailing in the mitochondrial membranes at the contact sites between the
inner and outer membranes, where Bcl-2-family proteins are known to insert, the ability of
Bcl-2, BcI-Xl, and Bax to form conductance channels in synthetic membranes offers the
opportunity of speculating about the manner in which the Bcl-2 family may adjust the
apoptotic threshold of the cell. In this context it is worth remembering that the ability of if
Bcl-2, BcI-Xl, and Bax to form conductance channels in synthetic membranes appears to
be linked to acidic lipid membranes, pH and voltage. Furthermore, the channels they form
are of different and varying conductance states, they display a degree of ion-selectivity, a
-helices 5 and 6 in Bcl-2 (and by inference their equivalents in the other family
membranes that possess them) are particularly important to pore forming function, there
is a suggestion of conductance being linked to the oligomerisation of these proteins, and
Bcl-2 appears to be capable of inhibiting the channel-forming activity of Bax in lipid
vesicles.
The stoichiometric relationship between Bcl-2 and the PBR, combined with the fact that 
Bcl-2 and Bax are both capable of forming open channels of large conductances up to -2  
nS, raises questions about how full a role the Bcl-2 family may play in the formation of the 
PT pore. It is certainly possible, even likely, that the Bcl-2 family may regulate the 
opening of the PT pore, and hence apoptosis, by allowing the passage of ions into or out 
of mitochondria, but to what extent may proteins belonging to the Bcl-2 family be involved 
in the formation of the pore?
Single-channel measurements of excised mitochondrial patches and reconstituted purified 
AD P/ATP carrier (AAC), have suggested that when converted into a large unselective 
channel, the AAC is a key component of the PT pore. This channel is low cation- 
selective, is pH sensitive, closing completely at pH 5.2, and its conductance has multiple 
sublevels varying from 300-600 pS. This channel shows remarkable similarities to those 
formed in synthetic membranes by Bcl-2, Bcl-X|_, and Bax, all of which appear to be 
capable of forming conductance channels of this magnitude in planar lipid bilayers, posing 
the question of whether they are involved directly in the formation of the PT pore?
Clearly that question cannot be answered on the basis of present knowledge, but it should 
make a potentially fruitful area of research and if the relationship of Bci-2 family members 
to the PT pore is not that of participants, it will be interesting to note the physical 
relationship between Bcl-2 family-formed pores and the PT pore.
Regardless of whether Bcl-2 family members are actually involved in the PT pore's 
structure, it will be also be interesting to determine if the manner in which pro- and anti- 
apoptotic members of the Bcl-2 family interact in vitro, is a reflection of the nature of 
interactions when they are located in intracellular membranes. The range of experiments 
to try and assess how Bcl-2, BcI-Xl, and Bax function when embedded in synthetic 
membranes, although valuable, has been very limited. In particular, although experiments 
have shown that Bcl-2, BcI-Xl, and Bax form conductance channels in synthetic 
membranes, this is not evidence that these proteins form channels in isolation of each 
other in vivo. The ability of Bcl-2 to inhibit carboxyfluorescein release through Bax 
conductance channels in liposomes may be a more accurate reflection of the functioning 
of these apoptosis-associated proteins in more natural circumstances. If that should 
prove to be the case it will be interesting to see if the fate of the cell is determined by the 
cellular stoichiometry of Bcl-2 family members, with individual conductance channels 
formed by both pro- and anti-apoptotic family members and either the open/closed 
conformation of the pores, or the nature and direction of ions allowed to pass through 
them, determined by the balance between them.
Attempts to determine the reasons for the apparently unregulated expression of members 
of the Bcl-2 family appear to have concentrated almost exclusively on Bcl-2 itself, and 
particularly on the possibility that expression of the protein is deregulated as a result of a 
genetic translation or extracellular stimulation. A number of studies using Southern 
blotting, including studies involving cohorts of 100 and 170 B-CLL patients, have found 
little or no evidence to suggest that the t{14;18) translocation of the Bcl-2 gene, or the less 
common translocation to the Igic or IgX, loci, is common in B-CLL. However, the rates of 
detection ranging from 0% to 12%, most of which range from 0-3%, are contradicted by 
the apparently more sensitive techniques of pulsed gel electrophoresis and fluorescence 
in situ hybridisation. Although these studies involve much smaller cohorts, they have 
shown a very high Incidence of translocation, 100% in one case, and have been shown to 
be highly effective in detecting the t{14;18) translocation in follicular lymphoma. These 
studies appear to deserve a degree of credence that is disproportionate to the number of 
patients involved.
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Although larger studies would be necessary to confirm the situation, it is clearly possible 
that deregulation of Bcl-2 expression in B-CLL as a result of the translocation of the bcl-2 
gene is more common than currently envisaged. However, it is clear that cellular Bcl-2 
levels are modulated throughout, for example, B-lymphopoiesis, as it becomes expedient 
to either make the developing cell more vulnerable to deletion or increase its longevity. In 
the circumstances, a malfunction of any of the mechanisms that modulate the levels of 
Bcl-2 family members could just as easily result in inappropriate expression of 
anti-apoptotic proteins as a translocation. In the absence of any substantial evidence to 
the contrary, this type of malfunction certainly cannot be excluded as being instrumental in 
the pathogenesis of B-CLL in at least some patients and it remains possible, if Bcl-2 
family member deregulation can be shown to be a ubiquitous feature of B-CLL, that the 
nature of the deregulation may contribute to the character and aggressiveness of the 
disease.
The most interesting, and potentially most productive aspect of the role of the Bcl-2 family 
of proteins in the pathogenesis of B-CLL, is the extent to which their levels may be 
modulated by largely extracellular influences including IL-4, IL-5, IL-8. IL-10, IFN-a, IFN-y, 
bFGF, TG Fpi, BM stromal cells. CDw32, CD95, CD6, CD4G, IgM, and the p53 gene. It is 
clear that these may play a significant role in the pathogenesis of the disease and as 
such, present numerous opportunities for further research aimed at understanding the 
cause of the disease. However, a better understanding of their role may also provide the 
opportunity to manipulate the mechanisms involved to significant therapeutic advantage.
The fact that lower Bcl-2:Bax ratios correlate with non-progressive disease, lack of 
previous treatment, and particularly increased sensitivity to the induction of apoptosis 
using cytotoxic agents in vitro, combined with the ability to manipulate levels of Bcl-2 and 
Bax, and by inference other family members involved in B-CLL, potentially offers 
opportunities to treat the disease, or to make existing treatments more effective by 
preceding them with a modulation phase. During this modulation phase the neoplastic 
cells could be made more vulnerable, e.g. to chemotherapy, by having their ratios of 
anti-apoptotic to pro-apoptotic family members reduced, an option which might be of 
particular value in refractory disease. Manipulation of receptor or cytokine levels often 
has an adverse effect on normal cells, but the wide range of entities which affect the 
apoptotic threshold in B-CLL cells provides an opportunity to exploit a potential synergy 
between them, with levels of individual cytokines, or receptors modulated in such a way as 
not to have undue pathological effects on normal cell populations.
I l l
Of the entities that appear to regulate the Bcl-2:Bax ratio in B-CLL cells, IL-4, IL-5, IL-8, 
CD6, BM stromal cells, CDw32, the p53 gene and CD95 appear to be of particular value, 
or of such potential value as to make them worthy of further investigation. The effect of 
CD95 is potentially very interesting if its ligation were eventually proven to induce an 
apoptotic pathway unregulated by Bcl-2, as a Bci-2-independent pathway could prove a 
very useful adjunct to therapy in any disease associated with the protein. However, a 
great deal more work is necessary to establish the extent of the influence on molecular 
entities listed above on the various members of the Bcl-2 family in B-CLL, the extent to 
which these play an active part in the neoplastic process in the disease, and the 
mechanisms through which they act.
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